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ABSTRACT 
 
Endothelial microparticles (EMPs) are complex structures with pleiotropic properties 
and are emerging as an index of endothelial damage. Increased circulating levels 
of EMPs have been identified in several inflammatory disorders and are reduced 
following anti-inflammatory treatment. Since they are cell-to-cell communicators, 
this study aimed to identify specific effects on both endothelial and vascular smooth 
muscle cell (VSMC) function. We hypothesise that EMPs have a dual role, 
depending on the stimuli involved in their release, potentially playing a role in 
vascular homeostasis, but also in exacerbating vascular damage under disease 
conditions and this can be executed via activating the endothelium, and also in the 
cross-talk to the smooth muscle layer, in terms of depositing a calcified matrix.  
The study is presented in two sections: first, to investigate the effect of EMPs on 
endothelial cells, by studying EMP release, endothelial cell activation and migration, 
and second, to investigate whether they modulate osteogenic differentiation of 
VSMCs in vitro, focusing on the mechanistic pathways involved using a microRNA 
and proteomic screening. To achieve these aims, three different sets of extracellular 
vesicles were generated (probably containing EMPs and exosomes): i) uEMPs, 
which were generated from healthy growing untreated human umbilical vein 
endothelial cells (HUVECs), ii) sEMPs, from Tumor Necrosis Factor alpha (TNFα)-
stimulated HUVECs and iii) AoEMPs, from TNFα-stimulated human aortic 
endothelial cells. In the first study, HUVECs were treated with either uEMPs or 
sEMPs for 24 hours to investigate their effects on endothelial cell function, while in 
the second study, VSMCs were treated with AoEMPs for 3 weeks in osteogenic 
media to assess their effects on vascular calcification.  
The study confirmed that EMP content, which depends on their cellular origin and 
the stimuli involved in their release, defines their properties. Both uEMPs and 
sEMPs increase vascular cell adhesion protein (VCAM-1) and intercellular adhesion 
molecule 1 (ICAM-1) and cell migration. However, sEMPs increase EMP release 
and carry elevated Chemokine (C-C motif) Ligand 20 (CCL20), identified in the 
proteomic screening and validated by flow cytometry, in comparison to uEMPs, thus 
contributing to the elevated EMP levels and disease pathogenesis via CCL20 and 
dysregulated inflammatory pathways. In addition, Alizarin Red S and calcium 
deposition assays demonstrated that VSMCs treated with AoEMPs in osteogenic 
media for 3 weeks show enhanced calcification in vitro, using Alizarin Red staining 
and calcium deposition assays. These findings may be in part, linked with miRNA-
3148/osteoprotegerin signalling pathway, as miRNA-3148 was identified in the 
microRNA screening and using transfection studies, we identified its relationship 
with its target osteoprotegerin RNA. This study provides improved understanding of 
the mechanisms in which EMPs affect endothelial function and VSMC calcification 
in vitro. Further research will help understanding the ultimate role of EMPs on the 
vessel wall. 
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CHAPTER 1: INTRODUCTION 
1.1. Clinical problem: vasculitis and inflammation in systemic lupus 
erythematosus 
Vasculitis is an inflammatory condition with a wide range of clinical manifestations. 
It is known that patients suffering autoimmune disorders may develop vascular 
problems and therefore, may have a higher risk of suffering cardiovascular disease 
(CVD), which is a major cause of mortality (1). An example of this is systemic lupus 
erythematosus (SLE), which is the focus of this study. 
SLE is a chronic multi-system inflammatory autoimmune disease that can affect 
most of the organs in the body, leading to a wide range of diverse clinical 
manifestations (1). It is characterised by an immune system dysfunction that leads 
to the loss of immunologic tolerance and the creation of antibodies targeting nuclear 
material (2). It has been reported that SLE patients have a higher probability of 
suffering coronary heart disease (CHD) as well as an increased chance of producing 
atherosclerosis plaques, thus a lower life expectancy compared to a healthy 
population is expected, due to the increased risk of CVD and accelerated vascular 
ageing (3). Despite mortality rate being reduced during the last decades, CVD 
remains a major cause of mortality worldwide, with SLE patients having more than 
50 times the risk of general population (4).  
SLE has been shown to have a higher influence in female rather than male 
individuals, predominantly in fertile age, with an impact ratio of 6-10:1. In the USA 
and Europe, SLE has a very similar incidence rate, ranging from 1.8 and 7.6 cases 
per 100.000 people a year respectively (2). SLE presents with a gradual progression 
over the years and some of its common clinical manifestations may include fatigue 
or weight loss; while others include malar rash, photosensitivity (cutaneous 
hypersensitivity), non-erosive polyarthritis, and often neurological and vascular 
problems. SLE is a disease characterised by alternate flare and remission periods 
that are associated with a decreased quality of life and a lower life expectancy 
mainly due to its activity, but also to organ damage and an increased risk of suffering 
CVD (3).  
Due to the heterogeneity of SLE and its wide range of clinical manifestations, 
treatment options are not ideal and thus, the management of patients with SLE 
focuses on controlling the inflammatory activity in order to preserve organ function 
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and minimise side effects. Rituximab and standard immunosuppressive agents are 
common medications prescribed to manage the disorder (4). 
1.1.1. Endothelial dysfunction and cardiovascular disease in SLE 
The definition of endothelial dysfunction can be described from a physiological point 
of view, as a loss of response of the vascular endothelium to the stimuli promoting 
its vasodilation and contraction (5). In other words, endothelial dysfunction refers to 
the inability of the endothelium to vasodilate and contract, as well as to its incapacity 
to control inflammation, cell proliferation and thrombosis. This coincides with the 
cellular and molecular aspects of activation of adhesion molecule expression. The 
role of the endothelia in the maintenance of vascular homeostasis is widely known, 
e.g. the endothelium is known to control vascular inflammation, smooth muscle cell 
proliferation, platelet adhesion and fibrinolysis among others (6). A scheme of the 
structure of the vessel wall be found in Figure 1. 
 
Figure 1. Schematic representation of the vessel wall. The vessel wall is 
composed of different elements: a single layer of endothelial cells, the internal 
elastic lamina, which separates the endothelium from the smooth muscle cell layer, 
followed by the external lamina and the adventitia, which is composed mostly of 
connective tissue. Adapted from Blausen (7) 
It is important to evaluate endothelial function within the content of its cross-talk with 
smooth muscle cells. Along with endothelial dysfunction, SLE is an independent risk 
factor for CVD and is associated with a 5-fold increased risk in adults and a 50-fold 
increase in younger patients (8). In order to gain insight to develop improved and 
more individualised therapeutic approaches, this study has focused on 
understanding the basis of endothelial dysfunction observed in SLE patients (Figure 
2) compared to the normal function of endothelial cells, and if any links can be made 
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on the inflammatory effects resulting from an activated endothelium and the 
response within the medial layer of smooth muscle cells (9).  
 
 
 
 
 
 
 
 
 
Figure 2. SLE patients have impaired endothelial function. Previous research 
has demonstrated that SLE patients show decreased flow-mediated dilatation 
(FMD) reflected in reduced endothelial function when compared to healthy controls. 
Adapted from Kerekes et al (9) 
 
1.1.2. Tumor Necrosis Factor-alpha, a key cytokine in inflammation in SLE 
Inflammation is a known stimulus for the development of vasculitis, and in particular, 
it is known to be elevated in SLE patients compared to age-matched controls (6).  
It is generally accepted that several kinds of stimuli may result in an increased 
expression of adhesion molecules on the endothelial cell monolayer. Adhesion 
molecules allow endothelial cells to capture leukocytes (monocytes, etc.) which later 
will differentiate into macrophages and form foam cells, which will take part in the 
progression of the lesion. Ultimately causing migration and phenotypic switching of 
smooth muscle cells into a secretory cell depositing a matrix that will form a fibrous 
cap. Thin fibrous caps can lead to a rupture which in turn cause thrombosis (10).  
Tumor Necrosis Factor-alpha (TNFα) is a cytokine produced predominantly by 
activated macrophages and T lymphocytes that has been shown to play a role in 
the course of several inflammatory diseases, but understanding how its pleiotropic 
properties affect inflammation is challenging (11). For example, TNFα can act as a 
growth factor in B cells, thereby inducing the production of Interleukin-1 (IL-1) or 
Interleukin-6 (IL-6) (12, 13), but it can also act as an inhibitor or as a promoter of 
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cell apoptosis and regulate the expression of anti-apoptotic or adhesion molecules, 
ultimately leading to inflammation (14). 
The relevance of TNFα in the pathogenesis of SLE has been extensively reviewed 
(11, 14-16) and as such, anti-TNFα drugs are often used in the management of the 
disease, but it has been shown to be protective or detrimental depending on the 
mouse model of the disease investigated (17, 18). Previous findings have shown 
that serum concentration of TNFα is high in active SLE patients and that it correlates 
with disease activity (17). Other studies found that TNFα only produces a mild SLE-
like phenotype in New Zealand black and white (NZB/W) mice, which are prone to 
autoimmune diseases (18).  
Although TNFα receptors are expressed on different cell types, many of its 
inflammatory effects can be explained through its effects on vascular endothelium 
and leukocyte interactions in which endothelial cells promote inflammation by up-
regulating the expression of adhesion molecules for leukocytes such as intercellular 
adhesion modelule-1 (ICAM-1) and vascular cell adhesion molecule-1 (VCAM-1), 
thereby facilitating extravasation (19, 20). Despite the fact that TNFα is considered 
not to be as relevant in SLE as in other vascular conditions, elevated circulating 
TNFα levels have been reported in patients with very active SLE (21, 22). Since 
endothelial damage is an early event prior to the development of inflammatory and 
cardiovascular conditions, it is necessary to assess the risk of CVD in SLE patients. 
 
1.2. Microparticles in health and disease 
Extracellular vesicles are membrane-bound vesicles released from cells that can 
transport nucleic acids and proteins. It is recognised that three main categories of 
extracellular vesicles exist: exosomes (< 100 nm), microparticles (MPs) (> 100 nm 
and < 1 µm) and apoptotic bodies (< 1 µm). Extracellular vesicles are often 
investigated together, albeit important differences have been reported in the 
literature with regards to their generation mechanisms and contents (23-25). A 
summary of the main characteristics and differences between exosomes, MPs and 
apoptotic bodies reported by the literature can be found on Table 1. 
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Characteristics 
Origin Size Contents 
Exosomes 
Multivesicular 
bodies 
20 – 100 nm 
Nucleic acids, proteins, 
membrane receptors 
Microparticles 
Cell surface, 
membrane blebbing 
100 – 1000 nm 
Nucleic acids, proteins, 
membrane receptors 
Apoptotic 
bodies 
Cell surface, 
apoptotic cells 
Larger than 
1000 nm 
Nuclear fractions, 
organelles 
Table 1. Differences between MPs, exosomes and apoptotic bodies. Based on 
their biogenesis and origin, three main classes of extracellular vesicles have been 
described: exosomes, microparticles and apoptotic bodies. Adapted from El 
Andaloussi et al. (25) 
 
Vascular cells, just like many other cell types, participate in the release of 
microparticles. MPs are a heterogeneous submicron sized circulating population (< 
1 µm) of vesicles present in the blood stream which contain cytosolic components 
generated usually from apoptotic or activated cells. They have shown to be involved 
in many different conditions including SLE, although they are also found in healthy 
individuals (26, 27). Although the mechanisms underpinning their generation are still 
poorly understood, several authors have reported that they might be a result of 
vesicles blebbing off from the plasma membranes in response to a certain stimulus 
such as TNFα, mainly due to cell activation or apoptosis (28). Also, their 
phenotypical characteristics can be distinguished from their cellular origin, as 
reviewed by Hugel et al. (29).  
A correlation between the stage of some diseases and MP levels from a certain 
cellular origin has been reported in the literature including SLE (10, 11), making 
them a potential biomarker for predicting CVD risk and, since they have been 
reported to trigger an endothelial repair response (12). They may also act as a novel 
therapeutic approach (30). It has been widely reported that platelet derived 
microparticles (PMPs) levels are increased in many autoimmune diseases; 
however, few studies have investigated the differences in endothelial derived 
microparticle (EMP) levels in these conditions, probably due to the higher 
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concentration of PMPs compared to EMPs in the blood stream (13). Moreover, 
differences in storage, manipulation and processing of plasma samples (as well as 
activation, isolation and measurement method) have shown to have an important 
effect in MP detection in in vitro models (14-16); despite several attempts to 
standardise the variables (17) these differences still exist, providing the impetus for 
a standardised approach in detection and measurement (31, 32).  
As it has been discussed previously, SLE patients are more likely to develop 
endothelial dysfunction increasing their predisposition to cardiovascular disorders. 
Our laboratory have previously demonstrated that MP circulating levels are 
modulated in different conditions, including SLE, and that their levels can be 
reduced by pharmacological treatment (33). MP research is of growing importance 
as evidenced by the numbers of EMP reports in the literature during the past 2 
decades (Figure 3). Despite clinical trials have already investigated using MPs as 
biomarkers of disease prognosis in patients with cerebral infarction, heart failure, 
acute coronary syndrome or diabetes mellitus (34, 35), their mechanism of action 
has yet to be elucidated before they can be used as a biomarker of CVD and a 
potential therapeutic target (33, 36). 
Our laboratory is particularly interested in investigating the role that MPs play in 
endothelial and smooth muscle cell signalling, with a focus on how these MPs 
modulate endothelial function and vascular calcification in inflammatory conditions 
such as SLE (27). The following points will discuss the different types of MPs, 
although of particular interest are EMPs. Furthermore, the different methods used 
to quantify MPs will be discussed, as well as their role in SLE, endothelial and 
smooth muscle cell signalling, and their potential diagnostic and therapeutic utility. 
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Figure 3. Evidence of increased EMP publications in PubMed on an annual 
basis. The number of publications in PubMed containing the words “endothelial 
microparticles” has increased year after year during the last 22 years. 
 
1.2.1. Endothelial microparticles: origin, formation and composition 
1.2.1.1. EMP origin and formation 
MPs are derived from many different cell types and as such, they share 
characteristics with their cell of origin, such as surface markers (37). Platelet-derived 
microparticles (PMPs) are the most abundant type of MPs found in circulation, along 
with EMPs (38). However, MPs derived from megakaryocytes (39) and leukocytes 
(40) have also been found in circulation. Although it is possible to detect MPs in 
healthy individuals, several conditions such as inflammatory diseases exacerbate 
the generation and release of MPs as a result of membrane shedding due to 
apoptosis or cell activation (33). A common characteristic of all MP populations is 
their formation and shedding, which involves the reorganisation of the phospholipid 
membrane distribution, exposing phosphatidylserine (PS) on the outer membrane 
of the cell. 
Most available knowledge of the molecular mechanisms leading to MP release has 
its origin in in vitro studies, in which a variety of stimuli (including TNFα) can induce 
the release of MPs by endothelial cells (21, 41). Other inflammatory cytokines, 
reactive oxygen species, thrombin, c-reactive protein, plasminogen activator 
inhibitor among others have also been shown to induce EMP release (42). In 
quiescent cells, the membrane is characterised by exposing neutral phospholipids 
such as phosphatidylcholine and sphingomyelin on its external layer, and 
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phosphatidylserine (PS) on its inner side; an equilibrium regulated by the three 
proteins flippase, floppase and scramblase. When cell activation or apoptosis 
processes occur, calpain is activated, allowing intracellular calcium to increase, 
which induces aminophospholipid movements from the inner to the outer leaflet, 
leading to membrane blebbing due to the disruption of the phospholipid membrane 
and cytoskeleton reorganisation ultimately leading to EMP formation (43-45) (Figure 
4).  
The mechanisms by which this process is regulated are still unclear and seem to be 
diverse. A study from Sapet et al. using siRNAs and pharmacological inhibitors of 
Rho-kinases first described an nuclear factor kappa B (NFκB)-dependent activation 
of Rho-associated protein kinase 2 (ROCK II) by caspase 2 as potentially 
responsible of EMP release in human microvascular endothelial cells (46). Another 
study by Curtis et al. described the role of the p38 MAPK pathway, and showed that 
the pharmacological inhibition of p38 in human aortic endothelial cells reduces 
TNFα-mediated EMP release (47). 
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Figure 4. Schematic representation of the mechanisms of EMP formation. A) 
In quiescent cells, PS localisation in the inner leaflet is regulated by flippase activity. 
B) Upon TNFα to its receptor, floppase and scramblase activate upon increased 
intracellular Ca2+ leading to cytoskeleton reorganisation and the release of EMPs 
exposing PS in the outer membrane. TNFα: Tumor necrosis factor alpha; PS: 
Phosphatidylserine; EMPs: Endothelial microparticles. Adapted from Baron et al. 
(30)  
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1.2.1.2. TNFα-mediated EMP generation 
It is well established that TNFα can induce MP generation in cell culture models (21, 
41), but also other inflammatory cytokines and stimuli are able to generate MPs in 
vitro. On the one hand, pro-apoptotic stimuli such as high concentrations of TNFα, 
IL-6, IL-8 or even DNA damage can lead to caspase activation and cell death, which 
is accompanied by the generation of apoptotic bodies (> 1 µm), but on the other 
hand, inflammatory stimuli, low shear stresses, vascular damage or the presence of 
particular growth factors may lead to endothelial cell activation and the production 
of EMPs (48-52) (Figure 5). Finally, and as an example of the many TNFα roles, it 
is able to induce a concrete vesiculation pathway present in endothelial cells that 
involves NFκB and TNF-related apoptosis-inducing ligand (TRAIL), leading to 
ROCK II activation by caspase 2 (46). 
 
Figure 5. TNFα-mediated EMP formation. High TNFα concentrations initiate cell 
apoptosis and ultimately the release of apoptosis-derived bodies, whereas lower 
TNFα concentrations initiate inflammatory or endothelial damage ultimately leading 
to EMP release. TNFα: tumor necrosis factor alpha; IL-6: interleukin 6; IL-8: 
interleukin 8. Adapted from Curtis et al. (53) 
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TNFα can either bind the TNFR1 or TNFR2, initiating either the NFκB, mitogen-
activated protein kinase (MAPK) or cell death signalling pathways (54, 55). The 
NFκB pathway, which is activated by a myriad of cytokines in addition to TNFα, is 
an important pathway that has been shown to be involved in many aspects of 
endothelial function, inflammation and homeostasis regulation (56). In the canonical 
NFκB pathway, the inhibitory protein IκBα binds to NFκB and retains it in the cell 
cytoplasm. Upon activation of the pathway due to TNFα, IκBα is phosphorylated and 
degraded, releasing NFκB which is then free to translocate to the nucleus, where it 
will act as a transcription factor of several proteins involved in inflammation, cell 
survival and cell proliferation (Figure 6). 
 
Figure 6. Proposed model of activation of the NFκB pathway and TNFα-
mediated EMP release. Upon activation of the pathway due to TNFα, IκBα is 
phosphorylated and degraded, releasing NFκB which is then free to translocate to 
the nucleus, where it will act as a transcription factor of several proteins involved in 
inflammation, cell survival and cell proliferation. As a consequence, EMPs 
containing inflammatory-derived proteins and miRNAs are generated and will act as 
paracrine signalling molecules. TNFα: tumor necrosis factor alpha; TNFR1/2: tumor 
necrosis factor receptor 1/2; EMPs: endothelial microparticles; NFκB: nuclear factor 
kappa b; IκBα: inhibitor kappa b alpha 
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1.2.1.3. EMP composition 
Microparticles are vehicles of biological information, which carry enzymes, bioactive 
lipids, proteins and/or RNAs, thus engaging in signalling pathways (10). As part of 
the research programme of work, we focused on MPs proteomic and microRNA 
(miRNA) content analysis. 
1.2.1.3.1. Cytokine content of EMPs 
Several research groups working with EMPs have shown that the proteomic content 
of these clearly depends not only on the cell lineage that generates the EMPs, but 
also on the sort of stimulus leading to vesiculation (57-59). For instance, Jimenez et 
al. demonstrated that endothelial cells release qualitatively and quantitatively 
distinct EMPs in response to TNFα (inflammatory model) and upon the induction of 
apoptosis by growth factor deprivation in vitro (60). Besides mediating exchange of 
intercellular information by their surface molecules, MPs have been shown to be 
carriers of important soluble mediators, such as cytokines (summarised in Table 2). 
Table 2. Cytokines transported by MPs from different cell types. MPs have 
shown to be vehicles of biological information and to act as paracrine signalling 
molecules by participating in the transportation of cytokines. MPs: microparticles; 
EMPs: endothelial microparticles; CCL: chemokine (C-C motif) ligand. 
Cytokine Cell line origin Reference 
Interleukin 1β (IL-1 β) 
Leukemic cell line (THP-1)-
derived MPs 
(61, 62) 
Interleukin 1α (IL-1 α) HUVEC-derived EMPs (63) 
Interleukin 18 (IL-18) Macrophage-derived MPs (64) 
Interleukin 32 (IL-32) Epithelial-derived MPs (65) 
Membrane-bound tumour necrosis 
factor α (TNFα) 
Synovial cell line (L929)-
derived MPs 
(66) 
Interleukin 6 (IL-6) 
Leukemic cell line (HMC-1)-
derived MPs 
(67) 
Vascular endothelial growth factor 
(VEGF) 
Carcinoma cell line (A2780)-
derived MPs 
(68) 
Interleukin 8 (CXCL8) 
HPC-4, A549 (tumor cell 
lines)-derived MPs 
(69) 
CCL2, CCL3, CCL4, CCL5 and 
CCL20 
Dendritic-derived MPs (70) 
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With these observations in mind, this thesis describes the investigation of the 
molecular differences (proteomic and miRNAs) between two different vascular beds 
(HAoECs and HUVECs) and two different EMP populations generated from 
HUVECs, uEMPs and sEMPs, in which the first was generated from unstimulated 
while the second was from TNFα-activated cells. 
1.2.1.3.2. microRNA signalling within EMPs 
MicroRNAs (miRNAs) are small non-coding RNAs that function as critical 
repressors/silencers of gene expression. Previous studies have demonstrated that 
MPs carry miRNAs (71) which play an essential role regulating processes such as 
endothelial cell proliferation or angiogenesis (72), suggesting that partly, MPs role 
in SLE may be one of signalling (73). 
miRNA production is a two stage process occurring in nucleus and in cytoplasm 
respectively. First, the enzymes DiGeorge syndrome chromosomal region 8 
(DGCR8) and Drosha catalyse the conversion of the primary miRNA transcripts into 
pre-miRNAs (60-70 bp) in the nucleus (74). The pre-miRNAs leave the nucleus and 
once in the cytoplasm, their terminal loop is cleaved by RNAase III Dicer, generating 
a miRNA-miRNA duplex. After this, the RNA-induced silencing (RISC) complex 
incorporated the -5p end to the duplex, which makes the miRNA functional and able 
to bind the 3’ UTR region of its target mRNA. There has been much discussion on 
the role of miRNAs and whether they silence/repress transcription or whether they 
degrade their target mRNA (75-77), but in either case, miRNAs will act as gene 
regulators by repressing the expression of their targets. 
miRNAs have been implicated at various stages of endothelial and smooth muscle 
cell signalling. For instance, miRNA-146 targets the signalling molecule TNF 
receptor associated factor 6 (TRAF-6), which is up-stream of the NFκB signalling 
pathway and results in the modulation of NFκB translocation and in turn, the 
reduction of TNFα (78-80). A summary of some the miRNAs identified in EMPs to 
date can be found in Table 3. 
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Table 3. miRNAs found in extracellular vesicles. Summary of the miRNAs carried 
by MPs which are reported to be associated with CVD. EMPs: endothelial 
microparticles; PMPs: platelet microparticles; miRNA: microRNA; HAoECs: human 
aortic endothelial cells; HUVECs: human umbilical vein endothelial cells; SPRED1: 
sprouty related EVH1 domain containing 1; TRPC6: Transient receptor potential 
cation channel, subfamily C, member 6; SPRY1: sprouty RTK signalling antagonist 
1; PU.1: Transcription factor PU.1; EPB41L3: erythrocyte membrane protein band 
4.1 like 3; MIF: macrophage migration inhibitory factor; TF: tissue factor; ZO-1: 
zonula occludens-1; INPP5D: inositol polyphosphate-5-phosphatase; RGS16: 
regulator of G-protein signalling 16. 
miRNA 
Extracellular 
Vesicles 
Function Target References 
miRNA-126 
EMPs 
(patients) & 
PMPs 
Promotes endothelial repair. 
Effects are impaired in 
hyperglycaemic conditions 
SPRED1 (81, 82) 
miRNA-26a 
EMPs 
(patients) 
Regulates insulin sensitivity 
and glucose metabolism. 
Reduced in EMPs in 
hyperglycaemia 
TRPC6 (82) 
miRNA-21 
EMPs 
(HAoECs) & 
PMPs  
Elevated in carotid artery 
disease 
SPRY1 (83-85) 
miRNA-155 
EMPs 
(patients) 
Modulates T-cell function 
and contributes to the 
development of myocarditis 
PU.1 (86) 
miRNA-223 
PMPs 
(patients) 
Promotes tumor progression 
in lung cancer 
EPB41L3 (87, 88) 
miRNA-423-5p 
EMPs 
(patients) 
Low levels are associated 
with poor long-term outcome 
in diabetic patients 
Unknown (82, 89) 
miRNA-451 
EMPs 
(epithelial 
cells)  
Inhibits cell proliferation, 
migration and invasion 
through regulating 
macrophage inhibitory factor 
in renal cell carcinoma 
MIF 
 
 
(90) 
miRNA-19 
EMPs 
(HUVECs) & 
PMPs 
Anti-thrombotic effect. 
Inhibits tissue factor on 
target endothelial cells 
TF (91-93) 
miRNA-105 
Exosomes 
from  
glioblastoma 
(patients) 
Overexpression in non-
metastatic cancer cells 
induces metastasis and 
vascular permeability 
ZO-1 (94) 
miRNA-155 
Exosomes 
(bone marrow-
derived 
dendritic cells) 
Promotes endotoxin-induced 
inflammation in mice 
INPP5D (95) 
microRNA-126 
Endothelial 
derived 
apoptotic 
bodies 
(HUVECs) 
Promotes the incorporation 
of Sca-1+ progenitor cells 
RGS16 (96) 
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It is important to remember that upon EMP formation/generation, cytoplasmic 
content is often encapsulated and released from the cell in the form of MPs. 
Therefore, it is during this process when pre-miRNAs or mature miRNAs are 
packaged in the MPs, which can then regulate gene expression and post-
translational regulation of mRNA (97). Also, a single miRNA can modulate several 
genes, and a single gene can be modulated by several miRNAs, and of note, some 
studies have identified that miRNAs carried by MPs have significant relevance in 
immunological disorders (98). As such, it makes sense to understand MPs as key 
signalling molecules, with a huge potential to affect cell function possibly via 
horizontal transfer of miRNAs. 
 
1.2.2. Identification and quantification of EMPs in vivo and in vitro 
Flow cytometry is the gold-standard technique for quantifying MPs in plasma and in 
whole blood (32, 33, 99). Despite MPs having components from their cells of origin 
and their phospholipid and protein composition varying depending on their cell of 
origin and their releasing method, the exposure of PS is generally accepted 
regardless of the fact that several authors have reported to have found vesicles of 
the size of MPs not containing PS, as is often used for their characterisation (100). 
However, PS does not differentiate between different cellular origins and therefore, 
other surface markers specific to the cell of origin are used to differentiated between 
MPs.  
As a common criteria for MP detection, PS positive particles (AnnexinV+) smaller 
than 1 µm are considered as MPs; however, other criteria to assess their cell of 
origin or their nature as extracellular vesicle should be applied. For each cell type 
involved in MP generation, various surface markers can be used depending on the 
cell origin of interest. Apart from PS, EMPs may express adhesion molecules 
specific to mature endothelial cells such as CD54 (ICAM-1), CD62E (E-selectin) or 
CD31 (PECAM). However, CD31 is also detected on platelet microparticles (PMP), 
thus a usual labelling strategy for EMP detection would include labelling with positive 
and negative markers to eliminate other hematopoietic cells e.g. CD31+/CD41- or 
CD31+/CD42b-, since CD41 nor CD42b are expected to be present in EMPs (30). A 
summary of the most commonly used markers is shown in Table 4. Characterisation 
of the cell of origin is not a necessary requirement when working with in vitro 
generated EMPs, as a single pure population of one cell phenotype is being used, 
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and in this case, the sole use of AnnexinV+ (in combination with sizing beads to 
detect MPs) is commonly accepted (32, 101). 
 
Table 4. Commonly used antigen markers in flow cytometry for PMP, EMP, 
exosome and apoptotic bodies quantification. CD31, CD51 and CD105 are not 
specific to endothelial-derived MPs and are often used in combination with other 
markers to identify EMPs. PMP: platelet microparticles; EMP: endothelial 
microparticles; TSG101: tumor susceptibility gene 101; PI: propidium iodide. 
 
As mentioned before, a fraction of smaller sized particles (< 100 nm), named 
exosomes, has been extensively described in the literature and its generation 
mechanisms, contents and effects on target cells have often been studied alongside 
those of MPs (42, 118, 119). Together with apoptotic bodies (> 1 µm), exosomes 
pose a challenge in MP isolation as the lack of standardisation in EMP isolation 
techniques often means the exosomal and MP fractions are not separated. There 
are commercially available kits that use specific markers for exosomes (CD63, 
CD81 or others) in order to isolate populations, but their accuracy is debatable, as 
most of the markers are also found on MPs. Current MP isolation techniques include 
centrifugation at high speed for specific periods of time. However, it is important to 
mention that several groups have reported that differences in centrifugation speeds 
and timings can significantly affect MP quantification, suggesting the need for 
standardisation (30, 31). Centrifugation speed and length have been shown to be 
paramount in isolating MP populations avoiding the apoptotic fraction, therefore, it 
has been suggested that a consensus is needed to ensure consistency between 
laboratories when describing studies using MPs. A summary of some of the 
Vesicle type Antigen 
PMP CD41 (102), CD42a (103), CD42b (104),CD61 (105),CD62P (73) 
EMP 
CD31* (106), CD62E (107), CD34 (108), CD51* (109), CD54 (110), 
CD105* (111), CD144 (102), CD146 (112) 
Exosomes CD63 (113), CD9 (114), TSG101 (113), CD81 (115) 
Apoptotic 
bodies 
Heavy phosphatidylserine externalisation (116), PI (117) 
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currently described centrifugation techniques used by different laboratories to 
isolate EMPs can be found in Table 5. 
Cell model used 
Preparation of 
supernatant 
Isolation of EMP pellet Reference 
Human umbilical vein 
endothelial cells 
(HUVECs) 
4,300 x g 5 min 100,000 x g 90 min 10 °C (41) 
Rat renal 
microvascular 
endothelial cells 
(RMVECs) 
5,000 x g 5 min 100,000 x g 120 min (120) 
HUVECs 4,000 x g 5 min 100,000 x g 90 min 10 °C (121) 
Human Jurkat T cells 1,500 x g 5 min 100,000 x g 20 min 20 °C (52, 122) 
Human microvascular 
endothelial cells 
(HCMECs) 
4,300 x g 5 min 20,000 x g 120 min 4 °C (123) 
HUVECs 200 x g 4 min 100,000 x g 60 min 4 °C (124) 
T cells 
800 x g 5 min then 
4,500 x g 5 min 
100,000 x g 60 min 4 °C (125) 
Human aortic 
endothelial cells 
(HAoECs) 
4,300 x g 5 min 200,000 x g 120 min 20 °C (126) 
HAoECs, Human 
lung microvascular 
endothelial cells 
(HMVECs) 
400 x g 15 min 3 x (21,000 x g x 45 min) (127) 
HUVECs 3890 x g 5 min 100,000 x g 90 min 4 °C 
(21), (52), 
(128), (48), 
(50), (129) 
Table 5. Summary of centrifugation methods used for isolating in vitro 
generated EMPs. Considerable variation in centrifugal speeds used to pellet EMPs 
is apparent between different laboratories, hence discrepancies can arise between 
publications regarding the signalling pathways activated since there could be MP 
preparations that also contain an exosomal fraction. The studies performed in this 
thesis used similar centrifugal speeds to those described in Heathfield et al. (21). 
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1.2.3. Mechanisms of EMP:cell interaction 
It has been shown that the mechanisms in which exosomes and MPs interact with 
their targets cells are diverse and involve endocytic pathways and membrane fusion 
among others (130). A study by Valadi et al. demonstrated that exosomes act as 
signalling molecules and transfer functional mRNA and miRNAs from MC/9 mouse 
to HMC-1 human mast cells in vitro, as mouse proteins were found in the human 
cells (71). Another study by Alvarez-Erviti et al. showed that in vitro generated 
exosomes injected in mice can knockdown GAPDH gene expression by carrying 
and delivering siRNAs (131). Similarly, Montecalvo et al. used dendritic-derived 
exosomes loaded with luciferin to treat bone marrow derived dendritic cells that had 
been transfected with luciferase, thereby producing bioluminescence and 
confirming the transfer of functional material from the exosomes to the target cells 
(132).  
MP uptake can be visualised directly using fluorescence microscopy. However, the 
mechanisms involved in such process are complex and diverse and have raised 
great debate in the literature (119, 130). Various mechanisms for MP:cell interaction 
have been suggested, including membrane fusion (133), ligand-receptor interaction 
(134), lipid-mediated endocytosis (135), caveolin-1/caveolae-mediated endocytosis 
(136), phagocytosis/macropinocytosis (137) and extracellular degradation. 
However, the question of whether or not MP uptake is a cell type-dependent process 
remains to be elucidated, as the majority of research in the literature investigating 
internalisation and cell interaction has been performed on exosomes rather than 
MPs. Whereas some studies have shown that internalisation and exosome:cell 
interaction is a highly specific process and requires the presence of the right 
combination of ligands and receptors either on the cells or on the exosomes, some 
others have shown that exosomes can be taken up by many cell types (135, 138).  
The current lack of knowledge in MP:cell interaction probably accounts for the 
difficulty and lack of standardisation of MP isolation techniques. However, a 
summary of the most accepted mechanisms for MP:cell interaction can be found on 
Figure 7. In this study, Calcein-AM was used to demonstrate that EMPs enter their 
cells to deliver their contents, but the mechanisms by which EMPs interact with their 
target cells was beyond the scope of this thesis. 
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Figure 7. Proposed putative pathways/mechanisms of EMP:cell interaction. MPs act as cell to cell communicators as they carry proteins 
and RNAs from their cell of origin. However, the mechanisms by which MPs interact with their targets cells are still being investigated. A) 
Membrane fusion, B) ligand-receptor interactions, C) extracellular degradation, D) caveolin-1/caveolae endocytosis, E) phagocytosis, and F) 
macropinocytosis are some of the suggested mechanisms by which EMPs exert their effects on target cells. EMP: endothelial microparticle.
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1.2.4. The role of EMPs in endothelial cell signalling 
Increased microparticle concentrations of various cellular origins have been found 
in individuals under certain pathological conditions, which are usually associated 
with an increased thrombotic risk and endothelial dysfunction. Currently, endothelial 
function ex vivo is often measured using wire myography, a technique in which a 
blood vessel is cannulated and endothelial function and vasoconstrictor or 
vasodilator properties of the vessel in response to different pathophysiological 
stimuli are measured (139). Since elevated levels of EMPs compromise 
homeostasis of the vascular tone by decreasing nitric-oxide-dependent vasodilation, 
increasing arterial stiffness, promoting inflammation and initiating thrombotic events, 
they play a key role in the regulation of the different inflammatory and thrombotic 
diseases (140). Accumulating evidence strongly suggests that EMPs have pro-
coagulant, pro-inflammatory and pro-angiogenic effects, indicating that they are not 
only an indicator of endothelial damage or CVD risk but also possible pathogenic 
factors (141). For instance, PS exposure in the outer membrane of EMPs (often 
accompanied by tissue factor) is associated with an increased thrombotic activity. 
Such pro-thrombotic and pro-coagulation activity of EMPs was studied in an 
investigation carried out by Abid Hussein et al., which demonstrated that thrombin 
formation in vitro and thrombus formation in vivo is triggered by HUVEC-derived 
EMPs in a tissue factor-dependent manner (142), and another study by Leroyer et 
al. found EMPs in atherosclerotic plaques in patients undergoing carotid 
endarterectomy (143).  
It has been demonstrated that MPs can be detected in plasma of healthy individuals 
at a level of 105 EMPs/mL (33). Under healthy conditions, vessel homeostasis is 
driven by the anti-inflammatory, anti-thrombotic and anti-atherogenic properties of 
the endothelial monolayer, and it is suggested that endothelial integrity is maintained 
by cell regeneration and the mobilisation of endothelial progenitor cells from the 
bone marrow (140). Some studies have found a protective function of EMPs too 
(144, 145), such as one from our laboratory in which we found that EMPs prevent 
lipid-induced endothelial damage via Akt/eNOS signalling in vitro (146). Another 
study by Hussein et al. showed that EMPs regulate pro-apoptotic activity and cell 
detachment by encapsulating caspase-3 away from the endothelial cells, and that 
inhibiting EMP release pharmacologically lead to the accumulation of caspase-3 and 
ultimately cell detachment and cell death, thus demonstrating their role in increasing 
cell survival (147). Moreover, a different study by Perez-Casal et al. found that EMPs 
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participate in the regulation of the coagulation cascade by exposing endothelial 
protein C receptor on their surface thus acting as anticoagulant molecules (144), 
much to the contrary of the pro-thrombotic activity effects reported also by Hussein 
et al. just a year before (142). To simplify this, a schematic representation of the role 
of EMPs on endothelial cell function and its associated proteins is illustrated in 
Figure 8. 
 
Figure 8. Schematic representation of the functional role of EMPs and their 
associated proteins. EMPs carry molecular components involved in different 
endothelial cell functions such as tissue factor, VCAM-1, ICAM-1 and eNOS and 
therefore, they are associated with both damage and repair mechanisms. EMP: 
endothelial microparticle; VCAM-1: vascular cell adhesion molecule-1; ICAM-1: 
intercellular adhesion molecule-1; Sirt-1: silent mating type information regulation 2 
homolog 1; MMP-10: matrix metalloproteinase 10; MMP: matrix metalloproteinase; 
VE-Cadherin: vascular endothelial cadherin; CXCL1: chemokine (C-X-C motif) 
ligand 1; eNOS: endothelial nitric oxide synthase; NOX-4: Nicotinamide adenine 
dinucleotide phosphate oxidase 4. Adapted from Pieri et al. (148) 
 
The literature suggests that EMPs could act as a potential biomarker of disease 
stage and CVD risk, as well as a potential therapeutic tool (36) or a signalling 
mechanism. Of note, since they may provide valuable information of hard to access 
tissue, distinct EMP levels may be representative of the progression of CVD or 
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endothelial dysfunction (149); for example, a recent study in our laboratory found 
that EMPs are elevated in patients with unstable asymptomatic carotid artery 
plaques (145). EMPs are biological effectors of cardiovascular pathophysiology and 
may not only play a role as disease biomarkers, but also as promoters of endothelial 
dysfunction and inflammation. Therefore, it is necessary to gain further 
understanding of the whole process, including their role in disease and their 
mechanism of action. New knowledge would provide the necessary insight to allow 
research into developing novel therapies. 
 
1.2.5. The role of EMPs in vascular smooth muscle cell signalling 
Endothelial dysfunction in rheumatic autoimmune diseases such as SLE involves 
innate immune responses, including macrophages and dendritic cells and 
expression of scavenger and toll-like receptors for low density lipoprotein (LDL), as 
well as the activation of complement and dysregulation of adaptive immune 
responses (150). As it has been demonstrated (151), EMPs may have a pro-
inflammatory effect, thus they might lead to the production of cytokines that increase 
the expression of adhesion molecules. Adhesion molecules such as ICAM-1 and 
VCAM-1 when up-regulated, cause activation and adhesion of inflammatory 
circulating cells, which in turn triggers a response in the media layer, often resulting 
in the aberrant proliferation of smooth muscle cells (SMCs), which migrate to the 
intimal layer and in some cases cause the deposition of a fibrous matrix and 
thickening of the vessel wall, contributing to the formation of fibrous tissue and so 
leading to the development of CVD (152). 
Smooth muscle cells are capable to undergo phenotypic changes during 
development, both in vitro and in association with diseases. In diseases such as 
SLE, a dysregulation in the molecular signals regulating the differentiation of smooth 
muscle cells (SMCs) can occur, which leads to inappropriate differentiation into cells 
with features of other mesenchymal lineages such as osteoblasts or chondrocytes, 
a process known as vascular calcification (153). Vascular calcification is a relevant 
clinical problem in many conditions (including SLE among others) and it is 
considered to be an independent predictor of CVD (10). It is characterised by the 
loss of contractility by the SMCs and the expression of lower levels of contractile 
proteins (SMC-actin and SMC-myosin heavy chain) (154), and the formation of 
calcium deposits in the arteries, ultimately reducing elastic compliance and 
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therefore, inducing an impaired circulation activity. It is well established that vascular 
calcification is a cell-regulated process with many similarities to bone formation; i.e. 
human vascular smooth muscle cells (hVSMCs) express osteogenic-related 
proteins, ultimately leading to matrix mineralisation (155-157).  
It has been reported recently that microparticles are able to induce a senescent 
phenotype in endothelial cells (EC) (158). In that study, the authors demonstrated 
that MPs promoted EC senescence through nicotinamide adenine dinucleotide 
phosphatase oxidase and mitochondrial-derived reactive oxygen species. These 
findings form the basis for further studies involving different cell populations and 
pathobiologies. In a similar line, our study investigates the potential effects that EMP 
populations may exert in smooth muscle cells in an in vitro calcification model. 
It has been increasingly recognised that hVSMCs generate matrix vesicles that 
deposit in the vessel wall, where they act as a nucleation and vascular medial 
calcification niche (159). Very much like endothelial-derived MPs, these membrane-
bound vesicles carry proteins that are related to extracellular mineralisation, cellular 
stress and other proteins that regulate Ca2+ and phosphate trafficking. A study by 
Kapustin et al. demonstrated that elevated intracellular Ca2+ levels initiate the 
translocation of the cell membrane in hVSMCs, leading to the secretion of Ca2+ 
containing vesicles (160), suggesting that the generation mechanism of these 
vesicles is of similar nature to that of EMPs described in section 1.2.1.1, which 
makes us question whether EMPs are also playing an active role in the regulation 
of smooth muscle cell calcification. 
The mechanisms by which endothelial and smooth muscle cells communicate are 
diverse, and as reviewed by Straub et al., myoendothelial junctions (MEJs) play an 
active role in this (161). MEJs are cellular extensions from an endothelial cell (and 
from smooth muscle cells to a lesser extent), of approximately 0.5 µM in width and 
depth, that allow either direct or indirect contact between the endothelial and the 
smooth muscle cell layer by protruding through the internal elastic lamina. MEJs 
have been cited as possible key elements in the control of several vascular 
pathologies (162) and therefore, they may not only be able to facilitate the transport 
of different vascular factors released from endothelial cells to smooth muscle cells, 
such as calcium and potassium (163, 164), but also possibly EMPs (Figure 9). 
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Figure 9. MEJs allow the cross-talk between endothelial and smooth muscle 
cells. MEJs are recognised as facilitators of the intercellular communication 
between endothelial and vascular smooth muscle cells of several vascular factors, 
and possibly, EMPs. EMPs: endothelial microparticles; SMC: smooth muscle cells. 
Adapted from Gladwin et al. (165) 
 
1.2.5.1. Regulatory molecules involved in vascular calcification 
Vascular calcification is a regulated process with similarities to osteogenesis which 
has been extensively investigated during recent years and as such, a variety of 
osteogenic regulatory molecules have been identified contributing to this 
pathological process (157), and it is the imbalance between such molecules that 
leads to pathogenic vascular calcification. Osteocalcin (OCN), C-met and 
hepatocyte growth factor (HGF) among others have been identified as promoters 
(166) whereas osteoprotegerin (OPG) is known to be a regulator of the receptor 
activator of nuclear factor kappa-B (RANK) pathway, where it acts as a scavenger 
for receptor activator of nuclear factor kappa-B ligand (RANKL), a calcification 
initiator, thereby inhibiting calcification (167).  
Alterations to the expression of calcification promoters and inhibitors heavily 
influences the development of calcification (168, 169). For instance, the inhibition of 
the calcification inhibitors Matrix Gla Protein (MGP) (170) and Fetuin-A leads to soft 
tissue and intravascular calcification in mice (171), whereas Alkaline Phosphatase 
(ALP) has been shown to be up-regulated in human vessels as they calcify (172). 
Many studies have found that regulatory proteins involved in calcification are also 
present in the calcification sites, such as the transcription factor Cbfa1/Osf2, which 
regulates the expression of both OCN (a calcification promoter with mineral binding 
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capacity) (173) and osteopontin (OPN) (a calcification inhibitor) (174), therefore, an 
imbalance in Cbfa1/Osf2 could have a great impact in osteogenic differentiation 
(175).  
Bone morphogenetic protein 2 (BMP-2), another protein that has been shown to be 
implicated in the osteoblastic differentiation of mesenchymal progenitor cells by 
inducing Msx2 gene expression via Notch in vitro (176), and bone morphogenetic 
protein 4 (BMP-4), which is an active mediator in RANKL mediated-calcification and 
like Cbfa1/Osf2, have been found to be localised in calcified areas (177). 
Furthermore, inflammatory cytokines such as IL-8 or TNFα have also been shown 
to promote osteogenic differentiation (178), and may also participate in the 
generation of calcium-rich osteoblast/chondrocyte-derived MPs, which are known 
to act as nucleation sites for calcium phosphate crystal formation (157, 179).  
As part of this study, we investigated whether EMPs also play a role in the regulation 
of the calcification process. A summary of some of the mechanisms regulating 
vascular calcification can be found in Figure 10.  
 
 
 
Figure 10. Proposed schematic summary of the mechanisms regulating 
vascular calcification. The imbalance between calcification inhibitors and 
promoters is known to play an important role in the regulation of smooth muscle cell 
calcification. However, elevated Ca2+ and phosphate concentrations in the 
microenvironment are also known to be important effectors. In addition, 
inflammatory cytokines may promote the generation of osteoblast/chondrocyte-
derived Ca2+-rich MPs. MGP: matrix Gla protein; OPN: osteopontin; OPG: 
osteoprotegerin; IL-8: interleukin 8; TNFα: tumor necrosis factor alpha; OCN: 
osteocalcin; ALP: alkaline phosphatase; RANKL: receptor activator nuclear factor 
kappa B ligand; BMP-2: bone morphogenic protein 2; BMP-4: bone morphogenic 
protein 4; EMPs: endothelial microparticles; hVSMCs: human vascular smooth 
muscle cells. 
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As previously described, TNFα activates endothelial cells, elevating the expression 
of adhesion markers such as ICAM-1 or VCAM-1 leading to the secretion of 
inflammatory molecules which ultimately induces smooth muscle cell 
reprogramming and EMP release. As reviewed by Bruce et al. (180), EMP levels 
are found to be increased in autoimmune and vasculitis disease patients and 
therefore, it is possible that they play a role not only in endothelial dysfunction but 
also in vascular calcification. However, the mechanisms for the phenotypic 
reprogramming of VSMCs into osteoblast-like cells is still only partly understood and 
accumulating studies indicate that an imbalance between calcification promoters 
and inhibitors is the most relevant mechanism underlying vascular calcification 
(169), therefore, EMPs may play a significant role as signalling molecules. This 
study will investigate whether EMPs may play a role in the phenotypic switching of 
smooth muscle cells into osteoblast-like cells, contributing to vascular calcification. 
 
1.3. Remodelling the vasculature: inflammation and vascular calcification 
1.3.1. An in vitro model of inflammation  
In vitro models of inflammation are diverse, but provide valuable insight into 
mechanisms underpinning vascular inflammation, as they remove the complexity of 
interactive physiology associated with animal or patient studies. The culturing of 
endothelial cells from different vascular beds in combination with inflammatory 
stimuli (such as TNFα) has been used extensively to investigate the molecular 
mechanisms involved in the regulation of endothelial function and homeostasis. In 
this thesis, this model is used to investigate the effects of EMPs (and their proteomic 
and miRNA content) in endothelial cell function. 
The literature is extensive in reporting the effects of different inflammatory cytokines 
on endothelial function. For instance, when endothelial cells are cultured in the 
presence of TNFα, the pathways activated and in turn, its effects on endothelial cell 
function strongly depend on the concentration of TNFα used (181-183). It is known 
that lower concentrations of TNFα activate canonical pathways, such as the NFκB 
pathway described in section 1.2.1.2 which will lead to inflammation and the 
expression of adhesion molecules VCAM-1 and ICAM-1 (182, 184, 185). However, 
higher concentrations TNFα will lead to caspase-3 activation and ultimately cell 
apoptosis and death (186).  
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In this study, a concentration of 10 ng/mL of TNFα, which has been proven not to 
activate apoptotic pathways after 24 hours (21), was used on HUVECs to simulate 
an inflammatory environment, in combination with healthy and inflammatory-derived 
EMPs (uEMPs and sEMPs respectively) generated from HUVECs, in order to study 
their effects on endothelial function in disease (Figure 11). HUVECs were chosen 
to generate EMPs and to perform functional assays due to their well described 
culture conditions and ease of access. 
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Figure 11. Proposed in vitro model of inflammation. HUVECs were treated with uEMPs or sEMPs and with or without TNFα (10 ng/mL) to 
investigate their effects on EMP release, activation, migration, proliferation, and activation of NFκB. EMPs: endothelial microparticles; EC: 
endothelial cell; ICAM-1: intercellular adhesion molecule 1; VCAM-1: vascular cell adhesion molecules 1; NFκB: nuclear factor kappa B.
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1.3.2. An in vitro model of vascular calcification 
In vitro models of calcification have been used extensively and involve culturing 
vascular smooth muscle cells and their ability to deposit a mineralised matrix. In 
vitro calcification models provide an excellent tool to investigate the molecular 
mechanisms underlying osteogenic differentiation of smooth muscle cells (187, 
188). In this thesis, this model was used to investigate the effects of EMPs (and their 
proteomic and miRNA content) in vascular smooth muscle calcification. 
When cultured in the presence of βGP (β-glycerophosphate) and increased calcium 
levels (> 2.6 mM), vascular smooth muscle cells deposit a mineralised matrix (189). 
Such deposition is often accompanied by the loss of characteristic hVSMC markers, 
such as alpha smooth muscle actin (accompanied by the loss of contractility), the 
dysregulation of calcification inhibitors such as OPG, OPN or MGP, and the gain of 
osteogenic markers, such as ALP or OCN (190). In this thesis, human coronary 
artery smooth muscle cells (HCoASMCs) were obtained from Caltag, cultured in 
osteogenic media containing 5 mM βGP and 2.6 mM CaCl2+ for three weeks and 
treated with EMPs generated from human aortic endothelial cells stimulated with 
TNFα (AoEMPs) to study their effects on vascular calcification (Figure 12). 
HCoASMCs and AoEMPs were chosen for this study as the coronary artery and the 
aorta are two areas prone to calcify and reflect both macro and micro vessels (10), 
and their normal function is paramount in disease. 
As discussed in section 1.2.5. MEJs and potentially MMP activity in EMPs, together 
with increased membrane permeability in endothelial dysfunction, are mechanisms 
that could regulate the cross-talk between the endothelial cells and the smooth 
muscle cell layer. However, this study focused on understanding the effects of EMPs 
on smooth muscle calcification, thus the mechanisms involved in EMP-driven cross-
talk remain to be elucidated. 
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Figure 12. Proposed in vitro model of calcification. HCoASMCs were cultured in osteogenic media and treated with AoEMPs to investigate 
their effects on vascular smooth muscle cell calcification. TNFα: tumor necrosis factor alpha; EMPs: endothelial microparticles; SMC: smooth 
muscle cell.
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1.4. Hypothesis 
We hypothesise that EMPs have a dual role, depending on the stimuli involved in 
their release, potentially playing a role in vascular homeostasis, but also in 
exacerbating vascular damage under disease conditions and this can be executed 
via activating the endothelium, and also in the cross-talk to the smooth muscle layer, 
in terms of depositing a calcified matrix. The overarching aim of this study was to 
identify the role of EMPs in vascular disease using an in vitro endothelial and smooth 
muscle cell model. 
 
1.5. Aims and objectives 
 
1. Develop an in vitro model of SLE using human umbilical vein and aortic 
endothelial cells stimulated with TNFα for the isolation of EMPs from different 
vascular beds and study their protein and miRNA profile. In order to achieve this 
aim, the following objectives were addressed: 
 
 To identify the protein and microRNA content of two distinct EMP 
populations using a proteomic and microRNA screen.  
 To determine whether a correlation exists between protein content, 
function and morphology of EMPs. 
 
2. To establish the role of two distinct EMP populations generated from human 
umbilical vein endothelial cells under i) unstimulated (uEMPs) conditions, to 
reflect those generated in healthy subjects, and ii) TNFα-stimulated (sEMPs) 
conditions, reflecting the inflammatory milieu associated with SLE, in order to 
establish whether the content of EMPs effects their function on vascular cells. 
The following objectives were addressed: 
 
 To determine whether EMPs enhance EMP generation under different 
environmental conditions.  
 To elucidate the differences between untreated (healthy) and stimulated 
(disease) EMPs on endothelial cell function. 
 To establish the mechanism of action responsible for such effects.  
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3. To elucidate the effect on EMPs on the osteogenic differentiation of SMCs 
using a well-established in vitro SMC calcification model. In order to achieve 
this aim, the following objectives were addressed: 
 
 To determine whether AoEMP treatment of HCoASMCs enhances 
vascular calcification compared to untreated cells grown in osteogenic 
conditions. 
 To elucidate the content of AoEMPs (proteins, microRNAs and Ca2+) in 
order to identify relevant molecules and pathways involved in vascular 
calcification. 
 To identify novel molecular components of AoEMPs using a microRNA 
and proteomic analyses and their effects on osteogenic differentiation. 
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CHAPTER 2: MATERIALS AND METHODS 
The following sections describe the general methods and techniques used in the 
experimental design presented in this thesis. 
2.1. Mammalian cell culture 
All cells were grown in either 25 cm2, 75 cm2 flasks, 12 or 6-well plates (NuncTM, 
Thermo Scientific, Paisley, UK) and incubated at 37 ºC with 5 % CO2 (v/v). The 
media was replaced every 48 or 72 hours. All cell culture work was carried out in a 
class II safety cabinet and performed under sterile conditions.  
2.1.1. Maintenance of Human Umbilical Vein Endothelial Cells (HUVECs) 
HUVECs were obtained from Caltag Medsystems (Buckingham, UK) from pooled 
donors, seeded into 0.1 % (w/v) gelatin-coated flasks or plates, and cultured in M199 
medium (SLS, Nottingham, UK) supplemented with 20 µM L-Glutamine (Lonza, 
Verviers, Belgium), 10 µg/mL of Heparin (Sigma, Dorset, UK), 30 µg/mL Endothelial 
cell growth supplement (ECGS) and 20 % (v/v) heat inactivated Fetal Bovine Serum 
(FBS) from Gibco (Paisley, UK). HUVECs from passage 3 to 10 were used in 
experiments and were passaged at approximately 80 % confluency at 1:3. 
2.1.2. Maintenance of Human Aortic Endothelial Cells (HAoECs) 
HAoECs were sourced from Promocell (Heidelberg, Germany) from pooled donors 
and were cultured in endothelial cell growth medium MV2 (Promocell) supplemented 
with 25 % (v/v) heat inactivated FBS, 5 ng/mL epidermal growth factor, 10 ng/mL 
basic fibroblast growth factor, 20 ng/mL insulin-like growth factor, 0.5 ng/mL 
vascular endothelial growth factor 165, 1 μg/mL ascorbic acid and 0.2 μg/mL 
hydrocortisone according to the manufacturer’s instructions. HAoECs from passage 
3 to 10 were used in experiments and were passaged at approximately 80 % 
confluency at 1:3. 
2.1.3. Maintenance of Human Coronary Artery Smooth Muscle Cells 
(HCoASMCs) 
HCoASMCs were obtained from Caltag Medsystems and were cultured in smooth 
muscle media (Promocell), supplemented with 25 % (v/v) Fetal Calf Serum, 0.5 
ng/mL epidermal growth factor, 2 ng/mL basic fibroblast growth factor and 5 μg/mL 
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insulin). HCoASMCs from passage 3 to 6 were used in experiments and were 
passaged at approximately 90 % confluency at 1:2. 
2.1.4. Passaging cells 
Once cells had reached 80-90 % confluency, the media was removed and cells were 
washed twice with pre-warmed Phosphate Buffered Saline (PBS; Lonza) and 
incubated with pre-warmed trypsin-ethylenediaminetetra-acetic acid (EDTA) 
(Lonza; 3 mL per 75 cm2 flask) for 2 minutes at 37 ºC with 5 % CO2 (v/v). Trypsin 
was inhibited by adding twice the volume of complete media and centrifuged at 304 
x g for 5 minutes at room temperature. The supernatant was discarded and the cells 
were resuspended in warm complete media before plating evenly into 75 cm2 flasks 
as outlined above.  
2.1.5. Mammalian cell freezing and revival 
To cryopreserve cells from a 25 cm2 flask, cells were trypsinised as described 
(section 2.1.4), resuspended in 1 mL complete media containing 10 % (v/v) 
dimethylsulphoxide (DMSO) (Hybri-Max, Sigma) and transferred to 1.2 mL 
cryopreservation tubes. Cells were then placed in a Mr. Frosty (Thermo Scientific) 
freezing container at -80 ºC overnight prior to long-term storage in liquid nitrogen. 
 
2.2. Generation, isolation and quantification of endothelial microparticles 
in vitro 
Microparticles were generated from HUVECs and HAoECs in order to study the 
effects of distinct populations of EMPs on endothelial function and vascular 
calcification respectively.  
2.2.1. Generation of HUVEC-derived EMPs (uEMPs and sEMPs) 
HUVEC-derived EMPs were generated and used to study their effects on 
endothelial function and homeostasis. HUVECs were cultured in 75 cm2 flasks until 
they reached 90 % confluence. Cells were washed with PBS twice and treated with 
10 ng/mL TNFα (PromoCell) for 24 hours at 37 ºC with 5 % CO2 (v/v) to generate 
TNFα-stimulated EMPs (sEMPs). EMPs derived from unstimulated HUVECs 
(uEMPs) were isolated from conditioned media of healthy growing cells 24 hours 
after a media change. In both cases, conditioned media was collected and sEMPs 
and uEMPs isolated as described in section 2.2.3.  
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2.2.2. Generation of HAoEC-derived EMPs (AoEMPs) 
HAoEC-derived EMPs (Aortic-EMPs: AoEMPs) were generated using an 
established protocol from the Alexander laboratory (21) and used to study their 
effects on vascular calcification. HAoECs were cultured in 75 cm2 flasks until they 
reached 90 % confluence. Cells were washed with PBS three times and incubated 
in serum-free endothelial cell medium (supplemented with 5 ng/mL epidermal 
growth factor, 10 ng/mL basic fibroblast growth factor, 20 ng/mL insulin-like growth 
factor, 0.5 ng/mL vascular endothelial growth factor 165, 1 μg/mL ascorbic acid and 
0.2 μg/mL hydrocortisone) for 24 hours at 37 ºC with 5 % CO2 (v/v). Cells were then 
treated with 10 ng/mL TNFα for further 24 hours. Conditioned media was collected 
and AoEMPs isolated as described in section 2.2.3.  
2.2.3. Isolation of EMPs generated in vitro 
To isolate uEMPs, sEMPs and AoEMPs, conditioned media was collected and 
centrifuged at 4,300 x g for 5 minutes at room temperature in order to remove cell 
debris. MPs are present in the supernatant and as such, 90-95 % of supernatant 
was collected into sterile 50 mL falcon tubes and stored at -80 ºC before isolation 
using ultracentrifugation. For large volumes of conditioned media (>200 mL), an 
OptimaTM XE ultracentrifuge (Beckman Coulter, High Wycombe, UK) was used. 
Samples were transferred to 31 mL thick-walled polycarbonate ultracentrifugation 
tubes (Beckman Coulter) and centrifuged in a swing out SW32Ti rotor at 100,000 x 
g for 2 hours at 4 ºC. Pellets were carefully washed in PBS and centrifuged again 
under the same conditions. Finally, pellets were resuspended in 1 mL PBS and 
stored at -80 ºC for quantification.  
2.2.4. Quantification of EMPs generated in vitro  
EMP quantification was carried out by flow cytometry using a BD FACSVerse flow 
cytometer. EMP suspension (50 µL) was diluted in AnnexinV binding buffer (900 µL, 
Becton Dickinson, Oxford, UK). Flow-Count™ Fluorospheres (50 μL; Beckman 
Coulter) were added in order to assess absolute number of EMPs. Photomultiplier 
tube (PMT) voltages and microparticle gates were defined using the Megamix-Plus 
SSC size beads (Stago, Marseille, France) of 0.5 μm, 0.24 μm, 0.2 μm and 0.1 μm. 
Samples were labelled with AnnexinV-FITC (5 μL) mouse anti-human IgG1 (Becton 
Dickinson) and incubated on ice in the dark for 15 minutes. Flow cytometry analysis 
was performed by gating the counting fluorospheres on Forward scatter (FSC) vs 
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Side Scatter (SSC) (linear scale). An example of the gating strategy can be seen in 
Figure 13. Samples were acquired at low flow rate until 1000 counting beads were 
detected. AnnexinV-FITC-positive events were selected as microparticles. Absolute 
EMP numbers were calculated using the following equation: 
V =
Z
(X Y⁄ )
⁄
20
 
Where z = total volume of sample; x = total number beads added; y = number of 
beads counted; and 20 is the dilution factor. Once the volume of EMPs analysed is 
known, the total number of AnnexinV positive events is multiplied by (1000/v) to 
generate a number of EMPs/mL. 
 
Figure 13. Representative dot plots of the EMP gating strategy. Flow cytometry 
analysis was performed using a BD FACSVerse and samples were acquired at low 
flow rate. A) Photomultiplier voltages were optimised using the Megamix-Plus SSC 
sizing beads. B) AnnexinV+ events were gated and considered as MPs.  
 
After quantification, a known volume of EMPs suspension was centrifuged at 
100,000 x g for 2 hours at 4 ºC. After centrifugation, supernatant was discarded and 
EMP pellets were resuspended in a determined volume of PBS at a final 
concentration of 105 EMPs/µL of PBS. 
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2.3. RNA analysis 
2.3.1. RNA isolation 
All RNA work was carried out in a designated RNA workstation. Cells were lysed 
directly in flasks by adding 1 mL of TRIzol reagent (Invitrogen, Paisley, UK) per 10 
cm2 and scraped and stored in RNase-free tubes at -80 ºC until RNA isolation was 
performed.  
Cell lysates were defrosted and sonicated for 1 minute in a water bath sonicator to 
ensure complete cell lysis; tubes were cleaned after sonication using RNAse ZAP 
solution (Invitrogen) Chloroform (0.2 mL per mL of TRIzol) was added, shaken by 
hand for 15 seconds and incubated at room temperature for 3 minutes. Samples 
were then centrifuged at 12,000 x g for 15 minutes at 4 ºC and the upper clear 
aqueous phase (RNA containing fraction) was transferred to a fresh RNase free 
tube, carefully avoiding the DNA-containing interphase. 0.5 mL of 2-propanol per 
mL of TRIzol were added to precipitate the RNA at -20 ºC overnight. Samples were 
incubated at room temperature for 10 minutes and centrifuged at 12,000 x g for 10 
minutes at 4 ºC. The supernatant was discarded and the RNA pellet was washed 
with 1 mL of 75 % (v/v) ethanol, by vortexing briefly, and centrifuging at 7,500 x g 
for 5 minutes at 4 ºC. The ethanol was discarded and the pellet was left to air-dry 
for 15 minutes before resuspending in RNase-free water (15 μL). Samples were 
incubated at 55 ºC in the heat block for 10 minutes to allow the pellets to dissolve 
completely.  
RNA content and purity were quantified using a NanoDrop. If RNA purity was lower 
than 1.6 (A260/280 nm < 1.6), samples were DNase-treated as follows: 1 μg of total 
RNA was treated with 1 unit of DNAse I amplification grade (Invitrogen) in 1 μL of 1 
x DNase I Reaction Buffer in a total volume of 10 μl. Samples were incubated for 15 
minutes at room temperature. DNase I was inactivated by adding 1 μL of 25 mM 
EDTA and heated for 10 minutes at 65 ºC. RNA samples were then ready to reverse 
transcribe into complementary DNA (cDNA) 
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2.3.2. Reverse transcription  
Total RNA was reverse transcribed using the Tetra cDNA synthesis kit (Bioline, 
London, UK) in a PCR machine (Agilent Surecycle 8800). Typically, a master mix 
containing Oligo (dT)18, 10 mM deoxynucleotides (dNTP) mix, 5 x RT Buffer, 
RiboSafe RNase Inhibitor, Reverse Transcriptase (200 units/μL) and RNase free 
dH2O was prepared and used to reverse-transcribe 1 μg of RNA into cDNA in a final 
volume of 20 μL: samples were incubated at 45 ºC for 40 minutes and the reaction 
was terminated by incubation at 85 ºC for a further 5 minutes. The resulting cDNA 
was stored at -20 ºC until real-time PCR was performed. 
2.3.3. Quantitative real-time PCR (RT-qPCR) 
PCR reactions were set up as follows: 1 μL cDNA (50ng), 5 μL of SensiFAST™ 
SYBR® Lo-ROX Kit (Bioline), 0.4 μL of forward primer (10 μM), 0.4 μL of reverse 
primer (10 μM) and 3.2 μL of RNase-free water. RT-qPCR was performed using a 
Stratagene Mx3000P. All primers used in real time PCR were obtained from 
Invitrogen and are listed with the PCR parameters in Table 6. Transcripts were 
normalised to GAPDH and mRNA abundance was calculated using the 2-ΔΔCT 
method. 
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Primer Name Sequence (5’ -> 3’) Ta Product size (bp) 
GAPDH F 
GAPDH R 
GGAGCGAGATCCCTCCAAAAT 
GGCTGTTGTCATACTTCTCATGG 
56 197 
VCAM-1 F 
VCAM-1 R 
CAGGCTAAGTTACATATTGATGACAT 
GAGGAAGGGCTGACCAAGAC 
52 116 
ICAM-1 F 
ICAM-1 R 
CCTATGGAACGACTCCTTC 
TCTCCTGGCTCTGGTTCC 
52 110 
IκBα F 
IκBα R 
CTATTCTCCCTACCAGCTCAC 
CTCTCCTCATCCTCACTCTCT 
55 114 
CCL20 F 
CCL20 R 
GCAAGCAACTTTGACTGCT 
ATTTGCGCACACAGACAACT 
55 150 
OPG F 
OPG R 
CCTGGCACCAAAGTAAACGC 
GCACGCTGTTTTCACAGAG 
55 163 
OPN F 
OPN R 
GCCGAGGTGATAGTGTGGTT 
AACGGGGATGGCCTTGTATG 
55 149 
OCN F 
OCN F 
TGCTCCCTGCCTGCTAAGAC 
GGCAGCACAAACGCCAAAAG 
56 178 
C-met F 
C-met R 
GAAGTCCCAGCTACCAGTGTC 
CTGCCAGTAGACACCTGCTTC 
55 89 
PCR 
conditions: 
95 ºC for 10 minutes, then 40 cycles of: 95 ºC (denaturing step) for 30 
seconds, annealing temperature (Ta) for 30 seconds and 72 ºC for 30 
seconds (extension step). Finally, one additional cycle of 95 ºC for 1 
minute, Ta for 1 minute and 72 ºC for 1 minute. 
Table 6. DNA oligonucleotide primers for quantitative real-time PCR. Primers 
were obtained from Invitrogen and were reconstituted in nuclease-free water at a 
concentration of 100 μM and stored at -20 ºC. Working solutions were made as 
required by diluting the stock solution 1:10 in nuclease-free water (final working 
concentration 10 μM). F= forward primer. R = reverse primer.  
 
2.4. Protein analysis 
Protein extraction for the calcium deposition assay was carried out using RIPA 
buffer and quantified using the bicinchoninic acid (BCA) assay (see section 2.4.1). 
Protein extraction for western blotting analysis was performed using 
FractionPREP™ Cell Fractionation Kit (BioVision, Milpitas, US) and quantified using 
the Bradford assay.  
2.4.1. Protein extraction and quantification  
RIPA buffer was used to extract protein from HCoASMCs for calcium deposition 
assays, and from EMPs (uEMPs, sEMPs and AoEMPs) for proteomic quantification 
by Olink Bioscience (see section 2.4.1). Briefly, cells were washed twice in ice-cold 
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PBS, and 100 μL of RIPA buffer was added to the cells, which were thoroughly 
scraped off the cell culture dish and incubated on ice for 30 minutes, vortexing every 
5 minutes. Samples were then centrifuged at 20,000 x g for 10 minutes at 4 ºC and 
the supernatant was transferred to a fresh Eppendorf tube and stored at -20 ºC 
before quantification. RIPA extracted protein quantification was carried out using the 
BCA assay (Thermo Scientific). Albumin standards ranging from 0.05 mg/mL to 2 
mg/mL were prepared and 50 parts of reagent A were mixed with 1 part of reagent 
B in a Falcon tube. BCA reagent mix (200 μL) was added to each sample or standard 
(10 μL) and incubated for 30 minutes at 37 ºC. Absorbance was read at 562 nm 
using a Synergy HT plate (Biotek) reader and protein concentration determined 
using Gene5 Microplate Reader software, which generates a standard curve. 
Protein extraction using the FractionPREP™ Cell Fractionation Kit was carried out 
according to manufacturer’s instructions. Briefly, cells were trypsinised (as 
described in section 2.1.4) and washed in ice-cold PBS. Cell pellets were 
resuspended and incubated for 20 minutes in 400 μL of Cytosol Extraction Buffer-
Mix (containing Protease Inhibitor Cocktail and 0.1 M dithiothreitol (DTT)). Samples 
were then centrifuged at 700 x g for 10 minutes and the cytosol-containing 
supernatant was stored at -20 ºC. Pellets were resuspended in 400 μL of Membrane 
Extraction Buffer-A (containing Protease Inhibitor Cocktail and 0.1 M DTT); 22 μL 
Membrane Extraction Buffer-B was added and samples were incubated for 1 minute 
prior to centrifugation at 1,000 x g for 5 minutes. The membrane-containing 
supernatant fraction and the nuclear/cytoskeleton-containing pellets were stored in 
-20 ºC until quantification was carried out. Protein quantification of fractionated 
samples was carried out using the Bradford assay (Bio-Rad, Hertfordshire) as the 
protein extraction buffer used for fractionation was not compatible with the BCA 
method. Bovine serum albumin (BSA) standards ranging from 0.05 mg/mL to 0.5 
mg/mL were prepared. Briefly, dye reagent was prepared by diluting 1 part of Dye 
Reagent Concentrate with 4 parts deionised water and filtered through an 0.2 μM 
filter. 10 μL of each sample were used and 200 μL of diluted dye were added and 
incubated for 5 minutes at room temperature. Albumin ranging from 0.05 mg/mL to 
0.5 mg/mL were prepared and used as standards. Absorbance was read at 595 nm 
using a Synergy HT plate reader (Biotek) and standard curve and protein 
concentration determined using Gene5 Microplate Reader software. 
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10 KDa molecular weight cut-off protein concentration columns (Thermo Scientific) 
were used in those cases where protein concentration was low. Briefly, protein 
lysate was centrifuged at 15,000 x g in protein concentration columns for 15 
minutes. Concentrated protein was recovered and quantified again as described 
above. 
2.4.2. Western blotting (gel electrophoresis, transfer and protein 
detection) 
Proteins were separated by SDS polyacrylamide gel electrophoresis using the 
Thermo Fisher system with pre-made NuPAGE® Bis-Tris gels (4-12 % 
acrylamide/bisacrylamide). Protein samples (20 µg) were prepared by boiling 1 x 
NuPAGE LDS loading buffer (containing 250 mM DTT) for 5 minutes at 100 ºC. All 
samples were loaded onto the gel and electrophoresed in 1 x MOPS SDS Running 
Buffer (50 mM MOPS, 50 mM Tris Base, 0.1 % (w/v) SDS, 1 mM EDTA, pH 7.7) at 
200 V for 50 minutes or until the dye front hand reached the bottom of the gel. 
SeeBlue Plus2 Pre-Stained protein standard molecular weight markers (Thermo 
Fisher) were also loaded.  
Following gel electrophoresis, wet transfer was performed using the XCell II™ Blot 
Module. Blotting pads and filter papers were soaked in 1 x NuPAGE Transfer Buffer 
(containing 10 % (v/v) methanol); in the meantime, PVDF membranes (New 
England BioLabs, Hitchin, UK) were activated in methanol for 30 seconds, washed 
in dH2O and soaked in transfer buffer. The gels were gently removed from the 
cassettes and a transfer assembly was prepared by bringing together the blotting 
pads, filter paper, the PVDF activated membrane, the gel, filter paper and blotting 
paper (in that order). Protein transfer was performed at 30V for 1 hour.  
After transfer, membranes were blocked in PBST (0.5 % (v/v) Tween 20) containing 
4 % (w/v) skimmed milk powder (Marvel) for 1 hour at room temperature. Primary 
antibodies (Table 7) were prepared in blocking buffer and membranes were 
incubated overnight at 4 ºC on a rocking platform. Membranes where washed with 
PBST 4 times (5 minutes each) and incubated with the appropriate horseradish 
peroxidase (HRP)-conjugated secondary antibody for 1 hour at room temperature 
on a rocking platform. Following incubation, membranes were washed in PBST 5 
times over an hour prior to being developed in enhanced chemiluminescence (ECL) 
reagent. Pierce ECL Western-Blotting substrate mix (Thermo Fisher) was prepared 
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by mixing equal parts of reagents A and B and adding 1 mL of the substrate to each 
membrane. Membranes were incubated for 5 minutes with ECL prior to be analysed 
using the Chemidoc Touch system, with exposure times varying from 30 seconds 
to 3 minutes, depending on the antibody. 
Antibody Supplier Catalogue number Dilution used 
Rabbit anti-VCAM-1 Abcam ab134047 1:200 
Rabbit anti-ICAM-1 Abcam ab53013 1:200 
Rabbit anti-IκBα Santa Cruz sc-203 1:500 
Rabbit anti-NFκB Santa Cruz sc-372 1:500 
Mouse anti-α-tubulin Abcam ab7291 1:500 
Rabbit anti-Mouse-HRP Dako P0161 1:2000 
Goat anti-Rabbit-HRP Dako P0448 1:2000 
Table 7. Antibodies used for western blot analysis. Antibodies were stored at     
-20 or 4 ºC according to manufacturer’s instructions and diluted to the appropriate 
concentration in blocking solution before use. VCAM-1: vascular cell adhesion 
molecule 1; ICAM: intercellular adhesion molecule 1; IκBα: inhibitor-kB alpha; NFκB: 
nuclear factor kappa-B; HRP: horseradish peroxidase 
 
2.4.3. Densitometry 
Densitometry analysis of western blot images acquired with the Chemidoc Touch system 
was performed using ImageJ analysis package. Each of the bands in the blot was selected 
using the rectangular selection tool and histograms indicating the intensity of each of the 
bands were generated. A numerical value for densitometry was generated by calculating 
the area in each of the histograms.  
 
2.5. EMP content analysis 
uEMPs, sEMPs and AoEMPs were generated as described in sections 2.2.1 and 
2.2.2 and were subjected to proteomic and microRNA screening to characterise 
their molecular components. Protein and microRNA extraction and validation 
experiments were performed as described in the sections below. All EMP subsets 
were also analysed by Scanning Electron Microscopy to investigate phenotypical 
differences as detailed in section 2.6. 
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2.5.1. Proteomic analysis and Ca2+ content of in vitro generated EMPs 
For proteomic screening, 107 uEMPs, sEMPs and AoEMPs were centrifuged at 
100,000 x g for 2 hours at 4 ºC. The supernatant was removed and the EMP pellets 
were resuspended in 50 μL of RIPA buffer (containing Protease Inhibitor Cocktails) 
and protein content was quantified as described in section 2.4.1. Proteomic 
screening was performed by Olink Bioscience (Uppsala, Sweden) against set 
panels of 92 inflammatory and CVD associated proteins identified using Proseek® 
Multiplex technology (Figure 14). The subsequent downstream targets were then 
detected and quantitative analysis was carried out using standard RT-qPCR. 
Proseek Multiplex data are normalised for both intra- and inter-plate variation. In the 
final step of the data pre-processing procedure, the values are set relative to a fixed 
correction factor determined by Olink Bioscience. The generated normalised protein 
expression unit is on a log2 scale where a larger number represents a higher protein 
level in the sample, typically with the background level at around zero. 
 
Figure 14. Main steps involved in a Proseek assay. A) A pair of oligonucleotide-
labelled antibodies (Proseek probes) are allowed to bind to the target protein 
present in the sample by proximity. B) When the two probes are in close proximity, 
a new PCR target sequence is created by a proximity-dependent DNA 
polymerisation event. C) The resulting sequence is detected and quantified using 
standard real-time PCR. Adapted from Olink (191) 
 
Subcellular localisation analysis was carried out using fatiGo (Babelomics 5). 
Further target validation was performed using enzyme-linked immunosorbent assay 
(ELISA) and flow cytometry.  
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For determining Ca2+ in EMPs, 107 uEMPs, sEMPs and AoEMPs were incubated 
with 1 N HCL (50 μL) overnight to extract the calcium. Ca2+ was then measured as 
described in section 2.9.1.2 using a calcium deposition quantification kit. 
2.5.1.1. Validation of proteomic content by flow cytometry 
Flow cytometry was used to further validate the presence of CCL20 in uEMPs and 
sEMPs and its relative abundance in the two different subsets. 107 uEMPs and 107 
sEMPs were centrifuged at 100,000 x g for 2 hours at 4 ºC and incubated in 1 x 
Cytofix/Cytoperm buffer (100 μL, Becton Dickinson) for 30 minutes. Perm/Wash 
buffer was added (2 mL) and samples were centrifuged at 100,000 x g for 2 hours 
at 4 ºC. The supernatant was removed and samples incubated in the dark in 50 μL 
of 1 x Perm/Wash buffer containing CCL20-APC (5 μL, R&D systems, Abingdon, 
UK). After incubation, AnnexinV solution mix (containing 5 μL of AnnexinV, 50 μL of 
counting beads and 895 μL of 1x AnnexinV binding buffer) was added. Flow 
cytometry was performed using a BD FACSVerse using the gating strategy 
described in section 2.2.4. An IgG1 APC-conjugated Isotype Control was used to 
confirm specific staining. 
 
2.5.2. microRNA array analysis of EMPs generated in vitro 
107 uEMPs, sEMPs and AoEMPs were centrifuged at 100,000 x g for 2 hours at 4 
ºC and the pellets were washed in 1 mL of cold PBS and centrifuged for further 2 
hours under the same conditions. The supernatant was removed and TRIzol (1 mL) 
was added to extract the total RNA. 20 µg of molecular biology grade Glycogen was 
added to each sample to act as a carrier and increase the recovery of nucleic acids 
during RNA precipitation, mixed well and transferred to microfuge tubes. RNA was 
isolated as described in section 2.3.1. microRNA screening was performed by 
Ocean Ridge Biosciences (Florida, USA): microRNA was purified from total RNA by 
ultrafiltration and quantified by fluorometry and subjected to Ocean Ridge 
Biosciences proprietary microRNA microarray analysis. Validation of the identified 
microRNAs was carried out by RT-qPCR in our laboratory. 
2.5.2.1. Validation of microRNA analysis 
microRNA was extracted from 107 uEMPs, sEMPs and AoEMPs using the Isolate II 
miRNA kit from Bioline, according to manufacturer’s instructions, and quantified 
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using a Qubit BioAnalyzer (Thermo Scientific). cDNA amplification and RT-qPCR 
were carried out as described in sections 2.3.2 and 2.3.3. Primers for microRNA RT-
qPCR validation were designed using miRprimer2 software (Table 8) and obtained 
from Thermo Scientific. Bioinformatic analysis of validated microRNAs was 
performed to identify relevant pathways and targets using DIANA-miRPath and 
microRNA.org (TargetScan and miRBase). Target predictions with low mirSVR 
scores were considered as relevant and were pursued. 
Primer (hsa-miRNA) Sequence (5’ -> 3’) Ta Score 
1224-3p F 
1224-3p R 
CCCACCTCCTCTCTCCT 
GGTCCAGTTTTTTTTTTTTTTTCTGA 
53 0.72 
34a F 
34a R 
GCAGTGGCAGTGTCTTAG 
GGTCCAGTTTTTTTTTTTTTTTACAAC 
52 0.49 
608 F 
608 R 
GGGTGGTGTTGGGACA 
GTCCAGTTTTTTTTTTTTTTTACGGA 
53 0.64 
328 F 
328 R 
GCCCTCTCTGCCCTTC 
GGTCCAGTTTTTTTTTTTTTTTACG 
52 0.44 
1231 F 
1231 R 
TGTCTGGGCGGACAG 
GTCCAGTTTTTTTTTTTTTTTGCAG 
52 0.33 
532-3p F 
532-3p R 
GCCTCCCACACCCA 
GTTTTTTTTTTTTTTTGCAAGCCT 
52 0.33 
483-3p F 
483-3p R 
GCAGTCACTCCTCTCCTC 
GTCCAGTTTTTTTTTTTTTTTAAGACG 
52 0.34 
595 F 
595 R 
GAAGTGTGCCGTGGTG 
GGTCCAGTTTTTTTTTTTTTTTAGAC 
51 0.64 
129-5p F 
129-5p R 
CAGCTTTTTGCGGTCTG 
TCCAGTTTTTTTTTTTTTTTGCAAG 
51 0.24 
210-3p F 
210-3p R 
GCTGTGCGTGTGACA 
GTTTTTTTTTTTTTTTCAGCCGCT 
54 0.26 
574-3p F 
574-3p R 
ACGCTCATGCACACAC 
GTCCAGTTTTTTTTTTTTTTTGTGG 
52 0.29 
1225-3p F 
1225-3p R 
GTGAGCCCCTGTGC 
GGTCCAGTTTTTTTTTTTTTTTCTG 
52 0.42 
185-3p F GCAGTGGGCGTATCTGT 53 0.44 
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185-3p R GGTCCAGTTTTTTTTTTTTTTTAGCA 
551a F 
551a R 
GCGACCCACTCTTGGT 
GGTCCAGTTTTTTTTTTTTTTTGGAA 
53 0.49 
1538 F 
1538 R 
CGGGCTGCTGCTGT 
GGTCCAGTTTTTTTTTTTTTTTAGGA 
52 0.72 
423-3p F 
423-3p R 
GCAGAGCTCGGTCTGAG 
GGTCCAGTTTTTTTTTTTTTTTACTGA 
52 0.33 
423-5p F 
423-5p R 
CAGTGAGGGGCAGAGAG 
GGTCCAGTTTTTTTTTTTTTTTAAAGTC 
52 0.39 
3148 F 
3148 R 
CAGTGGAAAAAACTGGTGTGT 
GGTCCAGTTTTTTTTTTTTTTTAAGCA 
53 0.48 
let-7b-5p F 
let-7b-5p R 
CAGTGAGGTAGTAGGTTGTGT 
GGTCCAGTTTTTTTTTTTTTTTAACCA 
53 0.81 
let-7a-5p F 
let-7a-5p R 
GCAGTGAGGTAGTAGGTTG 
GGTCCAGTTTTTTTTTTTTTTTAACTATAC 
51 0.16 
221-3p F 
221-3p R 
GCAGAGCTACATTGTCTGCT 
CAGTTTTTTTTTTTTTTTGAAACCCA 
51 0.64 
125b-5p F 
125b-5p R 
GCAGTCCCTGAGACCCT 
CCAGTTTTTTTTTTTTTTTCACAAGT 
51 0.42 
149-3p F 
149-3p R 
AGGGACGGGGGCT 
GTCCAGTTTTTTTTTTTTTTTGCAC 
52 0.21 
222-3p F 
222-3p R 
GCAGAGCTACATCTGGCT 
CCAGTTTTTTTTTTTTTTTACCCAGT 
52 0.49 
PCR 
conditions: 
95 ºC for 10 minutes, then 40 cycles of: 95 ºC (denaturing step) for 30 
seconds, annealing temperature (Ta) for 30 seconds and 72 ºC for 30 
seconds (extension step). Finally, one additional cycle of 95 ºC for 1 
minute, Ta for 1 minute and 72 ºC for 1 minute. 
 
Table 8. DNA oligonucleotide primers for miRNA validation using quantitative 
real-time PCR. Primers were designed using miRprimer2 software and obtained 
from Invitrogen and were reconstituted in nuclease-free water at a concentration of 
100 μM and stored at -20 ºC. Working solutions were made as required by diluting 
the stock solution 1:10 in nuclease-free water (final working concentration 10 μM). 
A lower score means that primer pairs are less likely to form dimers. F= forward 
primer. R = reverse primer. 
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2.6. Scanning electron microscopy analysis of HUVECs and EMPs 
Square glass coverslips (22 mm x 22 mm) were coated with 0.1 % (w/v) gelatin 
overnight at 37 ºC and washed once in PBS. EMPs (106), unstimulated and TNFα-
stimulated HUVECs (105) were added to the centre of the cover slips, fixed with 2.5 
% (v/v) glutaraldehyde in 0.1 M PBS at 4 ºC for 15 minutes and washed twice with 
0.1 M PBS. Sequential steps using increasing concentrations of methanol were 
performed to dehydrate the sample (20 minutes each of 20 %, 40 %, 60 %, 80 % 
and 100 % (v/v) methanol in dH2O) and samples were left to air-dry overnight. 
Gelatin coated coverslips, without EMPs, were included as controls. Samples were 
gold-coated using a Polaron SC7640 sputter coater and Scanning Electron 
Microscopy was performed using a Zeiss Supra 40VP microscope.  
 
2.7. Specific protein analysis of EMPs using ELISA  
A Human MIP3a/CCL20 ELISA Kit (Abcam, Cambridge, UK) was used to further 
validate CCL20 content following extraction from uEMPs and sEMPs. A Human 
HGF Quantikine ELISA Kit (R&D, Abingdon, UK) was used to validate HGF content 
following extraction from the AoEMPs. 
2.7.1. MIP3a/CCL20 assay procedure 
For MIP3a/CCL20 ELISA, 107 uEMPs and 107 sEMPs were isolated by 
ultracentrifugation at 100,000 x g for 2 hours at 4 ºC and resuspended in 1 x cell 
extraction buffer PTR (50 μL, as supplied by the manufacturer) for protein extraction. 
For performing the ELISA, protein from uEMPs and sEMPs (50 μL) were added to 
the wells, as well as MIP3a/CCL20 standards ranging from 2,500 pg/mL to 39.06 
pg/mL and an antibody cocktail was added (50 μL per well). The plate was sealed 
and incubated for 1 hour at room temperature on a plate shaker (400 rpm). Sample 
wells were then washed 3 times with 1 x wash buffer PT prior to adding TMB 
substrate (100 μL) to each sample well. Samples were then incubated for 10 
minutes in the dark on a plate shaker (400 rpm). After incubation, stop solution (100 
μL) was added to each well and the plate was shaken for a further minute to allow 
complete mixing. Absorbance was measured at 450 nm using a Synergy HT plate 
reader (Biotek, Swindon, UK). 
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2.7.2. HGF Quantikine assay procedure 
For the HGF Quantikine ELISA, 107 AoEMPs were isolated by ultracentrifugation for 
2 hours at 100,000 x g at 4 ºC, resuspended in PBS at 4 ºC (50 μL), and sonicated 
for 15 minutes in a water bath sonicator for protein extraction. Assay diluent RD1W 
was added to each well (150 μL), prior to adding the samples (50 μL), as well as 
HGF standards ranging from 8,000 pg/mL to 125 pg/mL, and the plate was sealed 
and incubated for 2 hours at room temperature. After incubation, wells were washed 
four times with washing buffer (400 μL) and human HGF conjugate was added to 
each well (200 μL) and incubated for 1 hour and 45 minutes at room temperature. 
The plate was then washed four times with washing buffer (400 μL) and substrate 
solution (200 μL) was added to each well and incubated for 30 minutes at room 
temperature protected from light. After incubation, stop solution (50 μL) was added 
to each well and the plate was shaken for a further minute to allow complete mixing. 
Absorbance was measured at 450 nm as described above. 
 
2.8. HUVEC treatment with EMPs as an in vitro model of inflammation 
In order to investigate the effects of inflammation-derived microparticles (sEMPs) 
and to understand the effects of the microenvironment on EMP generation and role 
in endothelial function, a second set of healthy-derived microparticles (uEMPs) was 
used. HUVECs from passages 3 to 8 were seeded into 25 cm2 flasks (Thermo 
Scientific) for EMP release experiments and protein assays, or into 6-well plates for 
RT-qPCR or wound healing, at a density of 5 x 103 cells/cm2.  
Cells were treated with uEMPs or sEMPs at a concentration of 106 EMPs/mL and in 
the presence or absence of TNFα (to simulate an inflammatory environment) (10 
ng/mL) for 6 hours for the scratch assays, and for 24 hours for EMP generation 
experiments, RT-qPCR and western blotting. 
2.8.1. Quantification of EMPs released in vitro  
HUVECs were cultured on gelatin-coated 25 cm2 flasks until confluent and treated 
with either uEMPs or sEMPs for 24 hours. Conditioned media was collected and 
centrifuged at 4,300 x g for 5 minutes at room temperature and 90-95 % of 
supernatant was ultracentrifuged at 100,000 x g for 2 hours at 4 ºC using a Beckman 
Coulter ultracentrifuge. EMP-containing pellets were resuspended in PBS (50 μL) 
68 
 
and EMP quantification was carried out using flow cytometry (AnnexinV+ events) as 
described in section 2.2.4. 
 
2.8.2. Functional analysis of EMPs on endothelial cells 
2.8.2.1. Wound healing (scratch assays)  
HUVECs were seeded on gelatin-coated 6-well plates and cultured to confluence in 
M199 complete media for 24 hours. A straight scratch was made across the centre 
of the cell monolayer in each well using a sterile 200 μL pipette tip, followed by 
treatment with 106 uEMPs or sEMPs per mL (in the presence or absence of 10 
ng/mL of TNFα) for 6 hours. Phase contrast imaging was performed with a 10 x 
objective lens (Zeiss) at 6 hours. Cell migration was determined using ImageJ and 
calculated as percentage of initial cell-free areas vs percentage of cell-free areas 
after treatment.  
2.8.2.2. Endothelial cell proliferation assays 
In parallel with the functional scratch assays, the level of cell proliferation was 
determined using a cell proliferation kit (Abcam) according to manufacturer’s 
instructions. Briefly, HUVECs were cultured sub-confluently (2.5 x 103 cells/cm2) in 
96-well plates in 100 µL/well of complete M199 media in the presence or absence 
of TNFα (10 ng/mL), and treated with uEMPs and sEMPs for 6 hours. WST-1 
reagent and Electro Coupling Solution (10 mL) was added per well and cells were 
incubated for further 30 minutes. To ensure homogenous color distribution, the plate 
was shaken for a minute and the absorbance was read at 420 nm. 
2.8.2.3. Adhesion assays (RT-qPCR and western blot) 
Inflammation is linked with an increase in the endothelial cell adhesion markers 
VCAM-1 and ICAM-1. Western blot and RT-qPCR were performed to investigate 
the effects of both uEMP and sEMPs on adhesion markers at a proteomic and RNA 
level respectively. HUVECs were seeded on gelatin coated 6-well plates (for RT-
qPCR) or 25 cm2 flasks (for western blot analysis) and treated with uEMPs or sEMPs 
(106 per mL) for 24 hours in the presence or absence of TNFα (10 ng/mL; positive 
control). Cells were then collected in TRIzol as described in section 2.3.1 for RT-
qPCR analysis of VCAM-1 and ICAM-1 mRNA expression, or in FractionPREP™ 
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Cell Fractionation buffer as described in section 2.4.1 for western blot analysis of 
VCAM-1 and ICAM-1 protein quantification. 
2.8.2.4. Immunofluorescence of NFκB 
HUVECs were cultured subconfluently in µ-Slides VI 0.4 ibiTreat (Ibidi, Glasgow, 
UK) and left overnight. The M199 complete media was replaced 24 hours later with 
low serum M199 media (1 % (v/v) FBS, no heparin and no ECGS) and left to 
equilibrate for a further 24 hours. uEMP or sEMP treatments were performed for 30 
minutes and 16 hours, using 10 ng/mL TNFα as a positive control. After treatment, 
culture media was removed and cells washed twice with PBS. Samples were fixed 
with 4 % (v/v) paraformaldehyde(PFA)/PBS for 15 minutes at room temperature and 
washed twice with PBS prior to incubation for one hour in blocking buffer (5 % (v/v) 
goat serum/0.1 % (v/v) Triton X-100/ PBS). Samples were then incubated overnight 
with primary antibody (rabbit anti-human anti-NFκB diluted 1/500 in blocking buffer; 
Santa Cruz, Heidelberg, Germany) at 4 ºC. Samples were washed with PBS 4 times 
(5 minutes per wash) and secondary antibody Alexa 488-labelled goat anti-rabbit 
IgG (1/500 in blocking buffer) was added for one hour at room temperature in the 
dark. Finally, samples were washed quickly in PBS 4 times, mounted in prolong gold 
antifade mountant (containing diamidino-2-phenylindole (DAPI); Vector 
Laboratories, Peterborough, UK) and left to set overnight in dark at 4 ºC. Slides were 
analysed using a Leica DMI6000B fluorescent microscope; 10 x and 20 x images 
were taken. 
 
2.9. In vitro model of calcification  
HCoASMCs were seeded in 6-well plates at a density of 1.5 x 104 cells/cm2 and 
cultured in osteoinductive media (DMEM 10 % (v/v) FBS, 1 % (v/v) L-Glutamine, 1 
% (v/v) Penicillin-Streptomycin, 5 mM βGP (β-glycerophosphate) and 2.6 mM 
CaCl2+) for up to 21 days and treated with 106 AoEMPs per mL. Alizarin red S, 
calcium deposition, Bioplex analysis, ELISA and transfection experiments were 
performed. All experiments were performed in triplicate and the media was removed 
(and stored at -80 ºC for secretome analysis, where appropriate) every 72 hours 
and fresh media added. 
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2.9.1. Quantification of smooth muscle cell osteogenic differentiation 
2.9.1.1.  Alizarin red S staining 
Alizarin red S was used to assess the level of calcification in AoEMP-treated SMCs; 
the staining produces a red-orange staining of calcium deposits observed by eye 
under the microscope and can be quantified colorimetrically. After 21 days of 
treatment with AoEMPs in osteoinductive conditions, the media was discarded and 
cells were washed three times with room temperature PBS. Cells were then fixed in 
4 % (v/v) PFA for 10 minutes at room temperature and washed with PBS. Cells were 
stained with 500 mL of 2 % (w/v) Alizarin red S pH 4.2 (Sigma) for 5 minutes on a 
rocking platform. Excess dye was removed and the cells were washed 5 times with 
distilled water over a period of an hour, prior to observation under a microscope. 
Alizarin red S dye was then eluted to allow quantification of the staining: 10 % (v/v) 
formic acid (800 μL) was added to each well and the plate was incubated at room 
temperature for 5 min with shaking. 200 μL of elution was transferred per triplicate 
to a flat bottom 96 well plate and absorbance was measured at 414 nm using a 
Synergy HT plate reader (Biotek). 
2.9.1.2. Calcium deposition assays 
Calcium deposition was measured using a colorimetric Ca2+ detection kit (Abcam). 
Media was discarded and cells were washed three times with PBS. Cells were 
incubated in 800 μL of 0.6 N HCL overnight at 37 ºC and 5 % CO2 (v/v) to extract 
the calcium. 50 μL of Calcium-containing HCL samples were incubated for 5 minutes 
at room temperature with 90 μL of the chromogenic reagent and 60 μL of calcium 
assay buffer and protected from light. Calcium standards ranging from 2 μg/well to 
0.4 μg/well were prepared, and calcium content was quantified by measuring 
absorbance at 575 nm using a Synergic HT plate reader (Biotek). 
Finally, Calcium content was normalised to total protein content, which was 
extracted from every sample using RIPA buffer and measured using the BCA assay 
and BSA as the control standard protein (see section 2.4.1). 
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2.9.2. AoEMPs internalisation by HCoASMCs 
Calcein-AM (Thermo Fisher) was used to stain AoEMPs in order to investigate their 
uptake by target HCoASMCs. 106 AoEMPs were pelleted by ultracentrifugation for 
2 hours at 100,000 x g at 4 ºC and incubated with 10 µM Calcein-AM for 30 minutes 
at 37 ºC in the dark. After incubation, AoEMPs were washed by adding PBS and 
concentrated by ultracentrifugation as outlined above. The supernatant was 
removed and Calcein-AM-labelled AoEMPs were resuspended in osteogenic media 
and added to the HCoASMCs. A control with Calcein-AM in the absence of AoEMPs 
was used to identify baseline and background fluorescence. Pictures were taken 
after 3, 6 and 24 hours using a Leica DMI6000B fluorescent microscope and uptake 
was quantified in ImageJ.  
 
2.10. Bioplex suspension array analysis 
Bioplex technology (also named Multiplex) is based on immunoassay and 
fluorescent principles, allowing the detection of multiple analytes in a single sample 
using a mixture of antibody-conjugated fluorescent beads. Bioplex human 
angiogenesis/growth factor and bone-panel kits were obtained from Merck Millipore 
(Watford, UK; Table 9) and were used to analyse the content of EMPs and the 
secretome of AoEMP-treated HCoASMCs using a Luminex LX100/LX200.  
2.10.1. Sample preparation 
For analysing EMP content, protein was extracted by sonicating 107 uEMPs and 107 
sEMPs for 15 minutes in a water bath sonicator and used in the Bioplex on the same 
day. For analysing the secretome of HCoASMCs, conditioned media from AoEMP-
treated cells was collected twice a week and centrifuged at 4,300 x g for 10 minutes 
to remove cell debris, and supernatant was stored at -80 ºC until the assays were 
conducted. 
2.10.2. Assay protocol 
All reagents were brought to room temperature. Antibody-immobilised beads were 
prepared in bead diluent buffer, sonicated and vigorously vortexed; quality controls 
and protein standards were reconstituted in 250 μL of deionised water. 200 μL of 
assay buffer were added intro each well of the microtiter plates and incubated for 
10 minutes at room temperature on a plate shaker. Assay buffer was discarded and 
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25 μL was added again to every well on the plate. Standards and quality controls 
were added to the corresponding wells (25 μL) and topped up to a 50 μL with PBS 
(25 μL). Samples (25 μL) were added into the appropriate wells, and topped up with 
assay buffer (25 μL) to a final volume of 50 μL. Antibody-binding beads were 
vortexed and added to each well (25 μL); plates were sealed and incubated 
overnight on a plate shaker at 4 ºC. Following incubation, plates were washed 3 
times using an automated plate washer (Biotek), detection antibodies (50 μL) were 
added into each well and plates were incubated on a plate shaker for 1 hour at room 
temperature. Streptavidin-Phycoerythrin substrate (50 μL) was added to each well 
and incubated for further 30 minutes at room temperature on a shaker. Plates were 
washed 3 times using the automate plate washer and sheath fluid (provided with the 
kits) was added (100 μL) and samples were incubated for 5 minutes on a plate 
shaker prior to being analysed in the Luminex. 
 Protein Minimum 
concentration 
detected (pg/mL) 
Maximum 
concentration 
detected (pg/mL) 
Angiogenesis/Growth 
factor panel kit 
Angiopoietin-2, 
FGF-1, 
FGF-2, 
VEGF-A 
13.7 10,000 
Endoglin 27.4 20,000 
Endothelin-1 2.7 2,000 
IL-8 1.4 1,000 
VEGF-C 6.9 5,000 
Bone panel kit OPG 7 30,000 
OC 146 600,000 
OPN 98 400,000 
SOST 24 100,000 
IL-6 1 6,000 
TNFα 0.24 1,000 
Table 9. Characteristics of the bioplex kits used in the study. The 
angiogenesis/growth factor kit was used to identify proteins in uEMP and sEMP 
lysates. The bone panel kit was used to investigate the secretome of AoEMP-treated 
HCoASMCs. Maximum and minimum detection limits for the kits are described in 
the table. FGF-1: fibroblast growth factor-1; FGF-2: fibroblast growth factor-2; 
VEGF-A: vascular endothelial growth factor-A; IL-8: interleukin-8; VEGF-C: vascular 
endothelial growth Factor-C; OPG: osteoprotegerin; OC: osteocalcin; OPN: 
osteopontin; SOST: sclerostin; IL-6: interleukin-6; TNFα: tumor necrosis factor-α. 
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2.11. miRNA analysis using transfection of human vascular cells 
2.11.1. hsa-miRNA-129-5p and hsa-miRNA-3148 plasmids 
pEZX-MR04 plasmids, containing either hsa-miRNA-129-5p or hsa-miRNA-3148 or 
a scrambled control with a CMV promoter and carrying ampicillin and Puromycin 
resistant genes, as well as eGFP as a reporter gene, were purchased from 
GeneCopoeia (Figure 15) as bacterial glycerol stocks. A bacterial stab of the 
plasmids was grown in 100 mL of LB culture medium containing ampicillin and 
incubated overnight at 37 ºC with agitation. A scrambled control clone was also 
obtained from the same company. 
Figure 15. Schematic representation of pEZX-ME04. Puromycin resistant 
plasmids with an eGFP reporter gene were obtained from GeneCopoeia for hsa-
miRNA-3148, hsa-miRNA-129-5p and a scrambled control. 
 
2.11.2. Midi-preparation of plasmid DNA 
The plasmid DNA was purified using the PureLink HiPure Plasmid Filter Midiprep 
Kit (Thermo Scientific). Briefly, cells were pelleted by centrifugation at 4,000 x g for 
10 minutes and resuspended in Resuspension buffer R3 (10 mL), prior to the 
addition of Lysis buffer L7, mixed gently by inversion and incubated for 5 minutes at 
room temperature. Precipitation buffer N3 (10 mL) was added and mixed by 
inversion before centrifugation at 12,000 x g for 10 minutes at room temperature. 
The supernatant was loaded onto a pre-equilibrated column and the solution was 
allowed to drain by gravity. The column was washed twice with Wash buffer W8 (10 
mL each wash) and the flow through was discarded. The plasmid DNA was eluted 
in Elution buffer E4 (5 mL) into fresh Falcon tubes. Isopropanol (3.5 mL) was added, 
followed by centrifugation at 12,000 x g for 30 minutes at 4 ºC. The supernatant was 
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discarded and the pellet was washed using 70 % (v/v) ethanol (3 mL), followed by 
centrifugation at 12,000 x g for 5 minutes at 4 ºC. The supernatant was discarded 
and the plasmid-containing pellet was allowed to air-dry for 10 minutes before 
resuspending in TE buffer (200 µL), sterile filtered and stored at -80 ºC. DNA 
concentration and quality (A260/280 ratio) was determined using a NanoDrop. 
2.11.3. Plasmid transfection (AMAXA)  
Plasmid DNA transfection was performed in a Nucleofector 2b device using Amaxa 
Nucleofector® technology (Lonza), where specific suspension buffers are used for 
each cell type being transfected. The solution and program used in this study was 
optimised for HUVEC and HCoASMC transfection using electroporation principles, 
in which an electrical field being applied to the cells increases the permeability of 
the cell membrane, allowing cells which are normally resistant to the uptake of DNA, 
to be successfully and efficiently transfected with the recombinant miRNA plasmids.  
Bioinformatic analysis of uEMPs and sEMPs content allowed the prediction of hsa-
miRNA-129-5p which targets CCL20 mRNA, therefore, transfection experiments 
were performed to validate this observation. For transfection of HUVECs, a 12-well 
plate was prepared by filling two wells with 750 μL of complete M199 media 
(supplemented with Heparin and ECGS as detailed in section 2.1.1) and pre-
incubated/equilibrated in a 37 °C and 5 % CO2 (v/v) incubator. Cells were then 
trypsinised as described in section 2.1.4 and counted using a Neubauer chamber. 
5 x 105 cells were centrifuged at 200 x g for minutes at room temperature, 
resuspended in room temperature Nucleofector Solution (100 μL), and combined 
with 5 μg of hsa-miRNA-129-5p plasmid. For transfection control, 5 x 105 cells were 
also centrifuged, resuspended in Nucleofector Solution, and combined with 2 μg 
pmaxGFP vector. HUVEC/plasmid suspension was then transferred to an Amaxa 
cuvette and electroporation was performed using program A-034 in the Nucleofector 
2b device. Pre-incubated/equilibrated M199 complete media (500 μL) was then 
added to the cuvette and transfected cells were gently transferred and distributed 
into the two pre-equilibrated wells in the 12-well plate (avoiding repeated aspiration 
of the sample) and incubated overnight in the incubator at 37 °C and 5 % (v/v) CO2. 
24 hours after transfection, efficiency was measured by fluorescence microscopy of 
the FITC channel, and an efficiency of 70 % was considered successful. pmaxGFP 
transfected cells were used as transfection controls. Media was replaced with M199 
media (supplemented with 0.25 μg/mL of Puromycin) for positive selection of 
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transfected cells (Puromycin resistant), and was replaced every 24 hours for 3 days. 
Cells were washed twice in PBS and treated with TNFα (10 ng/mL) in serum free 
M199 media for 24 hours to stimulate CCL20 transcription (192). RNA was then 
collected in TRIzol and CCL20 mRNA levels were assayed by RT-qPCR as 
described in section 2.3. 
Bioinformatic analysis of AoEMPs miRNA content predicted hsa-miRNA-3148 
targets OPG mRNA, therefore, transfection experiments were performed to validate 
this observation. For transfecting HCoASMCs, a 6-well plate was prepared by filling 
3 wells with HCoASMC complete media (1 mL each) and pre-incubated/equilibrated 
in a 37 °C and 5 % CO2 (v/v) incubator. Cells were then trypsinised as described in 
section 2.1.4 and counted using a Neubauer chamber. 1 x 106 cells were centrifuged 
at 100 x g for minutes at room temperature, resuspended in room temperature 
Nucleofector Solution (100 μL), and combined with 5 μg of hsa-miRNA-3148 
plasmid. For transfection control, 1 x 106 cells were also centrifuged, resuspended 
in Nucleofector Solution, and combined with 2 μg pmaxGFP vector. 
HCoASMC/plasmid suspension was then transferred to an Amaxa cuvette and 
electroporation was performed using program A-033 in the Nucleofector 2b device. 
Pre-equilibrated HCoASMCs complete media (500 μL) was then added to the 
cuvette and transfected cells were gently transferred and distributed into the three 
pre-equilibrated wells in the 6-well plate (avoiding repeated aspiration of the sample) 
and incubated overnight in the incubator at 37°C and 5 % CO2 (v/v). 24 hours after 
transfection, efficiency was measured by fluorescence microscopy of the FITC 
channel, and an efficiency of 70 % was considered successful. pmaxGFP 
transfected cells were used as transfection controls. Media was replaced with 
HCoASMC media (supplemented with 0.25 μg/mL of Puromycin) for positive 
selection of transfected cells (Puromycin resistant), and was replaced every 24 
hours for 3 days; cells were then washed twice in PBS and cultured in osteogenic 
media and collected in TRIzol after 4 days for RT-qPCR of OPG or left in osteogenic 
media for 21 days in order to perform Alizarin Red S staining (as described in section 
2.9.1.1). Fluorescence microscopy was used at 4, 7, 14 and 21 days to confirm 
sustained plasmid expression. In addition to OPG, OPN, OCN and C-met were also 
investigated due to their role as either inhibitors or promoters in the vascular 
calcification process. 
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A dose-response experiment with HUVECs and HCoASMCs to determine the 
optimal concentration of Puromycin for positive selection of transfected cells was 
performed. HUVECs and HCoASMCs were seeded on 12-well plates and 6-well 
plates respectively, and treated with Puromycin concentrations ranging from 0.1 
µg/mL to 2 µg/mL for 72 hours in M199 or HCoASMC media. Cells were observed 
every day and cell death was assessed visually; fluorescence microscopy was used 
to confirm that surviving cells were GFP+. A summary of the workflow in this section 
is presented in Figure 16. 
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Figure 16. Experimental timeline for HUVEC and HCoASMC transfection. Cells were transfected using AMAXA kits from Lonza and selected 
in Puromycin for 3 days as described above. After Puromycin selection, cells were cultured either in Puromycin-free M199 osteogenic media for 
the experiments. 
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2.12. Statistical analysis 
Data obtained from the experiments described in this thesis are representative of at 
least 3 independent experiments using cells from three different populations of cells 
representing biological triplicates as well as technical triplicates. Statistical analysis 
was carried out using GraphPad Prism 6 software and data are expressed as ± 
standard error mean (± SEM). Differences between groups were analysed with a 
Student's t test or one-way ANOVA (with Tukey correction for multiple comparisons) 
as appropriate. P values < 0.05 were considered significant unless stated otherwise.  
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CHAPTER 3: THE EFFECT OF EMPS ON ENDOTHELIAL CELL FUNCTION  
 
3.1. EMPs – agents of damage and protection 
SLE and other connective tissue diseases are characterised by increased 
inflammation and in turn, these inflammatory disorders are also associated with 
endothelial dysfunction, leading to an increased risk of CVD. Previous work from the 
Alexander group have shown that circulating levels of EMPs are increased in 
different disease conditions (33), however, whether EMPs act either to exacerbate 
the damage in the vessel wall or as a protective factor to enhance repair of the 
endothelial layer remains to be established and is one of the aims of this programme 
of work. 
 
The aim of the experiments presented in this chapter was to study the protein and 
miRNA profile of two distinct EMP populations generated from human umbilical vein 
endothelial cells under i) unstimulated (uEMPs) conditions, to reflect those 
generated in healthy subjects, and ii) TNFα-stimulated (sEMPs) conditions, 
reflecting the inflammatory milieu associated with SLE, in order to establish whether 
content of EMPs effects their function on vascular cells. In order to achieve this aim, 
the following 5 objectives were addressed:  
 
1. To identify the protein and microRNA content of two distinct EMP 
populations, uEMPs and sEMPs, using a proteomic and microRNA screen 
and validation of specific proteins and miRNAs, using flow cytometry, bioplex 
suspension arrays and RT-PCR analysis.  
2. To determine whether a correlation exists between protein content, function 
and morphology of EMPs, using scanning electron microscopy. 
3. To determine whether EMPs enhance EMP generation under different 
environmental conditions using flow cytometry for quantification.  
4. To elucidate the differences between untreated (healthy) and stimulated 
(disease) EMPs on endothelial cell function focusing on migration, 
proliferation and adhesion.  
5. To establish the mechanism of action responsible for such effects using 
fluorescence microscopy and western blot.  
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3.2.  Results 
 
3.2.1. uEMPs and sEMPs as models of health and disease 
TNFα, a known inflammatory stimulus, and one of which is raised in SLE, was used 
in this study to stimulate the release of MPs from HUVECs in order to investigate 
their function under inflammatory conditions compared to EMPs generated from 
untreated cells in standard physiological conditions. For the purposes of this study 
the 2 groups of EMPs generated from TNFα-stimulated and untreated HUVECs will 
be referred to as sEMPs and uEMPs respectively. Given that it is recognised that 
different stimuli and vascular beds lead to generation of distinct EMPs, we 
investigated the differences in the contents and roles of uEMPs and sEMPs, as well 
as their effects on endothelial function and the pathways associated with these 
effects. 
3.2.1.1. sEMPs and uEMPs are phenotypically similar 
Scanning Electron Microscopy (SEM) analysis was performed on unstimulated and 
TNFα-stimulated HUVECs. There appeared to be elevated EMP release in TNFα-
treated cells compared to untreated cells (Figure 17), which was investigated further 
by flow cytometric analysis and quantification of these findings are presented in 
section 3.2.3.  
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Figure 17. Representative Scanning Electron Microscopy micrographs of 
HUVECs releasing EMPs. A) Unstimulated HUVECs and B) TNFα-treated cells 
were grown on 0.1 % (w/v) gelatin coated cover slides and subjected to SEM 
analysis to observe EMP release. Black arrows indicate formation of EMPs. n = 3 
independent experiments. HUVECs: human umbilical vein endothelial cells; TNFα: 
tumor necrosis factor alpha. 
 
As shown in Figure 17A, unstimulated cells also release EMPs and therefore, SEM 
was performed to examine preparations of uEMPs and sEMPs as described in 
section 2.6 (Figure 18A and 18B). In all preparations, particles ranging from 200 nm 
to 1 µm were found. However, uEMPs appear to be slightly smaller than sEMPs (~ 
200 nm), as well as more rounded. Since it is likely that the phenotypical differences 
observed between the two EMP populations was due to differences in their content, 
a proteomic and a microRNA analysis of the two EMP populations was performed.  
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Figure 18. Phenotypic differences in uEMPs and sEMPs. Representative 
Scanning Electron Microscopy micrographs of uEMP (A) and sEMP (B) 
preparations. Particles ranging from 200 nm to 1 µm (± 400 nm SEM) were found in 
all preparations. Black arrows indicate the presence of EMPs. n = 3 (different uEMPs 
and sEMPs preparations). 
 
3.2.1.2. uEMPs and sEMPs carry molecular components involved in 
endothelial function and inflammation 
Since SLE is an inflammatory disorder associated with endothelial damage, it was 
of interest to establish whether any endothelial repair processes may be activated. 
A proteomic screen of inflammatory and proteins associated with CVD, a multiplex 
array of angiogenic/growth factor molecules were performed on concentrated 
preparations of EMPs. For the proteomic screen, proteins were extracted from the 
same number of uEMPs and sEMPs as detailed in section 2.5.1 in Methods and 
proteomic analysis performed by Olink Bioscience using Proseek technology as 
described in Figure 14 (n = 2 using different EMP batches). Out of the 92 
cardiovascular and inflammatory proteins screened, 21 were found in both uEMPs 
and sEMPs, and only those in which SD < 3 between replicates were considered for 
further analysis (Figure 19). Proteomic screening demonstrated that uEMPs and 
sEMPs carry the same proteins, albeit in different concentrations, strengthening the 
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finding of others that the microenvironment during EMP generation underpins their 
proteomic content (193). Proteins identified in both uEMPs and sEMPs include the 
CXC chemokines; CXCL10, CXCL5 and CXCL6, as well as CC chemokines; MCP-
1 and MCP-3 (Figure 19), albeit in increased concentration in sEMPs. Inflammatory 
cytokines TNFα, VEGF-A and IL-8 were also found in relatively similar levels, but a 
trend towards higher abundance in the sEMPs was found. However, of note, CCL20, 
was found to be more abundant in sEMPs than uEMPs, which is of interest because 
a parallel study in our laboratory also identified that circulating EMP levels correlate 
with circulating CCL20 levels in SLE patients (personal communication, unpublished 
data). 
 
 
Figure 19. Analysis of proteomic profiles of isolated uEMPs and sEMPs. 
Protein from 107 uEMPs/µL of PBS and 107 sEMPs/µL of PBS was extracted in 
RIPA buffer (containing Protease Inhibitor Cocktail) and quantified using a BCA 
assay. The proteomic screening was outsourced to Olink Bioscience and the results 
presented are normalised for both intra- and inter-plate variation by Olink 
Bioscience. Proteins identified in uEMPs and sEMPs include CCL20, a regulator of 
macrophage recruitment to sites of injury. Error bars are presented as SEM. n = 2 
(Olink Bioscience screenings performed on two different occassions using two 
different uEMPs and sEMPs preparations). CCL20: Chemokine (C-C motif) ligand 
20; CXCL5: C-X-C motif chemokine 5; CXCL6: C-X-C motif chemokine 6; CXCL10: 
C-X-C motif chemokine 10; MCP-1: Monocyte chemotactic protein 1; MCP-3: 
Monocyte chemotactic protein 3; TNFα: Tumor necrosis factor alpha; IL-8: 
Interleukin 8; VEGF-A: Vascular endothelial growth factor A. 
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Parallel to the proteomic screen in EMPs, Multiplex analysis 8 molecules 
(angiopoietin-2, endoglin, VEGF-C, FGF-1, FGF-2, endothelin-1, IL-8 and VEGF-A) 
of uEMP and sEMP lysates confirmed the presence of IL-8 and VEGF-A (also found 
in the Olink Bioscience proteomic screening). Of note, two key angiogenic factors, 
i) Angipoietin-2, a molecule involved in the detachment of smooth muscle cells, 
matrix degradation and inhibition of VEGF-mediated angiogenesis, and ii) Endoglin, 
which is involved in vessel maturation, were found to be elevated in uEMPs in 
comparison to sEMPs (1.5 and 1.46 fold-change respectively; Figures 20A & 20B). 
Similarly, VEGF-C, which is has been shown to stimulate angiogenesis in adults, as 
well as FGF-1 and FGF-2 which regulate cell proliferation and differentiation, were 
also elevated in uEMPs in comparison to sEMPs (1.4, 1.6 and 1.94 fold-change 
respectively; Figures 20C, 20D & 20E). In addition, Endothelin-1, a potent 
vasoconstrictor, was found to be elevated in sEMPs in comparison to uEMPs (1.2 
fold-change; Figure 20F). Finally, the pro-angiogenic molecules IL-8 and VEGF-A, 
which were also identified in the Olink Bioscience proteomic screening, were 
elevated in sEMPs in comparison to EMPs (10.4 and 6.3 fold-change respectively; 
Figures 20G & 20H). These results suggest that the content of both uEMPs and 
sEMPs may play a role in the disruption of endothelial repair mechanisms. 
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Figure 20. Angiogenic and growth factor molecules carried by uEMPs and 
sEMPs. Bioplex was carried out in single lysates of 107 uEMPs/µL of PBS and 107 
sEMP/µL of PBS to investigate the presence of angiogenesis/growth factor 
molecules. A) Angipoietin-2, B) Endoglin, C) Vascular Endothelial Growth Factor-C: 
VEGF-C, D) Fibroblast Growth Factor-1: FGF-1, E) Fibroblast Growth Factor-2: 
FGF-2, F) Endothelin-1, G) Interleukin-8: IL-8, H) Vascular Endothelial Growth 
Factor-A: VEGF-A. n = 1. 
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The data from the proteomic screenings (n = 2) was pooled and UniProtKB and 
Gene Ontology databases were used to determine the function and location of the 
proteins identified in the proteomic screening of the uEMPs and sEMPs. These data 
confirmed that the majority of proteins carried by the EMPs are either secreted (59 
%) or membrane-bound proteins (34 %), with just 7 % of proteins having their origin 
in the cytoplasm or the nucleus (Figure 21), strengthening the idea that EMPs act 
as paracrine signalling molecules or vehicles of biological information. 
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Figure 21. Proteins categorised by location using proteomic technology. 
uEMPs and sEMPs were lysed and sent for proteomic analysis by Olink Bioscience. 
Identified proteins were classified according to subcellular location using UniProtKB 
and Gene Ontology. % refer to the number of proteins. 
 
3.2.1.3. sEMPs carry CCL20  
Validation of the proteomic screening was performed in our laboratory using ELISA 
and flow cytometry. As described in 3.2.1.2, the proteomic screening found that 
CCL20, a protein involved in macrophage recruitment to sites of injury, was more 
abundant in sEMPs than uEMPs. CCL20 content in uEMPs and sEMPs was 
validated by ELISA and flow cytometry as described in section 2.5.1.1. CCL20 was 
detected in both uEMPs and sEMPs lysates by ELISA with a trend towards elevated 
levels in the sEMPs compared to uEMPs (~1.3 fold-change; Figure 22A). Since 
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CCL20 levels were close to the detection limit of the ELISA kit, further validation 
was carried out using an alternative method. 
Flow cytometry confirmed that sEMPs carried significantly more CCL20 compared 
to uEMPs (~8.75 fold, p < 0.05). Flow cytometry analysis also demonstrated that 
approximately 20 % of the total sEMP population (AnnexinV+ events) are CCL20+, 
in contrast with just 2 % of the uEMP population (Figure 22B, 22C). These 
observations, together with the fact a CCL20 was found to correlate with EMP levels 
in SLE patients (personal communication, unpublished), provided a rationale for 
further investigation of the role of CCL20 in SLE and the function EMPs have in its 
signalling. 
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Figure 22. Validation of CCL20 in uEMPs and sEMPs. A) Protein lysates of 107 
uEMPs/µL of PBS and 107 sEMPs/µL of PBS were used to validate CCL20 levels 
using ELISA (n = 2). B) Further validation of CCL20 content in EMPs was carried 
out by flow cytometry. A modified protocol for intra-cellular antibody labelling was 
used to investigate differences in CCL20 levels in uEMPs vs sEMPs. Two 
representative flow cytometry plots of AnnexinV+/CCL20+ events are shown. C) An 
unpaired t-student test was used to analyse the difference in the percentage of 
CCL20+ in uEMPs and sEMPs. Error bars are presented as ± SEM. n = 3 (different 
uEMP and sEMP preparations); *p < 0.05. CCL20: chemokine (C-C motif) ligand 
20. 
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3.2.1.4. miRNA-129-5p is elevated in uEMPs compared to sEMPs 
It is now recognised that EMPs carry nucleic acids, among which microRNAs have 
been extensively studied as relevant effectors of microparticle function (73, 92, 149). 
To investigate the differences in miRNA content between uEMPs and sEMPs, total 
RNA was extracted, quantified and sent to Ocean Ridge Biosciences for microRNA 
screening; microRNA was purified from total RNA by ultrafiltration, quantified by 
fluorometry and subjected to Ocean Ridge Biosciences proprietary microRNA 
microarray analysis. Of the 300 miRNAs identified, only the 28 most abundant ones 
in sEMPs (compared to uEMPs) were considered for RT-qPCR validation and were 
investigated further in the context of endothelial function. A full list of the miRNAs 
validated by RT-qPCR are shown in Table 10.  
Table 10. miRNA analysis of 
uEMPs and sEMPs. The most 
abundant miRNAs in sEMPs 
(compared to uEMPs) identified in 
the screen were shortlisted and their 
presence was validated using RT-
qPCR. microRNA was extracted from 
106 uEMPs or sEMPs using the 
Isolate II miRNA kit from Bioline, 
quantified using a Qubit BioAnalyzer, 
and only those miRNAs in which a 
unique amplicon was found in the 
dissociation curve, were considered 
validated.  
 
 
 
 
 
 
 
 
 
 
 
The validated microRNAs were subjected to bioinformatic analysis using an 
alignment algorithm in microRNA.org, which finds potential mRNA targets for 
miRNAs screened Validated by RT-qPCR 
hsa-miRNA-328 Yes 
hsa-miRNA-595 Yes 
hsa-miRNA-608 Yes 
hsa-miRNA-1224-3p Yes 
hsa-miRNA-125b-5p  Yes 
hsa-miRNA-129-5p  Yes 
hsa-miRNA-149-3p  Yes 
hsa-miRNA-185-3p  Yes 
hsa-miRNA-221-3p  Yes  
hsa-miRNA-222-3p  Yes 
hsa-miRNA-423-3p  Yes 
hsa-miRNA-423-5p  Yes 
hsa-miRNA-483-3p  Yes 
hsa-miRNA-532-3p  Yes 
hsa-miRNA-551a  Yes 
hsa-miRNA-let-7a-5p  Yes 
hsa-miRNA-let-7b-5p  Yes 
hsa-miRNA-1231 No 
hsa-miRNA-1538 No 
hsa-miRNA-1225-3p  No 
hsa-miRNA-574-3p  No 
hsa-miRNA-34a  No 
hsa-miRNA-210-3p  No 
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miRNAs, and predicted that CCL20 is a target of miRNA-129-5p (mirSVR score: -
0.2911; Figure 23A). miRNA-129-5p abundance in uEMPs and sEMPs was 
investigated by RT-qPCR and normalised to miRNA-222-3p levels, which has been 
shown to be a suitable single gene housekeeper miRNA, is highly expressed in 
endothelial cells, and was found to be similarly abundant in uEMPs and sEMPs in 
our proteomic screening (194, 195). Amplification plots and dissociation curves 
shown on Figure 23C. miRNA-129-5p was found to be significantly more abundant 
in uEMPs than in sEMPs (~4 fold-change; Figure 23B), suggesting that miRNA-129-
5p could be partially responsible for the reduced CCL20 levels found in uEMPs in 
comparison to sEMPs. As a result of this observation, the role of miRNA-129-5p on 
CCL20 signalling was investigated further. 
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Figure 23. Bioinformatic prediction of miRNA-129-5p targets and 
quantification in EMPs. microRNA was extracted from 106 uEMPs and sEMPs 
using the Isolate II miRNA kit from Bioline and quantified using a Qubit BioAnalyzer. 
A) miRNA-129-5p and CCL20 alignment and target prediction was performed using 
microRNA.org and DIANA-miRpath algorithms. An unpaired t-student test was used 
and error bars are presented as ± SEM. n = 3; *p < 0.05. B) RT-qPCR of miRNA-
129-5p (normalised to miRNA-222-3p) shows that uEMPs carry more miRNA-129-
5p than sEMP. C) Amplification plots and dissociation curves of miRNA-129-5p and 
housekeeper miRNA-222-3p are shown, demonstrating the presence of a single 
amplicon.  
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3.2.2. uEMPs and sEMPs effects on CCL20 
In order to determine the effects of uEMPs and sEMPs on TNFα-induced CCL20 
expression, HUVECs were treated with uEMPs or sEMPs in combination with TNFα 
and analysed using RT-qPCR. Results showed that CCL20 mRNA abundance was 
decreased in uEMP-treated cells in comparison to TNFα-treated control and to 
sEMP-treated cells (~2.3 fold-change, p < 0.005, Figure 24), suggesting that uEMPs 
(but not sEMPs) can reduce TNFα-induced CCL20 expression, potentially due to a 
higher abundance of miRNA-129-5p; therefore, transfection experiments were 
performed to validate CCL20 as a target of miRNA-129-5p. 
 
Figure 24. The effect of uEMPs and sEMPs on CCL20 mRNA abundance in the 
presence of TNFα. HUVECs were treated with TNFα (10 ng/mL of media) in 
combination with 106 uEMPs/mL of media or 106 sEMPs/mL of media for 24 hours 
and total RNA was isolated and analysed using RT-qPCR. Reduced CCL20 mRNA 
levels in uEMP treated cells compared to TNFα and sEMP-treated cells. A one-way 
ANOVA test with Tukey correction was used for statistical analysis. Error bars 
represent ± SEM. n = 3 (different uEMP and sEMP preparations); **p < 0.005. 
 
3.2.2.1. miRNA-129-5p does not regulate CCL20 mRNA levels 
To investigate if these effects were due to miRNA-129-5p content in uEMPs, 
HUVECs were transfected with miRNA-129-5p precursor or a scrambled control 
using an Amaxa Nucleofector® kit as described in section 2.11.3. Since miRNA-129-
5p and scrambled control plasmid carry a Puromycin resistant gene, transfected 
cells were selected in 0.25 µg/ml of Puromycin for 4 days (Figure 25A). After 
selection, an apparent 50-65 % transfection efficiency was achieved (visual 
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observation; Figure 25B). miRNA-129-5p and scrambled control transfected cells 
were treated with TNFα for 24 hours (in parallel with control-transfected cells) and 
harvested for RT-qPCR to elucidate the effects of miRNA-129-5p on CCL20 mRNA 
abundance.  
RT-qPCR for CCL20, which is only expressed upon TNFα activation and it is not 
present in untreated endothelial cells (192), showed that mRNA abundance was 
increased in miRNA-129-5p transfected HUVECs compared to the TNFα positive 
control after 24 hours (~27 fold-change, p < 0.001). Scrambled control transfected 
cells also showed increased CCL20 mRNA levels (~13.5 fold-change, p < 0.005) 
compared to the TNFα control but was still significantly lower than the miRNA-129-
5p transfected cells (Figure 26). This observation could be explained as follows: i) 
Puromycin treatment of the cells could have caused changes in the cells, thereby 
affecting CCL20 regulation in the scrambled and miRNA-129-p transfected cells, 
and upregulating CCL20 expression during the selection process, an effect not 
observed in the TNFα-treated control-transfected cells as they were not exposed to 
Puromycin; ii) the plasmid construct is partially responsible for the observed effects 
and therefore the elevation in CCL20 mRNA abundance in miRNA-129-5p 
transfected cells cannot be attributed to the presence of the microRNA, or iii) 
miRNA-129-5p has a different, unknown target, that leads to increased CCL20 
mRNA abundance.  
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Figure 25. Transfection and selection of transfected HUVECs. HUVECs were transfected using an Amaxa Nucleofector® kit and Puromycin 
was used to select the transfected cells. Representative micrographs taken at 10x magnification are shown. A) Non-transfected cells were used 
to identify the concentration of Puromycin for the selection of the successfully transfected cells. Scale bar = 100 µM. B) Transfected HUVECs 
were observed under the fluorescence microscope after 72 hours of Puromycin selection. An apparent transfection efficiency of 50-65 % was 
achieved (visual observation). Scale bar = 100 µM.
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Figure 26. Abundance of CCL20 mRNA in miRNA-129-5p transfected HUVECs. 
RT-qPCR of TNFα-treated cells (positive control for CCL20 mRNA expression), 
scrambled control-transfected cells and miRNA-129-5p transfected cells showed 
CCL20 mRNA levels are increased in both miRNA-129-5p and scrambled control 
transfected cells. These results demonstrate that i) the bioinformatic prediction was 
not precise and that miRNA-129-5p does not target CCL20 or ii) Puromycin 
selection affects CCL20 expression. A one-way ANOVA test with Tukey correction 
was used for statistical analysis. Error bars represent ± SEM. n = 3 (independent 
transfections); **p < 0.005; ***p < 0.001. 
 
3.2.3. EMP release by activated HUVECs 
In order to establish whether EMPs exerted any additional effects on activated 
HUVECs, two populations of MPs (sEMPs or uEMPs) were used, either on their own 
or in combination with TNFα, to treat HUVECs for 24 hours. After treatment, EMPs 
were isolated as described in 2.2.3 and quantified using flow cytometry as in 2.2.4. 
As expected, TNFα stimulated EMP release (~1.5 fold-change, p < 0.05, Figure 
27A) compared to untreated cells. These results are representative of the uEMP 
and sEMP generation process and consistently, 106 uEMPs and 5 x 106 sEMPs 
were generated per mL of media.  
When cells were treated with sEMPs, a significant increase in EMP release 
compared to untreated or uEMP-treated cells was detected (~1.5 fold-change, p < 
0.001, Figure 27B). Furthermore, uEMP treatment in the presence of TNFα 
significantly reduced EMP release (p < 0.05) compared to sEMPs, to almost 
untreated levels Figure 27C). These results suggest that EMPs play a role in 
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regulating EMP release, but their role depends on their mode of generation: uEMPs 
are protective against TNFα-driven EMP release, whereas sEMPs enhance EMP 
release, thus contributing to the elevated circulating EMP levels found in 
inflammatory diseases. 
 
 
Figure 27. The effects of uEMPs and sEMPs on EMP generation under 
homeostatic and pro-inflammatory conditions. HUVECs were cultured in T25 
flasks and treated with 106 uEMPs or 106 sEMPs/mL of media in the presence or 
absence of TNF for 24 hours. Conditioned media was collected and EMPs were 
quantified by flow cytometry. A) Conditioned media from untreated and TNFα-
treated cells after 24 hours was collected for EMP isolation and quantification. An 
unpaired student t-test was performed. B) EMPs were isolated and quantified from 
conditioned media from untreated, uEMP-treated and sEMP-treated cells. C) 
HUVECs were treated with TNFα in combination with uEMPs or sEMPs for 24 hours 
prior to EMP isolation and quantification. A one-way ANOVA test with Tukey 
correction was used for statistical analysis. (B, C) was used to determine 
differences. Error bars represent ± SEM. n = 3 independent experiments (three 
different populations of HUVECs and uEMP/sEMP preparations); *p < 0.05. 
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3.2.4. uEMPs and sEMPs enhance cell migration (wound healing assay) 
Cell migration is a key process in endothelial homeostasis and vascular damage. 
To establish whether EMPs had any differential effects on migration, uEMPs and 
sEMPs were used alone or in combination with TNFα to treat HUVECs for 6 hours 
in a scratch assay, as described in section 2.8.2.1. Representative micrographs at 
0 and 6 hours are shown in Figure 28A and cell migration was quantified using 
ImageJ (Figure 28B). TNFα enhanced cell migration significantly compared to 
untreated control cells (~1.8 fold-change, p < 0.05); uEMP- and sEMP-treated cells 
both showed an increased migration capacity compared to untreated cells and to a 
similar level as TNFα treatment (~1.5 and ~1.6 fold-change respectively, p < 0.005). 
However, TNFα treatment in combination with either uEMPs or sEMPs showed no 
significant increase in endothelial cell migration when compared to uEMP or sEMP 
treatment only, which differs from the effects detected on EMP release. 
To ensure that the results observed were due to cell migration and not enhanced 
cell growth, proliferation was measured using a kit based on the MTT assay principle 
(Figure 28C). No statistically significant differences were found between uEMP- and 
sEMP-treated groups compared to untreated or TNFα-treated cells, suggesting that 
the reported effects are due to endothelial cell migration and not proliferation. 
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Figure 28. The effects of uEMPs and sEMPs on endothelial cell migration. 
HUVECs were cultured in 6-well plates and a scratch assay was performed. Cells 
were treated with TNFα, uEMPs or sEMPs (106 EMPs/ml), or in combination with 
TNFα. Images were taken at 0 and 6 hours. A) Representative images taken at 10x 
magnification at 0 and 6 hours. The red dotted line represents the wounded area, 
while the yellow dotted box represents the original wounded area. Percentage of 
wound closure is shown in yellow text (average of 3 independent experiments). 
Scale bar = 100 µm. B) Quantification of wound closure after 6 hours: both uEMPs 
and sEMPs enhance cell migration. An unpaired student t-test and one-way ANOVA 
test with Tukey correction were used for statistical analysis. Error bars represent ± 
SEM. n = 3; *p < 0.05, **p < 0.005. C) 2.5 x 103 cells/cm2 were seeded in 96-well 
plates and proliferation assays at 6 hours confirmed that EMPs did not affect cell 
proliferation. All treated groups were normalised to untreated samples. Statistical 
analysis using a one-way ANOVA test with Tukey correction did not identify 
significant differences. 
 
 
3.2.5. Gene expression and protein analysis in uEMP and sEMP-treated 
HUVECs versus untreated cells 
The results show that EMPs enhance endothelial cell migration, which is often 
regulated by the expression adhesion molecules. It is well established that activated 
endothelial cells show an increase in adhesion molecule expression, therefore, the 
levels of VCAM or ICAM and associated pathways was investigated in cells treated 
with EMPs in the presence or absence of TNFα.  
HUVECs were treated with uEMP and sEMP in with the presence or absence of 
TNFα for 24 hours and the RNA harvested for RT-qPCR analysis. As shown in the 
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literature, TNFα increased VCAM-1 and ICAM-1 mRNA abundance by ~2 fold and 
~3 fold respectively compared to untreated cells (Figure 29A, 29D; p < 0.0001). Of 
note, the uEMPs increased VCAM-1 and ICAM-1 mRNA abundance by ~3 and ~4 
fold respectively (Figure 29B, 29E; p < 0.0001) and sEMPs also increased mRNA 
abundance of VCAM-1 and ICAM-1 by 4.5 fold (Figure 29B, 29E; p < 0.0001). The 
sEMP treatment increased mRNA abundance of VCAM-1 and ICAM-1 significantly 
more than uEMPs (Figure 29B, 29E; p < 0.001 and p < 0.05 respectively). In 
addition, uEMP treatment in combination with TNFα, increased mRNA abundance 
of VCAM-1 and ICAM-1 by 2 fold compared to TNFα treated cells (Figure 29C, 29F; 
p < 0.0001). Finally, increased VCAM-1 (but not ICAM-1) mRNA levels were found 
in TNFα plus sEMP-treated cells (Figure 29C, 29F; p < 0.0001).  
VCAM-1 and ICAM-1 are adhesion proteins present in the cell membrane of 
activated endothelial cells. In order to determine whether the changes in mRNA 
expression are also reflected at the protein level, western blot analysis of the 
membrane and cytoplasmic fraction of HUVECs treated with either uEMPs or 
sEMPs was performed. VCAM-1 and ICAM-1 were detected in HUVECs treated 
with TNFα. While there was no evidence of VCAM-1 or ICAM-1 protein in uEMPs 
nor sEMP-treated HUVECs, strong signals were found for both proteins in TNFα 
plus uEMP or sEMP-treated cells. This observation suggests that uEMPs nor 
sEMPs increase VCAM-1 nor ICAM-1 protein levels, as the proteins were only found 
in cells treated with TNFα, regardless of the presence of uEMPs or sEMPs. Alpha-
tubulin was used as a loading control and showed equal loading in all lanes (Figure 
30). 
These results show that EMPs modulate the mRNA abundance of VCAM-1 and 
ICAM-1, but do not increase their protein levels, suggesting they may not have an 
effect on endothelial cell activation per se (although it is possible that they affect the 
expression of other adhesion molecules). Cell migration and activation often occur 
together, and given that EMPs enhance migration but not activation, such effect is 
potentially indirect. The inflammatory pathway NFκB regulates key cell aspects such 
as migration, proliferation and activation and as such, the next section will 
investigate whether uEMPs and sEMPs mediate their effects via this pathway.
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Figure 29. The effect of EMPs on mRNA abundance of adhesion molecules ICAM-1 and VCAM-1. HUVECs were seeded in 6-well plates 
(5 x 103 cells/cm2) and treated with 106 uEMPs/mL of media or 106 sEMPs/mL of media for 24 hours prior to RNA isolation for RT-qPCR. A, 
D) TNFα increases VCAM-1 and ICAM-1 mRNA abundance. B, E) uEMPs and sEMPs increase mRNA abundance of VCAM-1 and ICAM-1. 
C, F) uEMPs, in combination with TNFα, increase VCAM-1 and ICAM-1 mRNA abundance. Unpaired student t-test (A, D) and one-way 
ANOVA with Tukey correction for multiple comparison (B, C, E, F) were used. Error bars represent ± SEM. n = 6 independent experiments; 
*p < 0.05, **p < 0.005, ****p < 0.0001. 
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Figure 30. The effect of EMPs on VCAM-1 and ICAM-1 protein levels. HUVECs 
were seeded in 25 cm2 flasks (5 x 103 cells/cm2) and treated with 106 uEMPs/mL or 
106 sEMPs/mL of media for 24 hours prior to protein extraction for western blotting. 
20 µg of total protein was loaded per lane. A representative blot of both the 
membrane and cytoplasmic fraction is shown. VCAM-1 and ICAM-1 were only 
detected in the TNFα-treated samples, but not in the samples treated with uEMPs 
or sEMPs only. n = 3 independent experiments. 
 
 
3.2.6. sEMPs, but not uEMPs, activate the NFκB pathway 
NFκB is a key regulator of inflammation and endothelial cell function. Upon 
activation by TNFα, NFκB translocates from the cytoplasm to the nucleus where it 
acts as a transcription factor for many genes regulating cell survival and 
proliferation. Given the important role the NFκB pathway plays in inflammation, 
NFκB (p65 subunit) translocation to the nucleus was investigated in uEMP and 
sEMP-treated HUVECs after 30 minutes (Figure 31) and 16 hours (Figure 32) using 
immunofluorescence, with TNFα as the positive control (translocation is presented 
in turquoise colour; Figures 31B and 32B). sEMPs were shown to activate NFκB 
translocation at both time points investigated, at 30 minutes and 16 hours (Figures 
31E and 32E), whereas uEMPs did not (Figures 31C and 32C). NFκB translocation 
was observed in cells treated with TNFα at either 30 minutes or 16 hours and 
regardless of the EMP treatment (Figures 31D, 31F and 32D, 32F). 
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Figure 31. The effect of sEMPs on NFκB activity after 30 minutes. Representative immunofluorescence micrographs taken at 20x 
magnification of HUVECs treated with TNFα and uEMPs or sEMPs for 30 minutes and stained for NFκB (green) and DAPI (blue nuclei). NFκB 
translocation presents as turquoise colour. A) Untreated cells, B) TNFα-treated cells, C) uEMP-treated cells, D) uEMPs and TNFα-treated cells, 
E) sEMPs-treated cells, F) sEMPs and TNFα-treated cells. White boxes are inset zooms of the indicated area. Arrows indicate NFκB nuclear 
translocation. Scale bar = 25 µM. n = 3.
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Figure 32. The effect of sEMPs on NFκB activity after 16 hours. Representative immunofluorescence micrographs taken at 20x magnification 
of HUVECs treated with TNFα and uEMPs or sEMPs for 16 hours and stained for NFκB (green) and DAPI (blue nuclei). NFκB translocation 
presents as turquoise colour. A) Untreated cells, B) TNFα-treated cells, C) uEMP-treated cells, D) uEMPs and TNFα-treated cells, E) sEMPs-
treated cells, F) sEMPs and TNFα-treated cells. White boxes are inset zooms of the indicated area. Arrows indicate NFκB nuclear translocation. 
Scale bar = 25 µM. n = 3.
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Upon activation, NFκB protein levels in the nucleus will increase in those cases 
where translocation occurred, therefore, a cell fractionation assay was carried out 
in order to confirm NFκB protein levels in the nuclear fraction of uEMP and sEMP-
treated HUVECs (Figure 33). An elevated content of NFκB was detected in TNFα-
treated cells (positive control; ~6 fold-change). Nuclear NFκB levels were higher in 
the sEMP-treated cells than in the untreated or uEMP-treated cells (~2.5 fold-
change, Figure 33B). Although in low abundance, some NFκB was found also in the 
untreated or uEMP-treated cells, possibly due to cytoplasmic fraction contamination. 
NFκB nuclear levels in uEMP or sEMP-treated cells in combination with TNFα were 
lower than in the TNFα treatment only (~3 fold-change, Figure 33B). 
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Figure 33. Quantification of NFκB protein translocation to the nucleus 
following HUVEC treatment of uEMPs and sEMPs. HUVECs were seeded in 25 
cm2 flasks (5 x 103 cells/cm2) and treated with 106 uEMPs/mL or 106 sEMPs/mL of 
media for 24 hours prior to protein extraction for western blotting. A) A 
representative blot of the nuclear fraction is shown (20 µg of total protein was 
loaded/lane). B) Densitometry analysis using ImageJ revealed that NFκB protein 
levels were elevated in the TNFα and in the sEMP-treated samples compared to the 
untreated cells. Error bars represent ± SEM. n = 2 independent experiments. 
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To further validate these observations, RT-qPCR was used to measure mRNA 
abundance of IκB, a key adapter protein and a transcript of NFκB (Figure 34). As 
expected, IκB mRNA abundance was increased in TNFα-treated cells (positive 
control, ~1.5 fold-change, Figure 34A). An increase in IκB mRNA abundance was 
also found in sEMP-treated (~2 fold-change, Figure 34B), but not in uEMP-treated 
cells, supporting the immunofluorescence observations that NFκB is only activated 
by sEMPs (Figure 34B). No statistically significant differences in IκB mRNA 
abundance were found between TNFα, uEMPs or sEMPs plus TNFα treated-cells 
(Figure 34C). 
 
 
 
Figure 34. IκB mRNA abundance in uEMPs and sEMPs-treated HUVECs. 
HUVECs were seeded in 6 well plates (5 x 103 cells/cm2) and treated with 106 
uEMPs/mL or 106 sEMPs/mL of media for 24 hours prior to RNA isolation for RT-
qPCR. A) IκB mRNA abundance was increased in TNFα-treated cells compared to 
untreated cells. B) sEMPs increased IκB mRNA abundance, whereas uEMPs did 
not. C) IκB mRNA levels were unaffected by either uEMP or sEMP-treatments in 
combination with TNFα compared to TNFα-treated cells. Unpaired student t-test (A) 
and one-way ANOVA test with Tukey correction (B, C) were used for statistical 
analysis. Error bars represent ± SEM. n = 6 independent experiments; *p < 0.05, 
****p < 0.0001. 
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3.3. Key findings 
The key findings of the experiments described in this chapter are: 
 
1. This study is the first one to describe that CCL20 and miRNA-129-5p are 
carried by both healthy and disease-like EMPs and that their abundance 
depends on their mode of generation.  
2. Although miRNA-129-5p is more abundant in uEMPs than sEMPs, it does 
not appear to target CCL20 mRNA and therefore it is unlikely to be 
responsible for reduced CCL20 mRNA levels in uEMP-treated ECs. 
3. uEMPs and sEMPs appear to be phenotypically different; uEMPs being 
rounder and smaller than sEMPs, which appear to have a more spreading 
phenotype, possibly reflecting more adhesive properties.  
4. EMPs generated with different stimuli play distinct roles in EC function:  
i. sEMPs enhance EMP release vs uEMPs, 
ii. uEMPs attenuate TNFα-driven EMP generation.  
5. EMPs have common roles to play in endothelial function: 
i. Both uEMPs and sEMPs enhance EC migration, 
ii. uEMPs and sEMPs increase VCAM-1 and ICAM-1 mRNA abundance 
of targets cells, but not at the protein level. 
6. Immunofluorescence, western blot and IκB RT-qPCR results demonstrate 
that sEMPs activate the NFκB pathway whereas uEMPs do not, reinforcing 
the idea that sEMPs and uEMPs work via different pathways under different 
circumstances. 
 
3.4. Summary 
We have established that EMPs released from cells under different conditions have 
distinct CCL20 and microRNA content and functional effects on cells; that EMPs are 
more highly released in activated endothelial cells compared to healthy cells and 
finally that EMPs have potential to exacerbate damage under disease conditions. 
Since EC damage also contributes to smooth muscle cell function, in particular 
facilitating vascular remodelling (196, 197), we hypothesised that EMPs could also 
have an effect on SMC function, therefore we questioned whether EMPs may 
ultimately affect SMC osteogenic differentiation. The series of experiments 
described in the next chapter aimed to shed light on the complex regulation of cell 
fate in the development of vascular calcification in vitro.  
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CHAPTER 4: THE EFFECTS OF AoEMPs IN CALCIFICATION OF VASCULAR 
SMOOTH MUSCLE CELLS 
4.1. EMPs as active regulators of vascular calcification 
As previously described in our laboratory and reviewed by others (198, 199), aortic 
vascular calcification is a relevant clinical problem in SLE and it is considered to be 
an independent predictor of CVD. Previous research in our laboratory has shown 
that EMP levels are increased in SLE patients (33); therefore, it is possible that they 
play a role not only in endothelial dysfunction but also in vascular calcification (188). 
The mechanisms for the phenotypic reprogramming of VSMCs into osteoblast-like 
cells is only partly understood, thus it was of interest to determine whether they may 
play a role in aortic and coronary calcification via their molecular content.  
The aim of the next series of experiments was to investigate the effects of EMPs on 
the osteogenic differentiation of vascular SMCs and to determine their mode of 
action. In order to achieve this aim, the following 3 objectives were addressed: 
 
1. To determine whether AoEMP treatment of HCoASMCs enhances vascular 
calcification compared to untreated cells grown in osteogenic conditions 
using Alizarin Red S staining and calcium deposition assays. 
2. To elucidate the content of AoEMPs (proteins, microRNAs and Ca2+) using 
bioplex suspension arrays, ELISAs and RT-qPCR, in order to identify 
relevant molecules and pathways involved in vascular calcification. 
3. To identify novel molecular components of AoEMPs using a microRNA and 
proteomic analyses and their effects on osteogenic differentiation, using 
transfection approaches. 
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4.2. Results 
 
4.2.1. Calcein-AM-labelled AoEMPs are taken up by HCoASMCs 
AoEMPs generated from serum-starved + TNFα-stimulated HAoECs were stained 
with 10 µM Calcein-AM and used to treat HCoASMCs to investigate their uptake. 
HCoASMCs were cultured in osteogenic media for 24 hours for pre-conditioning in 
order to avoid Calcein-AM uptake due to a sudden change of media. Fluorescent 
microscopy images were captured after 3, 6 and 24 hours of treatment with 106/mL 
Calcein-AM-labelled AoEMPs to visualise uptake (Figure 35A), which was 
quantified by measuring mean fluorescence intensity using ImageJ (Figure 35B). 
The results showed that the AoEMP internalisation was significantly increased (p < 
0.0001) after 24 hours, suggesting that AoEMPs are taken up in a time dependant 
manner. 
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Figure 35. Internalisation of Calcein-AM-labelled AoEMPs by HCoASMCs. A) 
Representative micrographs taken at x10 magnification of HCoASMCs treated with 
106/mL Calcein-AM-labelled AoEMPs (red) following 3, 6 and 24 hours, taken using 
a fluorescent microscope. 10 µM Calcein-AM + PBS was used as a control to 
establish the background fluorescence. Scale bar = 100 µM. B) Mean fluorescence 
intensity was used to quantify uptake from 3 different fields of view. A one-way 
ANOVA test with with Tukey correction was used for statistical analysis. Error bars 
represent ± SEM. n = 4 independent experiments (4 different AoEMP preparations 
and HCoASMC batches). ****p < 0.0001 
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4.2.2. AoEMPs enhance HCoASMC calcification in vitro 
HCoASMCs were treated with and without AoEMPs and grown in osteogenic media 
in vitro for 21 days. In addition to the phenotypic differences observed between the 
untreated and the AoEMP-treated HCoASMCs (the later were more contracted and 
with larger calcification nodules), Alizarin Red S staining was performed and an 
increase in stained nodules in the AoEMP-treated cells was observed, reflecting 
enhanced osteogenic differentiation (Figure 36A). In order to quantify these 
observations, Alizarin Red S staining was eluted with 10 % (v/v) formic acid and 
quantified by measuring the absorbance at 414nm. These data confirmed a 
significant increase in calcification in AoEMP-treated cells compared to untreated 
cells (p < 0.005; Figure 36B). 
Calcium levels were also measured in a parallel set of experiments and normalised 
to total protein content. AoEMP-treated cells showed significantly elevated levels of 
calcium compared to untreated cells (p < 0.05; Figure 36C), thus validating the 
Alizarin Red S findings. 
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Figure 36. The effects of EMPs on HCoASMCs calcification. A) Representative 
micrographs taken at 10x magnification of Alizarin Red S staining of HCoASMCs 
cultured in osteogenic media and treated with 106 AoEMPs/mL of osteogenic media 
twice a week show enhanced calcification nodules (black arrows). Scale bar = 100 
µm. B) Quantification of Alizarin Red S staining was performed by eluting the 
staining in 10 % (v/v) formic acid, confirming the visual observations. C) Calcium 
deposition assays also showed that more Ca2+ is deposited in the AoEMP-treated 
cells. An unpaired student t-test was used for statistical analysis. Error bars 
represent ± SEM. n = 4 independent experiments. *p < 0.05, **p < 0.005.  
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4.2.3. HCoASMC secretome is modulated by AoEMPs  
Conditioned media from the experiments described in section 4.2.2 was used to 
investigate the effects of AoEMPs on the HCoASMC secretome after 4, 7, 14 and 
21 days using a bone-panel multiplex assay containing proteins relevant in vascular 
calcification. The inflammatory cytokines IL-6 and TNFα were elevated throughout 
the 3 weeks in AoEMP-treated cells after 7 and 4 days respectively (Figure 37A and 
37B), suggesting a pro-inflammatory effect of the AoEMPs. Secreted OPG, a known 
inhibitor of calcification was reduced in the media during the first week of treatment 
but increased at the later stages (Figure 37C), which suggests that AoEMPs 
mediate their effects at the early stages of the calcification process, whereas OPN 
and SOST levels were unaffected (Figure 37D and Figure 37E). OCN, which is a 
pro-osteogenic protein, was found to be elevated in AoEMP-treated media at 7 days 
in comparison to untreated cells, but no differences were detected at 4, 14 and 21 
days (Figure 37F). Calcification is a highly regulated process and it is often the 
balance between calcification promoters and inhibitors that decides cell fate. In this 
study, the observation of increased OCN levels (calcification promoter) at day 7, 
together with the reduced OPG levels (calcification inhibitor) during first 7 days, may 
lead to the enhancement of calcification observed in AoEMP-treated HCoASMCs. 
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Figure 37. The effect of AoEMPs on HCoASMCs secretome during vascular 
calcification. Conditioned media of untreated and AoEMP-treated cells was 
collected during the 21-day experiments and analysed using a Multiplex 
immunoassay for bone-related proteins. A) IL-6: interleukin-6, n = 2; B) TNFα: 
tumour necrosis factor alpha, n = 2; C) OPG: osteoprotegerin, n = 3; D) OPN: 
osteopontin, n = 3; E) SOST: sclerostin, n = 3; F) OCN: osteocalcin. Solid and dotted 
lines represent untreated and AoEMP-treated HCoASMCs respectively. A two-way 
ANOVA was used for statistical analysis. Error bars represent ± SEM.  
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4.2.4. Molecular analysis of AoEMPs  
Given that AoEMPs appear to enhance the osteogenic differentiation of SMCs by 
enhancing calcification, they were submitted to phenotypical, proteomic and 
microRNA analysis to identify any putative promoters of calcification that could be 
driving this process. 
4.2.4.1. Phenotypical analysis of AoEMPs  
Scanning Electron Microscopy of AoEMPs was performed as described in section 
2.6. Of note, two differently sized particles were evident; particles in the range of 
0.4-1 µm and others smaller than 200 nm were detected throughout the different 
AoEMP preparations analysed, suggesting the presence of exosomes in the MP 
preparations. It may be that the exosomes and their content may be different from 
that contained within EMPs and could be having their effect on vascular calcification 
(Figure 38). Therefore, it is difficult to determine if the enhanced calcification 
observed in AoEMP-treated cells is due the EMPs or to the smaller exosome 
fraction. 
 
Figure 38. Representative phenotypical characteristics of AoEMPs. 
Representative Scanning Electron Microscopy micrographs of AoEMP 
preparations. Particles ranging from 200 nm to 1 µm (± 400 nm SEM) were found in 
all AoEMP preparations. Black arrows indicate the presence of AoEMPs. Black 
circles indicate the presence of exosomes. n = 3 (different AoEMP preparations). 
4.2.4.2. Inflammatory proteomic analysis of AoEMPs  
In order to assess the contents of AoEMPs and identify their molecular components, 
a proteomic screen was performed on concentrated preparations. Protein was 
extracted from the same number of AoEMPs as detailed in section 2.5.1 in Methods 
and subjected to proteomic analysis using an inflammatory panel of 92 molecules 
(n = 2; different AoEMP batches). Out of all proteins identified (41), only those in 
which SD < 3 between the two replicates (HGF, CXCL6, MMP-10, OPG, CCL23 and 
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MMP-1) were considered for further investigation in the context of vascular 
calcification. Protein screening identified the matrix metalloproteinases MMP-10 and 
MMP-1, as well as CXCL6, CCL23 and OPG. HGF (a protein that has been shown 
to be involved in the development of vascular calcification (166)) was also detected 
in the proteomic screening and was validated in our laboratory using an HGF 
Quantikine ELISA thus, confirming its presence (Figure 39).  
 
Figure 39. Proteomic screening of AoEMPs. Protein from 107 AoEMPs/µL of PBS 
was extracted in RIPA buffer (containing Protease Inhibitor Cocktail) and quantified 
using a BCA assay. Proteomic screening was performed by Olink Bioscience and 
results are presented as normalised protein expression (Proseek Multiplex data are 
normalised for both intra- and inter-plate variation). Error bars are presented as ± 
SEM. n = 2 (Olink Bioscience screenings performed on two different occasions using 
two different AoEMP preparations). HGF: Hepatocyte growth factor; CXCL6: 
Chemokine (C-X-C motif) ligand 6; MMP-10: Matrix metalloproteinase 10; OPG: 
osteoprotegerin; CCL23: Chemokine (C-C motif) ligand 23; MMP-1: Matrix 
metalloproteinase 1.  
 
 
4.2.4.3. EMPs carry Ca2+ 
Several studies have suggested that EMPs carry not only proteins, but also Ca2+. In 
order to investigate this, uEMPs, sEMPs and AoEMPs were incubated in HCL to 
extract Ca2+, which was measured using a calcium deposition quantification assay 
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as described in section 2.5.1. These data showed that uEMPs carry significantly 
more Ca2+ (~0.25 mg/107 EMPs) than inflammatory-derived sEMPs (~0.15 mg/107 
EMPs) or AoEMPs (~0.12 mg/107 EMPs; Figure 40). The results suggest that EMPs 
carry and deliver calcium, thereby playing a role in vascular calcification, and 
confirm that the different microenvironments during EMP generation may have an 
impact on their final Ca2+ content.  
C
a
2
+
 m
g
/1
0
7
 E
M
P
s
u E M P s s E M P s A o E M P s
0 .0
0 .1
0 .2
0 .3
0 .4
*
* *
 
Figure 40. Ca2+ content in EMPs. Calcium content was measured from 107 
uEMPs/µL, 107 sEMPs/µL and 107 AoEMPs/µL of PBS using a calcium deposition 
kit and expressed as mg/107 EMPs. A one-way ANOVA with Tukey correction was 
used and error bars are presented as ± SEM. n = 3 (different EMP preparations); *p 
< 0.05, **p < 0.005. 
 
4.2.4.4. AoEMPs contain miRNA-3148 
As reviewed by Goettsch et al., it is now recognised that microRNAs play a role in 
regulating the vascular calcification process (200), therefore, a microRNA screening 
of extracts of AoEMPs was performed as described in section 2.5.2. Of all the 
miRNAs identified, only the 28 most abundant ones in AoEMPs were considered for 
RT-qPCR validation, followed by investigation in the context vascular calcification in 
a bioinformatic analysis. Among the 28 microRNAs identified, miRNA-3148 was 
found to be one of the most abundant ones, and a bioinformatic analysis using 
microRNA.org and DIANA-miRpath predicted that OPG is a target of miRNA-3148 
(mirSVR score: -0.1687; Figure 41A) and could therefore be responsible the 
enhanced calcification observed in AoEMP-treated HCoASMCs in comparison to 
untreated cells. The presence of miRNA-3148 in AoEMPs was validated by RT-
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qPCR and normalised to miRNA-222-3p levels. miRNA-3148 was found to be 
carried by AoEMPs (Figure 41B), suggesting that miRNA-3148 could be playing a 
role by reducing OPG mRNA levels during the first stages of AoEMP-induced 
vascular calcification. 
A
 
 
Figure 41. Bioinformatic prediction of miRNA-3148 targets and quantification 
in AoEMPs. A) A target prediction using microRNA.org and DIANA-miRpath 
algorithms predicted that OPG is a target of miRNA-3148. B) Validation of miRNA-
3148 was performed by RT-qPCR and normalised to miRNA-222-3p. n = 1. 
 
4.2.5. Vascular calcification is enhanced in miRNA-3148 transfected 
HCoASMCs  
To elucidate the effects of miRNA-3148 on OPG mRNA, HCoASMCs were 
transfected with miRNA-3148 precursor and a scrambled control using an Amaxa 
Nucleofector® kit as described in section 2.11.3. Transfected cells were selected in 
0.25 µg/ml of Puromycin for 4 days (Figure 42A) with an apparent 60-70 % 
transfection efficiency (Figure 42B). Transfected cells were harvested following 
incubation in osteogenic media for 21 days and RT-qPCR was used to investigate 
OPG mRNA levels, as well as Alizarin Red S staining to determine the level of 
calcification.
B 
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Figure 42. HCoASMC transfection using Amaxa Nucleofector® kit. A) Representative micrographs taken at 10x magnification of transfected 
HCoASMCs with the scrambled control (CMI), GFP transfection control (PMI) and non-transfected cells were used to identify the concentration 
of Puromycin for the selection of the successfully transfected cells. Scale bar = 50 µm. B) Representative micrographs taken at 20x magnification 
of transfected HCoASMC observed under the fluorescence microscope after 72 hours of Puromycin selection. An apparent transfection efficiency 
of 60-70 % was achieved. Scale bar = 50 µm.
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4.2.5.1. OPG mRNA is reduced in miRNA-3148 transfected HCoASMCs 
Calcification is a complicated process involving many proteins and secreted 
molecules, and it the balance between these molecules that decides cell fate. As 
such, RT-qPCR of the calcification inhibitors OPG and OPN, as well as the active 
regulators OCN and C-met was performed in transfected HCoASMCs in osteogenic 
media for 3 days. Our data showed a significant decrease (~6.5 fold-change) in 
mRNA abundance of the calcification inhibitor OPG compared to untreated and 
scrambled control cells (p < 0.05, p < 0.005 respectively), confirming that miRNA-
3148 targets OPG mRNA (Figure 43A). OPN, another calcium inhibitor, was also 
decreased (~60 fold-change) in AoEMP-treated HCoASMCs (Figure 43B), whereas 
the calcium regulator OCN is increased (~4 fold-change) (Figure 43C). Furthermore, 
C-met mRNA abundance was also found to be reduced in both AoEMP and miRNA-
transfected HCoASMCs (~1.5 fold and 1 fold-change respectively) (Figure 43D). A 
statistically significant difference was found between the untreated and the 
scrambled control groups in OPN mRNA abundance levels (Figure 43B), indicating 
that any effects on these genes in the transfected cells cannot be attributed to the 
presence of miRNA-3148. A statistically significant difference was found between 
the untreated and the scrambled control groups in OPN mRNA abundance levels 
(Figure 43B), which suggests that any effects on OPN in the transfected cells cannot 
be attributed to the presence of miRNA-3148. 
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Figure 43. RT-qPCR analysis of molecules involved in vascular calcification 
in miRNA-3148 transfected HCoASMCs. RT-qPCR analysis of miRNA-3148 
transfected HCoASMCs in osteogenic media for 4 days confirmed that A) miRNA-
3148 targets the calcification inhibitor osteoprotegerin (OPG), reducing its mRNA 
abundance and validating the bioinformatic prediction. B) AoEMPs decrease 
osteopontin (OPN) and C) increase osteocalcin (OCN) mRNA levels. D) C-met 
mRNA levels were reduced in both AoEMP and miRNA-3148 transfected cells. A 
one-way ANOVA test with Tukey correction was used. Error bars represent ± SEM. 
n = 3 independent transfections; *p < 0.05, **p < 0.005; ***p < 0.001; ****p < 0.0001. 
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4.2.5.2. miRNA-3148 enhances matrix mineralisation 
Our data demonstrated that miRNA-3148 targets and reduces mRNA abundance of 
the calcification inhibitor OPG, thus suggesting that miRNA-3148 could be 
responsible for the AoEMP-mediated calcification. To test this, miRNA-3148 
transfected HCoASMCs were harvested in osteogenic media for 21 days in parallel 
with scrambled control transfected cells, untreated and AoEMP-treated cells (these 
last two were non-transfected). Representative Alizarin Red S images of transfected 
HCoASMCs in osteogenic media for 21 days showed increased calcification in 
miRNA-3148 transfected cells (Figure 44A), suggesting that miRNA-3148 could be 
partially responsible for the enhanced vascular calcification observed in AoEMP-
treated HCoASMCs. These observations were confirmed by the quantification of 
Alizarin Red S elution (Figure 44B).  
 
 
 
 
 
 
126 
 
 
 
Figure 44. The effect of miRNA-3148 transfection on HCoASMC calcification. 
A) HCoASMCs were transfected with scrambled control or miRNA-3148 and 
cultured in osteogenic media for 21 days. Representative micrographs of Alizarin 
Red S staining taken at 10x magnification exhibited an elevated number of calcium 
deposits in AoEMP-treated and miRNA-3148 transfected HCoASMCs. Scale bar = 
100 µm. B) Elution of Alizarin Red S in 10 % (v/v) formic acid confirmed that miRNA-
3148 enhances calcification after 21 days. A one-way ANOVA test with Tukey 
correction was used. Error bars represent ± SEM. Black arrows highlight the 
calcified nodules. n = 3 independent transfections; *p < 0.05.  
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4.3. Key findings 
The key findings of experiments described in this chapter show: 
 
1. Fluorescence microscopy of AoEMPs showed that are internalised by 
HCoASMCs, enhance matrix mineralisation and calcium deposition in vitro 
compared to untreated cells as shown by Alizarin Red S staining and calcium 
deposition assays. 
 
2. A bone-panel multiplex array found that the secretome of calcifying 
HCoASMCs is modulated by AoEMPs compared to untreated cells: IL-6, 
TNFα and OCN are increased, while OPG are decreased, during the first 
week of treatment with AoEMPs. SOST and OPN remain unaffected. 
 
3. Proteomic screening of AoEMPs found that they carry HGF and other 
proteins involved in vascular calcification, as well as Ca2+. 
 
4. This is the first study to describe the role of miRNA-3148, which a microRNA 
screening found that is carried by AoEMPs and we have shown that 
selectively targets OPG mRNA, is partially responsible for AoEMP-enhanced 
calcification. 
 
 
4.4. Summary 
We have found that AoEMPs are not only up-taken by their targets, but that they 
increase the secretion of the inflammatory molecules IL-6 and TNFα, as well as the 
calcification promoter OCN, suggesting an active role in enhancing calcification in 
vitro. Calcification is a complicated process involving many molecules (159, 169, 
201) but to our knowledge, this is the first study to describe that AoEMPs enhancing 
vascular calcification in vitro partially via the transmission of miRNA-3148, which we 
have found selectively targets the calcification inhibitor OPG. These findings 
suggest that, upon EC damage and EMP release, there could potentially be cross-
talk within the vessel wall between ECs and VSMCs via EMPs. The next chapter 
will describe the significance of these findings and their contribution to the existing 
knowledge in the link between CVD and vascular calcification. 
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CHAPTER 5: DISCUSSION, CONCLUSIONS AND FUTURE WORK  
5.1.    Discussion 
Inflammatory disorders such as SLE are associated with elevated endothelial 
dysfunction and accelerated vascular ageing, which lead to increased risk of CVD. 
Circulating EMP levels are increased in these disorders, but their role on the vessel 
wall is unclear. This study shows that EMP treatment of endothelial cells (HUVECs) 
and coronary artery smooth muscle cells (HCoASMCs) results in a modulation of 
endothelial function and in enhanced osteogenic differentiation of HCoASMCs 
respectively. HUVECs stimulated with sEMPs showed elevated EMP release 
compared to those treated with uEMPs, which could support the in vivo findings that 
patients with rheumatoid arthritis and SLE have elevated levels of EMPs (33, 202).  
Both sEMPs and uEMPs seem to have similar effects on endothelial cell migration, 
proliferation and adhesion molecule (VCAM-1 and ICAM-1) levels, which may reflect 
specific effects on the particular vascular beds and the fact that vein endothelial cells 
do not respond to the microenvironment in the same way as aortic cells, which form 
atherosclerotic plaques while vein cells do not. On the other hand, sEMPs activate 
the NFκB pathway whereas uEMPs do not. Finally, AoEMPs were able to induce 
osteogenic differentiation and calcification of HCoASMCs after 3 weeks, and we 
have described for the first time a link between miRNA-3148 and deposition of a 
mineralised matrix. These findings suggest that endothelial dysfunction induced by 
inflammation in SLE may further promote the generation of EMPs, further 
contributing to endothelial damage and ultimately, promote vascular calcification. A 
more detailed discussion of the study is outlined below. 
 
5.1.1.  EMPs as indicators of endothelial function and disease activity 
CVD is the largest cause of death in systemic inflammatory diseases such as SLE. 
As reviewed by Chironi and Boulanger et al., several studies have attempted to link 
the elevated circulating EMP levels observed in CVD patients with a potential key 
role in the regulation of inflammation, angiogenesis and thrombosis (140). Other 
studies in which circulating MPs from healthy individuals have been quantified have 
found that the majority of MPs are platelet-derived rather than of endothelial origin, 
and that the former are usually more abundant than the latter (39, 145). Given the 
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fact that endothelial dysfunction is apparent in patients with SLE which is an 
inflammatory disorder, and that reports suggest elevated EMPs in disease 
compared to healthy subjects, we focused our attention on understanding the role 
of EMPs in inflammation and endothelial function.  
In addition to being associated with endothelial dysfunction, EMPs may contribute 
directly to the development of certain inflammatory conditions and vascular ageing. 
In patients with active inflammation, EMP numbers correlate with decreased 
endothelial function as measured by flow mediated dilation (FMD) (33). Parker et al. 
demonstrated that anti-inflammatory treatment reduces circulating EMP levels in 
SLE patients, and that such a reduction correlates with an improvement in 
endothelial function (33). In this study, we investigated the role of two EMP 
populations, uEMPs and sEMPs, generated by different mechanisms, in order to 
compare their content and effects on endothelial cell function in vitro. Our results 
suggest that uEMPs and sEMPs not only carry different proteins and microRNAs, 
but also have different roles on endothelial function and activate different pathways. 
These observations, together with the observations of other researchers in the 
literature, reinforce the idea that EMPs may serve as indicators of endothelial 
function and disease activity. 
5.1.1.1. EMP content depends on the mode of EMP generation  
Not only can EMP levels be altered in disease, but the phenotype of the EMPs has 
also been demonstrated to be altered depending on the disease and other 
underlying environmental conditions. In a series of studies, Berezin et al. showed 
that the expression of surface markers on circulating EMPs CD31, AnnexinV and 
CD62E differ between pathologies, and that body mass index is a predictor of this 
in patients with chronic heart failure (203). Similarly, patients suffering metabolic 
syndrome and developing CVD have been shown to have an immunogenic MP 
phenotype with an altered ratio between circulating EMPs and apoptotic bodies 
(204). In the current study, small phenotypical differences between uEMPs and 
sEMPs were detected; sEMPs may not be fully encapsulated microvesicles as their 
membrane in some cases did not appear to be fully enclosed, whereas this is not 
the case for uEMPs (Figure 18). This phenomenon could be explained by the 
difference in the mode of generation, in that TNFα is a stressful stimuli that leads to 
a rapid and more abundant sEMP generation, leading to generation of “incomplete”, 
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open vesicles, compared to generation under standard conditions, which requires 
further investigation. This possibility, which has already been explored in apoptotic 
bodies (42, 205), means that the chance for multiple mechanisms of interaction 
between EMPs and target cells is real and would explain how encapsulated 
molecules in the EMPs interact with membrane receptors in their target cells, 
allowing for a more direct interaction.  
EMPs are vehicles of biological information, as they carry proteins and miRNAs from 
their cell of origin (10, 73, 92, 124), which also means that they are a good reflection 
of the status or health of the cell from which they originate. Techniques including 
western blotting and/or RT-qPCR have been used in the past to investigate MP 
content with flow cytometry to determine surface antigens. In this study, a proteomic 
screen and an angiogenic bioplex suspension array analysis of uEMPs and sEMPs 
to investigate the differences between both sets were performed (Figure 19 and 
Figure 20). Among proteins of the CXC chemokine family, other signalling molecules 
such as TNFα, IL-8 or VEGF-A were detected. CCL20, a protein involved in 
macrophage recruitment to sites of injury was found to be more abundant in sEMPs 
than in uEMPs in the proteomic screen and confirmed using flow cytometry (Figure 
22). CCL20 expression is mediated by TNFα and therefore, its abundance in the 
cytoplasm of the TNFα-stimulated HUVECs would have been high at the time of 
sEMP generation and thus reflects the status of the cell of origin.  
A review by Lee et al. summarised the importance of CCR6 and CCL20 in 
rheumatoid arthritis and other connective tissue diseases, and suggested that they 
are involved in disease progression (206). A parallel study in our laboratory 
(personal communication, unpublished) found a correlation between circulating 
EMPs and CCL20 levels in SLE patients. Koga et al. used a calcium/calmodulin-
dependent kinase IV knockout mouse model to demonstrate the importance of 
CCL20 in lymphocyte Th17-mediated inflammation, and found that the expression 
of CCR6 (the receptor of CCL20) in peripheral blood, positively correlates with the 
severity of organ damage in SLE patients (207). Similarly, an investigation by 
Manthey et al. highlighted the role of CCR6 as a promoter of monocyte-mediated 
inflammation in CCR6 and low-density lipoprotein receptor-deficient (CCR6-/- LDL-
/-) mice, and concluded that targeting CCR6 or its ligand CCL20 could be a 
promising therapeutic strategy to alleviate vascular damage (208). Another study by 
Calvayrac et al. showed an elevation of circulating CCL20 levels in 
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hypercholesterolemic individuals, as well as elevated levels in atherosclerotic 
plaques, and identified LDL as a mediator of such inflammation using a hVSMCs 
model in vitro (209). In this study, a microRNA screen identified miRNA-129-5p, to 
be more abundant in uEMPs than in sEMPs, and a bioinformatic analysis predicted 
its target to be CCL20. A review by Nakashima et al. describes the role of miRNA-
129-5p in other autoimmune disorders (210) lending credence to the idea that 
miRNA-129-5p could be responsible for the reduced CCL20 levels in uEMPs vs 
sEMPs and in uEMP-treated cells in comparison to sEMP-treated cells (Figure 24). 
However, following transfection studies over-expressing miRNA-129-5p, no 
decrease in mRNA abundance was detected suggesting that miRNA-129-5p does 
not target CCL20 mRNA in our in vitro model (Figure 26). It is possible that the 
bioinformatic alignment is not strong enough and therefore the prediction is 
inaccurate, but it is also possible that miRNA-129-5p has an unknown target that 
upregulates CCL20 expression. Alternatively, it would have been interesting to 
generate sEMPs enriched with miRNA-129-5p and quantify their CCL20 levels, very 
much like the work carried out by Jansen et al, in which they showed that EMPs 
reduced ICAM-1 expression via microRNA-222 transfer (211). 
5.1.1.2. EMPs effects on endothelial cell function  
This study confirms that TNFα enhances EMP release in vitro, as shown previously 
(21, 28, 41); however, whether these EMPs are the result of the beginning of an 
apoptotic process is debatable. In this study, complete media (with serum) with the 
addition of 10 ng/mL of TNFα, to stimulate EMP release from HUVECs was used. 
After 24 hours of TNFα treatment, no phenotypical differences between the 
untreated and TNFα-stimulated HUVECs were observed, although elevated EMP 
release was observed in the TNFα-treated cells (Figure 17). Our laboratory 
published a study on the effects of the anti-TNFα drug Certolizumab on endothelial 
cell function in vitro, and it was found that 10 ng/mL TNFα under these conditions 
did not adversely affect cell viability as shown by MTT and apoptosis assays (21). 
Additionally, a recently published study by Teasdale et al. demonstrated that 10 
ng/mL TNFα is not a high enough concentration to induce apoptosis in cells, as 
shown by no change in cleaved Poly (ADP-ribose) polymerase (PARP) or cell 
viability (212). Finally, it is generally accepted that TNFα is an inflammatory 
stimulant but, in the absence of mRNA or protein synthesis inhibition, does not 
directly promote cell death (213). As such, 10 ng/mL of TNFα was used to stimulate 
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HUVECs for 24 hours to model an inflammatory environment and to promote EMP 
generation (sEMPs).  
EMPs were also collected from healthy, non-stimulated HUVECs (uEMPs) in order 
to compare the content of the two populations. In order to generate EMPs in vitro, 
commercially available HUVECs (pooled donors) were used instead of isolating 
endothelial cells in our laboratory. The reasoning behind this is that EMPs can be 
widely heterogeneous and minimal differences in their mode of generation are 
expected to have a huge impact in their proteomic and nucleic acid content, and for 
the purposes of this study, minimal differences between uEMP and sEMP batches 
were sought in order to improve reproducibility. 
EMPs are thought to be paracrine and autocrine mediators of intracellular signalling 
due to their capacity to transfer a number of molecules to target/recipient cells and 
as such, have an effect in the vasculature (214). Lacroix et al. reported that HUVEC-
derived EMPs promoted angiogenesis at low concentrations, whereas they had an 
inhibitory effect at high concentrations, and that these effects are urokinase-type 
plasminogen activator (uPA) dependant (123), therefore, it was acknowledged that 
such effects may be concentration dependent. In this study, EMP concentrations 
used (106 EMPs/mL) were based on previously published EMP levels detected in 
patients. Previous findings from our laboratory demonstrated that EMP levels are 
elevated in inflammatory diseases compared to healthy controls, and that these 
levels are reduced following anti-inflammatory treatment (33). In such study, it was 
found that the highest concentration of EMP levels measured in plasma from SLE 
patients was in the magnitude order of 106 EMPs/mL, whereas the levels following 
treatment were 10-fold lower at 105 EMPs/mL. In light of these findings and reflect 
inflammation associated with SLE in vitro, 106 EMPs/mL was used in all 
experiments. However, it is acknowledged that EMP levels are highly variable and 
clearly depend on many underlying clinical parameters.  
Another study from our laboratory, investigating the levels of EMPs in patients with 
carotid artery disease, found that median EMP levels could be as high as 106 
EMPs/mL in asymptomatic patients with unstable plaques (similar to SLE), whereas 
symptomatic patients with stable plaques had significantly lower circulating EMP 
numbers (145). As such, it is challenging to scale down EMP concentrations in vitro 
and still resemble the in vivo situation in SLE. Nevertheless, in a recent study also 
134 
 
from our laboratory investigating the role of EMPs in lipid-induced endothelial 
damage (unpublished), 105 and 106 sEMPs/mL were used in the experiments and 
there was very little difference between the two EMP concentrations on a number 
of parameters tested (nitric oxide release, reactive oxygen species production and 
NADPH oxidase activity among others). 
In this study, it was found that treatment of HUVECs with sEMPs elevated EMP 
release compared to untreated or uEMP-treated cells, to almost TNFα levels. 
However, the combination of sEMPs and TNFα did not exert a synergistic nor 
additive effect on EMP release, suggesting that sEMPs may enhance EMP release 
via a similar mechanism to that of TNFα and that a threshold level of release exists. 
uEMPs not only did not enhance EMP release, but they attenuated TNFα-mediated 
EMP release (Figure 27). As far as we are aware, this is the first study to suggest 
that, EMP release may be governed by EMPs themselves in a self-regulating 
manner, possibly contributing to the maintenance of endothelial homeostasis. The 
incapacity of sEMPs to reduce TNFα-mediated EMP release, as well as their ability 
to actually enhance EMP release could explain the observation of higher circulating 
EMP levels in patients with systemic inflammatory conditions compared to healthy 
individuals.  
EMPs were initially characterised as being pro-inflammatory, with the potential to 
prevent vascular repair and exacerbate endothelial damage (36, 141, 144); 
however, findings from this study indicate a potential dual role, depending on 
whether they are released from healthy or activated cells. For example, endothelial 
cell migration is a tightly regulated process that plays a key role in a variety of 
physiological processes. The endothelial layer regulates the exchange of molecules 
and cells between the lumen and tissues, and as explained above, endothelial 
dysfunction is the first stage to the development of vascular complications often as 
a result of damage caused by sustained inflammatory stimuli. Therefore, when the 
endothelial layer is damaged, cells migrate to the sites of injury, a process regulated 
by a myriad of growth factors and cytokines such as fibroblast growth factor-2, 
hepatocyte growth factor, platelet-derived growth factor, epidermal growth factor, 
transforming growth factor-β, interleukins and TNFα among others (215-217), for 
endothelial repair.  
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It is well stablished that TNFα is a key player in the regulation of endothelial cell 
responses (218); Chaudhuri et al. demonstrated that TNFα contributes to tissue 
remodelling and fibrosis using human epithelioid dermal microvascular endothelial 
cells treated with 50 ng/mL TNFα (219). Cell migration and scratch assays are often 
used as in vitro models of endothelial repair. A study by Kanaji et al. using human 
pulmonary artery endothelial cells treated with low concentrations of TNFα (2 ng/mL) 
described its role on endothelial cell migration and survival via the NFκB pathway 
(220). As such, in this study TNFα was used as a positive control for endothelial cell 
migration. While sEMPs enhanced EMP release and uEMPs attenuated TNFα-
driven EMP release, both populations of EMPs enhanced endothelial cell migration 
to similar levels (Figure 28). Although there appears to be a trend towards inhibition 
of TNFα-mediated endothelial cell migration, this was not statistically significant.  
To ensure that closure of the wound was due to migrating cells and not due to 
endothelial cell proliferation, the proliferative capacity of the cells was also 
measured following treatment with EMPs. Neither uEMPs nor sEMPs had any effect 
on cell proliferation compared to untreated and TNFα-treated cells, which supports 
the data obtained from the uEMP and sEMP-induced endothelial cell migration.  
Jansen et al. have reported that EMPs generated from serum starved human 
coronary artery endothelial cells enhanced endothelial cell migration in vitro via 
sprouty-related enabled/VASP homology 1 domain-containing protein-1 (SPRED1) 
and miRNA-126, an effect not observed in EMPs generated in hyperglycaemic 
conditions (81). Our results are interesting since they raise the point to the functional 
role of EMPs being dependent upon their origin. However, no differences in the 
induced migration capacity of uEMPs and sEMPs nor a statistically significant 
reduction in TNFα-mediated migration or effects on cell proliferation when using 106 
EMPs/mL was observed. It is possible that these effects are concentration 
dependent and therefore, either the concentration of uEMPs was too high or the 
concentration of sEMPs too low. Since the objective was to investigate the 
differences between uEMPs and sEMPs, these effects were not investigated on a 
dose response manner.  
VCAM-1 and ICAM-1 are two important adhesion molecules involved in the 
progression of inflammation by regulating inflammatory cell adhesion, which 
ultimately leads to inflammatory cell infiltration in the vessel wall and vascular 
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damage (20, 221). It is well established that TNFα increases VCAM-1 and ICAM-1 
expression on endothelial cells in vitro (185, 222). The expression of VCAM-1, which 
is found mostly to be present just in endothelial cells and is known to play a key role 
in endothelial cell:T-cell interaction (223), and ICAM-1, which has differential spatial 
expression depending on cell type and vascular bed, plays a key role in leukocyte 
adhesion and migration (224), were investigated in this study.  
RT-qPCR of transcripts harvested from uEMP and sEMP treated HUVECs 
demonstrated that sEMPs and uEMPs increase mRNA abundance of VCAM-1 and 
ICAM-1 compared to untreated cells, and that sEMPs increased mRNA levels to a 
greater extent than uEMPs (Figure 29). sEMPs appeared to reduce TNFα-mediated 
VCAM-1 and ICAM-1 mRNA levels, an effect not observed with uEMPs in 
combination with TNFα. This is in contrast to our previous findings that uEMPs (but 
not sEMPs) attenuated TNFα-driven EMP release, highlighting the heterogeneity of 
EMP population effects during different pathological processes. However, an 
increase in mRNA abundance need not necessarily indicate altered protein levels, 
nor an enhancement of endothelial cell adhesion. Indeed, western blot analysis 
showed that sEMPs and uEMPs did not elevate VCAM-1 and ICAM-1 levels above 
the untreated controls, in contrast to published work (Figure 30); e.g. a study by Fink 
et al. showed an EMP-mediated modulation of VCAM-1 and ICAM-1 protein levels 
in HUVECs in an in vitro comparative study between EMPs isolated from healthy 
and from resuscitated patients and using lower EMP concentrations (225). We are 
inclined to suggest that either the endothelial cells are protecting themselves from 
activation, or that the diverse content of the uEMPs or sEMPs is regulating VCAM-
1 and ICAM-1 at the protein level.  
In addition to the effects of TNFα on EMP release and endothelial cell function 
discussed, it is well established that TNFα induces nuclear translocation of NFκB, a 
common pathway that also regulates cell migration, proliferation, adhesion 
molecules (226, 227), and that Sapet et al. showed that is involved in ROCK II 
mediated EMP release in human mammary epithelial cells in vitro (46). In the NFκB 
pathway, TNFα can either bind the TNFR1 or TNFR2, which leads to the 
phosphorylation and degradation of the inhibitory protein IκBα, releasing NFκB 
which is then free to translocate to the nucleus, where it will act as a transcription 
factor of several proteins involved in inflammation, cell survival and cell proliferation 
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(56, 227).Therefore, TNFα was used both as a positive control and to simulate an 
inflammatory microenvironment for co-treatment with uEMPs and sEMPs. 
Immunofluorescence microscopy demonstrated that cells treated with sEMPs, with 
or without TNFα, showed NFκB translocation to the nucleus, at both time points 
tested; 30 minutes and 16 hours. Such translocation was not observed in the 
untreated cells or uEMP-treated cells, suggesting that only TNFα is responsible for 
NFκB translocation in the uEMP-treated cells and that sEMPs are responsible for 
the translocation of NFκB (Figures 31 & 32).  
To further validate these findings, western blot analysis of NFκB in the nuclear 
fraction of these cells was performed. Residual NFκB was found in untreated and 
uEMP-treated cells (possibly from contamination from the cytoplasmic fraction), and 
as expected, TNFα increased nuclear NFκB in all cells. Our data also showed that 
NFκB was elevated in sEMP-treated cells compared to uEMP-treated and untreated 
cells (Figure 33).  
As a final probe into this pathway, RT-qPCR was used to measure mRNA 
abundance of IκB (an inhibitor protein of the NFκB complex). It was found that IκB 
mRNA was more abundant in sEMP-treated cells, as well as when TNFα was 
present, compared to uEMP and untreated cells. Taken together, it can be 
concluded that sEMPs act via NFκB, whereas uEMPs do not. This finding suggests 
that the difference in the content between sEMPs and uEMPs reflects the nature of 
the stimulus by which they were generated originally. sEMPs originate from TNFα-
stimulated HUVECs and therefore, they are expected to carry inflammatory-like 
proteins and nucleic acids (228), whilst uEMPs, generated under standard 
conditions, may be harbouring pro-homeostatic molecules. Of note, it may be 
possible that nucleic acid content of EMPs (such as microRNAs) exerts a greater 
effect on gene regulation once delivered into the cell (as they can regulate the 
expression of diverse genes) by the EMPs than proteins, whose effect may be 
greater via interaction with cell surface receptors. However, most of the recent 
literature around EMPs content points to their diverse microRNA content (229, 230), 
possibly because microRNAs are easier to detect and amplify compared with 
proteins, which are more difficult to detect at the low levels observed in EMPs and 
therefore, explaining the reduced number of investigations in their proteomic content 
compared to their microRNA content. The observations from this study, together 
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with data reported in the literature, confirms that MPs, their mode of generation, 
phenotype, composition and role strongly depends on different factors. These 
include the presence of other inflammatory molecules, the cell of origin and stimuli 
of generation. A summary of the suggested role and mechanism of action of EMPs 
in health and disease is illustrated in Figure 45.  
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Figure 45. Proposed effects of uEMPs and sEMPs in the vasculature. In health, uEMPs show a baseline level of EMP release, which 
appears to reduce TNFα-mediated EMP generation. In contrast, in disease, TNFα gives rise to EMP release, which we term sEMPs, which in 
turn elevate EMP release compared to release from untreated cells (uEMPs). sEMPs appear to activate NFκB signalling in endothelial cells. 
Finally, EMPs participate in paracrine CCL20 transport, acting as signalling molecules and participating in the cross-talk with the smooth muscle 
layer. PMPs: platelet microparticles; EMPs: endothelial microparticles; SMC: smooth muscle cell; CCL20: chemokine (C-C motif) ligand 20.
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5.1.1.3. Study limitations 
1. Although we have used the nomenclature of microparticles MPs in this study, 
there is a growing recognition to use the word term microvesicles to describe 
biological microparticles, since there is growing interest in the organ damage 
due to chemical air pollutants, which are also being described as 
microparticles. It is likely this thesis is the last of the documents from our 
group to use microparticles and the group will adopt the use of the term 
extracellular vesicles. 
2. EMP isolation techniques can vary from laboratory to laboratory with the 
recognition for the need for consistency if the field is to develop with 
accuracy. Thus the isolation procedure has become more refined to separate 
apoptotic bodies, MPs and exosomes. However, for consistency with 
previous work in our laboratory, ultracentrifugation at 100,000 x g for 2 hours 
at 4 ºC to isolate EMPs was used. Although this short, high-speed 
ultracentrifugation was efficient at producing MPs, it is unlikely to be long 
enough to extract exosomes as well, although it is possible that the 
preparations used in this study contain a small amount of exosomes. 
3. EMP levels vary between patients with different diseases, and are modulated 
to a different extent under distinct micro-environment conditions. Therefore, 
it is difficult to elucidate the appropriate concentration of EMPs/mL that 
should be used in in vitro assays. As such, effects may be EMP concentration 
dependent, but this was not investigated in this work. 
4. Generating EMPs in vitro is a common practice in many laboratories, 
however by doing so, all the complexity from an in vivo system is removed. 
The in vitro system is designed so that the specific effects of a single stimuli 
can be determined more easily.  
5. Despite the challenges in isolating microparticle populations from different 
cellular origins within patients, pursuing this MP isolation procedure from 
patients would allow for an in-depth analysis of the differences in proteomic 
and nucleic acid content of microparticles and their function in different 
patient and disease conditions. 
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5.1.2.  EMPs as a potential link between endothelial dysfunction and 
vascular calcification 
Given the prevalence and implications of vascular calcification in patients with SLE 
(231-233), and the fact that matrix vesicles have long been associated with the 
deposition of a mineralised matrix within the vessel wall as discussed in the 
insightful review by Aikawa and colleagues (234), it was of interest to establish 
whether EMPs could play a role in the cross-talk between the endothelium and 
smooth muscle cells. The results from this study suggest that AoEMPs are 
internalised by HCoASMCs and that they enhance calcification, partially via miRNA-
3148, which is discussed in detail in the next sections.  
5.1.2.1. AoEMPs as specific regulators of vascular calcification 
Tracking EMPs from the extracellular space through the cell membrane to the 
cytoplasm has proven to be challenging. In an elegant study by Jansen et al., 
Calcein-AM was used to track EMP internalisation by human coronary artery 
endothelial cells, where they described for the first time an 
AnnexinI/Phosphatidylserine receptor dependent uptake mechanism and a p38 
dependant EMP-mediated protection against apoptosis (235). A second study, 
which used a similar technique for EMP tracking, found that ROCK-dependent, 
miRNA-rich MPs were effectively transferring their contents to HAoECs in vitro (85). 
In a third study in which the interactions between Calcein-AM-labelled PMPs and 
human brain endothelial cells in vitro were investigated, cytochalasin D was used to 
inhibit the microfilament formation involved in endocytosis, confirming that PMPs 
are taken up via mechanisms involving phagocytosis or macropinocytosis (236). 
Finally, Buendia et al. demonstrated that Calcein-AM-labelled TNFα-derived EMPs 
carry a high content of calcium and BMP-2, thereby inducing calcification of 
hVSMCs in vitro (188).  
In this study, fluorescent microscopy was used to track Calcein-AM labelled 
AoEMPs and found that they are internalised by HCoASMCs (Figure 35). Our 
controls included Calcium-AM without AoEMPs, which showed no cellular uptake, 
thus indicating that the detected fluorescence was due to AoEMP uptake. 
Furthermore, the AoEMP uptake experiments were performed in pre-conditioned 
HCoASMCs in osteogenic media to ensure that EMP uptake was viable under these 
high calcium and phosphate conditions, since the vascular calcification experiments 
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were performed under these conditions. In this regard, an important limitation to our 
study and those performed by other groups, is the difficulty in demonstrating that 
AoEMPs are not increasing membrane permeabilisation and that the observed 
effects are due to the interaction between EMPs and HCoASMCs and the 
subsequent internalisation of bio-reactive molecules. Several authors have 
attempted to shed some light on this topic during the past five years using different 
techniques from tracking MPs (37, 237-240), but there is still no consensus and, as 
reviewed by Mulcahy et al. the mechanisms appear to be very diverse (130). For 
example, a study by Povero et al. used Calcein-AM labelled hepatocyte-derived 
MPs to track their uptake by HUVECs and concluded that this process is Vanin-1 
dependant (240), whereas Lopez-Vilchez et al. used electron microscopy to 
describe the uptake of Tissue Factor rich MPs by platelets via CD36 receptor and 
serotonin transporter (239, 241). Recent work by Andrews and Rizo also used 
Calcein-AM labelled EMPs generated from TNFα-stimulated mouse lung endothelial 
cells on EMP-driven endothelial activation in caveolin-1 knockout endothelial cells, 
and concluded that such activation requires caveolin-1/caveolae (136). However, 
the question of how EMPs interact with target cells is beyond the scope of this study 
and time restraints did not permit this line of study, but will be investigated in the 
future. 
SLE patients have increased risk of developing CVD and many studies have shown 
clear links between vascular calcification and SLE (232, 242, 243), however the 
mechanisms underpinning their relation are still unclear. A number of studies have 
established that inflammatory cytokines including IL-6, IL-8 and TNFα, which are 
also elevated in SLE, induce osteogenic differentiation and mineralisation of 
vascular cells in vitro and in vivo, suggesting this could be a possible mechanism 
for vascular calcification in SLE (244-246). In addition, circulating EMP levels are 
significantly higher in conditions where TNFα is elevated, such as in SLE patients 
compared to healthy controls, and may be a reflection of endothelial dysfunction, a 
key initiating factor in vessel disease. Therefore, we used an in vitro model of 
calcification to investigate the link between EMPs and vascular calcification using 
AoEMPs generated under inflammatory conditions. It was found that AoEMPs 
enhanced matrix mineralisation and calcium deposition of HCoASMCs after 3 weeks 
in osteogenic media (Figure 36), with a trend towards an increase in not only bone-
related proteins, but the pro-inflammatory molecules, TNFα and IL-6 (Figure 37). 
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These findings are supported by a recent study by Buendia et al. who found that 
HUVEC-derived EMPs promoted calcification and mineralisation in hVSMCs (188). 
In this study, EMPs derived from HAoECs were used to investigate their effects on 
HCoASMCs. We acknowledge that it may have been of some advantage to carry 
out the same set of experiments using human coronary artery endothelial cells 
(HCoAECs) derived EMPs or HAoSMCs for EMP treatment, which would allow to 
study the effects EMPs have on calcification in different vascular beds, a concept 
that has been investigated and discussed in the literature. For example, Kang et al. 
used adipose tissue-derived MPs to study their effects on HUVECs, concluding that 
they have angiogenic properties mediated by miRNA-31 (247), or another study by 
Jansen et al., in which the role of HCoAEC-derived MPs in atherosclerosis prone 
ApoE-/- mice was studied, concluding that hypoglycaemia increased EMP-mediated 
NADPH oxidase activity, thereby activating endothelial cells and promoting 
inflammation (248).  
Osteogenesis and vascular calcification are highly regulated processes involving a 
myriad of transcription factors, proteins and secreted molecules, and it is often the 
balance between these molecules that determines cell fate (168, 169). As well as a 
range of promoters of vascular calcification, such as OCN, ALP, BMP-2 and BMP-
4, there are a number of inhibitors, including OPG, OPN and MGP (167, 177). As 
extensively reviewed, overexpression of vascular calcification promoters is often 
accompanied by elevated levels of calcification inhibitors in calcified vessels, thus 
the balance between the two dictates whether calcification occurs (201, 249-251).  
In this study, the effects of AoEMP treatment on the secretome of HCoASMCs was 
investigated using Bioplex suspension array analysis of conditioned media sampled 
throughout the 21-day experiment (Figure 37). IL-6 and TNFα were elevated 
throughout the 3-week duration of the experiments, which suggests that AoEMPs 
may be implicated in IL-6 and TNFα mediated osteoblastic differentiation. Although 
not significantly, secreted OPG levels are slightly reduced during the first week of 
treatment in AoEMP-treated cells compared to untreated cells. Such a prompt 
reduction in OPG levels would support an enhanced calcification at the end of the 3 
weeks, despite elevated levels are detected towards the end of the experiment. 
Additionally, Maetzler et al. showed elevated microcalcification in an OPN knock-
out mouse model, demonstrating the inhibitory effects of OPN in vascular 
calcification (174), and similar results were found by Speer et al. hVSMCs isolated 
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from aortas of OPN knock-out mice and showing that retroviral transduction of 
mouse OPN cDNA into OPN-/- hVSMCs reversed the calcifying phenotype (252). 
In the current study, OPN is mildly affected throughout the 3 weeks of the 
experiment in the AoEMP-treated cells compared to untreated controls. Finally, 
OCN, a well-known calcification promoter, is elevated at the early stages of the 
treatments. In combination, these observations suggest that AoEMPs reduce the 
secretion of the calcification inhibitor OPG, whereas they increase inflammatory 
molecules IL-6 and TNFα, as well as the calcification promoter OCN, thereby 
creating an imbalance between calcification inhibitors and promoters, ultimately 
leading to vascular calcification. The molecular mechanism underlying AoEMP-
induced calcification was further investigated by analysis of the content of the EMPs 
and determining their function in SMC vascular calcification, an idea that is 
discussed in the next section, which provides a suggested mechanism of action of 
AoEMPs on HCoASMCs. 
5.1.2.2. OPG as a suggested player in the mechanism of action 
underlying AoEMP-mediated calcification 
In order to determine how AoEMPs enhanced smooth muscle cell calcification, the 
molecular components of AoEMPs were analysed since they could be responsible 
for the observed effects (Figures 38 – 40). Previous studies have demonstrated that 
EMPs carry proteins and miRNAs that contribute towards the calcification of smooth 
muscle cells (188, 253), but little is known about the mechanisms of action by which 
EMPs mediate their effects. As discussed previously, Buendia et al. found that BMP-
2-rich HUVEC-derived EMPs were up-regulating the osteoblast transcription factor 
Cbfa1 and decreasing the hVSMC-specific protein SM22α, thereby enhancing 
smooth muscle cell calcification in vitro, and that knocking down BMP-2 in HUVECs 
produced non-mineralizing TNFα-derived EMPs (188). Recent studies using murine 
models of calcification showed that vascular calcification involves bone remodelling 
and the activation of both osteoclastic and osteoblastic differentiation, with OPG 
attenuating osteoclastic differentiation (167, 254, 255). Additionally, Panizo et al. 
demonstrated that cells lacking RANK showed no increase in vascular calcification 
when incubated with RANKL, suggesting that it enhances mineralisation and that 
such effects are attenuated by OPG, which acts as a decoy receptor for RANKL, 
thereby confirming the inhibitory role of OPG in the vascular calcification process 
(177, 249, 256).  
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Potentially AoEMP-driven mineralisation could be due to the 
Phosphatidylserine:Annexin complex acting as a nidus for mineralisation, or to the 
calcium being internalised by the cells in the form of EMPs. Buendia et al. reported 
that TNFα-derived EMPs (equivalent to sEMPs used in this study) carry elevated 
calcium in comparison to EMPs derived from untreated cells (unstimulated EMPs 
(uEMPs) (188). However, we found that both sEMPs and AoEMPs carry significantly 
less calcium than uEMPs (Figure 40). A possible reason for the discrepancy could 
be that Buendia et al. used 20 ng/mL of TNFα for EMP generation, whereas 10 
ng/mL was used in this study. In vitro calcification models have been extensively 
used by various research groups to investigate vascular calcification, with most 
using high calcium (> 2.6 mM CaCl2+) and phosphate conditions to investigate the 
molecular mechanisms underlying osteogenic differentiation of smooth muscle 
cells. Therefore, the contribution of EMPs to total Ca2+ levels is negligible in 
comparison to the high calcium levels in the media, and as such their uptake by the 
HCoASMCs and the subsequent release of such calcium intracellularly may be key 
in the EMP-enhanced calcification process. Further investigation could utilise 
chelation techniques on AoEMPs to assess the effects of calcium free EMPs. 
It is currently accepted that EMPs carry not only nucleic acids such as miRNAs, but 
also functional proteins (42). In our proteomic study of AoEMP content, HGF 
previously described by our laboratory as an inducer of smooth muscle cell 
osteogenic differentiation (166), was found to be of high abundance. In such study, 
Liu et al. used adenoviral transfection techniques to overexpress HGF in hVSMCs 
isolated from limb amputations cultured in osteogenic media, and found that HGF 
enhances calcification via c-Met/Akt/Notch3 signalling (166). Additionally, matrix 
metalloproteinases MMP-1 and MMP-10, which have been associated with the 
degradation of the tunica intima, were also found in this proteomic screen. Previous 
studies have shown that MMP-1 plays an important role in cleaving fibrillar collagen 
type I, II and III, leading to the instability of the collagen fibres and its degradation 
by other members of the MMP family. In contrast, MMP-10 digests a number of 
extracellular matrix molecules and actively participates in MMP (including MMP-1) 
activation (257). Therefore, it could be suggested that MMP activity executed within 
the EMPs is a potential mechanism driving the cross-talk between the endothelial 
and the smooth muscle cell layer. 
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miRNAs are key regulators of diverse biological processes, and it is known that their 
dysregulation often results in impaired cell function and disease progression, and in 
some cases, vascular calcification (258, 259). A study by Balderman et al. reported 
that miRNA-30b/c, which targets and reduces the expression of the transcription 
factor Runx2, is downregulated via BMP-2 in HCoASMCs in vitro, thus inhibition of 
miRNA-30b/c led to matrix mineralisation (260). Another study by Raitoharju et al. 
found that, just like calcification promoters and inhibitors, miRNA expression of 
miRNA-21, miRNA-34a, miRNA-146a and miRNA-210 in calcified vessels is 
elevated in patients with coronary artery disease (261). As reviewed by Goettsch et 
al., MPs can often participate in the transport of miRNAs, thus participating in the 
regulation of calcification (200).  
miRNA-3148, which was identified in our miRNA screen and was predicted to target 
OPG in a bioinformatic analysis and was validated using transfection studies, has 
also been associated with SLE (262) and heart failure patients (263). Our data also 
suggests that miRNA-3148 selectively targets OPG and in turn, enhances vascular 
calcification (Figures 43). HCoASMCs transfected with a miRNA precursor of 
miRNA-3148 showed reduced OPG mRNA levels compared to both untreated cells 
and scrambled control cells after 4 days. A reduction in OPG mRNA abundance can 
also be observed in AoEMP-treated cells, although the difference compared to 
untreated cells was not statistically significant. This may due to the fact that a longer 
and more frequent exposure to AoEMPs is needed in order to observe a statistically 
significant reduction in OPG mRNA in AoEMP-treated cells, and in this study, RNA 
was extracted after 4 days of AoEMP treatment, which was only carried out once at 
the beginning of the experiments. 
The mRNA abundance of OPN (another calcification inhibitor) was significantly 
reduced in AoEMP-treated cells, suggesting that AoEMPs could have direct effects 
on OPN expression. A bioinformatic alignment discarded the possibility of miRNA-
3148 targeting OPN, suggesting that AoEMPs enhance vascular calcification via a 
different miRNA to miRNA-3148. However, a reduction in OPN mRNA abundance 
levels was not observed in the miRNA-3148 transfected cells, suggesting the 
selective targeting of OPG. In addition, our data suggest that AoEMPs enhance the 
calcification promoter OCN mRNA abundance compared to untreated and 
scrambled control-transfected cells. Since secreted OCN is also elevated in 
conditioned media of AoEMP-treated cells after 4 and 7 days, it is likely that elevated 
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mRNA reflects the higher protein levels detected, and plays a key role in the 
mechanism of action in our model. On the other hand, mRNA abundance levels of 
C-met, which is the receptor of HGF and has been shown to be involved in HGF-
accelerated hVSMC mineralisation in vitro (166), were found to be decreased both 
in AoEMP-treated and in miRNA-3148-transfected compared to untreated and 
scrambled control respectively. A bioinformatic alignment of miRNA-3148 and C-
met discarded the possibility of miRNA-3148 also targeting C-met, thus suggesting 
that the regulation of C-met in AoEMPs is due to a different miRNA. 
Finally, Alizarin Red S and calcium deposition assays were also performed 3 weeks 
after transfection with miRNA-3148 to determine whether its early effects on OPG 
mRNA abundance affect calcification. miRNA-3148 transfected cells showed 
enhanced calcification when compared to either untreated or scrambled control-
transfected cells, which is comparable to the data observed in AoEMP-treated cells 
(Figure 44). Despite no statistically significant differences between AoEMP-treated 
and miRNA-3148-transfected cells, there appears to be a trend towards lower 
calcification in the miRNA-3148-transfected cells in comparison to the AoEMP-
treated cells. This suggests that the AoEMPs could be carrying additional miRNAs 
or proteins that are regulating and enhancing their effects on calcification, and/or 
that there is an excess of AoEMPs, thus they act as a nidus for vascular calcification, 
as suggested in the past by Leopold et al. (159). The effect of miRNA-3148 could 
be further validated by transfecting the HCoASMCs with an inhibitor of miRNA-3148 
in addition to treatment with AoEMPs, or by producing miRNA-3148-poor AoEMPs 
and determine their effects on vascular calcification, but due to time constraints this 
assay was unable to be performed. 
As reviewed by Duncan and Richardson, exosomes, alongside EMPs, are active 
signalling molecules that participate in cell:cell communication (119). As such, a 
study by Kapustin et al. found that smooth muscle cell calcification is mediated by 
exosomes (264), and we acknowledge the possibility that our AoEMP preparations 
may also contain exosome-like particles. Moreover, other researchers have used 
RNAse treatments to investigate the relevance of the nucleic acid content on the 
final role of EMPs on their targets (265-267), which in combination with chelation 
techniques, should provide further information as to which one of the 3 main 
components of AoEMPs (proteins, calcium and nucleic acids) is the major regulator 
of the calcification process.  
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Vascular calcification is the consequence of a combination of several molecular 
factors and this study has shown that EMPs also play a regulatory role in such 
process. A summary of the findings from this study and the suggested mechanism 
of action is illustrated in Figure 46.  
 
 
Figure 46. Proposed dual mechanism of action in AoEMP-enhanced smooth 
muscle cell calcification. AoEMPs are internalised by HCoASMCs and their 
content is released in the cytoplasm. AoEMPs carry Ca2+ and miRNA-3148, which 
targets and reduces translation of the vascular calcification inhibitor protein, OPG, 
during the first stages of calcification, thereby contributing to enhanced vascular 
calcification. Additionally, AoEMPs elevate the calcification promoter OCN mRNA 
and protein levels. OPG: osteoprotegerin; OCN: osteocalcin; RANK: receptor 
activator of nuclear factor kappa-B; RANKL: receptor activator of nuclear factor 
kappa-B ligand. 
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5.1.2.3. Study limitations 
1. This study used an in vitro model of calcification which gives no distinctive 
findings for the spatial distribution which occurs in vivo, with regard to intimal 
calcification that occurs within atherosclerotic plaques nor medial calcification, 
which is more prevalent in the renal clinic, an area reviewed elsewhere (268, 
269). 
2. The in vitro calcification model involves 3 week long experiments and 
calcification in patients is predominantly associated with the ageing population 
and occurs over a longer period of time. Therefore, whether the in vitro model 
truly reflects what is happening physiologically is a challenge.  
3. EMP production in vitro is a time and labour intensive process, requiring the 
growth and maintenance of primary human vascular cells, so the generation of 
this molecular tool for experimentation needed to be carried out with extreme 
care and precision to remove any heterogeneity that may have been introduced 
artefactually. 
4. Despite confirming that miRNA-3148 selectively targets OPG, it is possible that 
this miRNA has differential effects on other cell types/targets. Therefore, further 
characterisation of its effects is needed before its therapeutic value can be 
carefully assessed. 
5. Mechanistic conclusions involving OPG and OCN regulation were only 
performed in HCoASMC cells after 4 days in culture. Similarly, secretome 
analysis only reported elevated OCN levels after 4 and 7 days. A more detailed 
time-course should have been carried out should more time have been available. 
6. Calcium scores in SLE patients are not measured as a routine clinical measure. 
However, the link between SLE and vascular calcification is becoming more 
apparent and this work would suggest that it is of potential interest to investigate 
further in the future. 
7. The use of isolated smooth muscle cells from patients with and without 
calcification would be of extreme interest. However, given that this study focused 
on patients with SLE with no tissue available from these patients, this avenue 
was not pursued. However, future work will identify SLE patients with and without 
calcification using imaging techniques and establish their systemic secretome 
and effects of serum on SMCs from different vascular beds. 
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5.2.    Conclusions  
Endothelial dysfunction refers to the inability of the endothelium to vasodilate and 
contract, as well as to its incapacity to control inflammation, cell proliferation and 
thrombosis. SLE is associated with accelerated vascular ageing and endothelial 
dysfunction. Several studies have investigated the role of EMPs in a range of 
disease contexts, including SLE, in which they are found to be reduced following 
treatment (27, 33). In contrast, vascular calcification refers to mineral deposition in 
the vascular system, leading to reduced elasticity and increased vascular stiffness. 
Accelerated vascular ageing and calcification are present in a number of diseases 
and a positive correlation with CVD is well established (270, 271). This study has 
used an in vitro model of inflammation and vascular calcification to investigate the 
role of EMPs on endothelial function and vascular calcification, and the 
mechanisms/molecular components whereby they exert their effects. The results 
demonstrate an association between the distinct role of EMPs and their different 
origin and mechanism of generation, which has an important impact on their 
molecular components, as well as a role in the regulation of endothelial function and 
vascular calcification. Therefore, the original objectives of this project have been 
met and the main findings are as follows: 
1. sEMPs enhance EMP release, whereas uEMPs do not. However, uEMPs 
attenuate TNFα-driven EMP release (Figure 27), suggesting that EMPs in SLE 
could partially be responsible for the elevated circulating EMP levels, as they 
may be governing EMP generation. 
2. sEMPs and uEMPs enhance cell migration, but not proliferation (Figure 28). 
Also, uEMPs and sEMPs modulate VCAM-1 and ICAM-1 mRNA abundance 
on HUVECs, but such effects are not found at a protein level (Figures 29 & 
30), suggesting that the diverse content of the uEMPs and sEMPs is regulating 
VCAM-1 and ICAM-1 at the protein level or that HUVECs protect themselves 
from EMP-mediated VCAM-1 and ICAM-1 expression. 
3. The NFκB pathway is activated by sEMPs, but not uEMPs (Figures 31 – 34), 
suggesting that EMPs generated from different stimuli mediate their effects via 
different mechanisms of action. 
4. sEMPs carry elevated CCL20 and reduced miRNA-129-5p compared to 
uEMPs (Figures 19 – 22). Despite a bioinformatic prediction, transfection 
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studies confirmed that miRNA-129-5p does not target CCL20 mRNA (Figures 
23 – 26), suggesting that a different mechanism is responsible for reduced 
CCL20 levels in TNFα + uEMP-treated HUVECs. 
5. Fluorescent microscopy confirmed that Calcein-AM-labelled AoEMPs are 
internalised (Figure 35). Alizarin Red S staining showed that AoEMPs enhance 
HCoASMCs calcification (matrix mineralisation), and Bioplex suspension 
arrays demonstrated that they also modulate their secretome during the 
process (Figures 35 – 37), potentially via miRNA-3148. 
6. Transfection studies based on a bioinformatic prediction confirmed that 
miRNA-3148 targets OPG and is partially responsible for AoEMP-driven 
calcification (Figures 41 – 44) 
 
5.3.    Future work  
This study has shown that EMPs contribute to both endothelial function and vascular 
calcification and have differential effects on endothelial function depending on their 
origin. Clearly, some interesting questions have arisen from this study and will form 
the basis of future hypothesis-driven investigations regarding the underlying 
molecular mechanism of action of EMPs in endothelial dysfunction and vascular 
calcification. For example: 
 Why do uEMPs attenuate TNFα-mediated EMP production? 
Our results suggest that sEMPs, but not uEMPs, have a direct self-feedback effect 
and are responsible for the elevated EMP levels observed in inflammatory diseases, 
as they appear to enhance EMP generation. Of note, uEMPs attenuate TNFα-driven 
EMP release, which raises questions underlying the mechanisms leading to EMP 
release and the molecular components responsible for such a response. Future 
work will investigate the outside-in effects of uEMPs and sEMPs through to the 
NFκB pathway, as a potential means to explain these observations (46). For 
example, it has been suggested that EMPs may activate the p38 mitogen-activated 
protein kinase pathway which is cytoplasmic and could in turn, be involved in both 
EMP release (47) and NFκB trafficking to the nucleus. 
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 What other key miRNAs/proteins in uEMPs/sEMPs are responsible for 
their functional effects? 
This study demonstrates that EMPs from different origin and generated via different 
stimuli carry distinct molecular components (miRNAs and proteins). A future study 
could investigate the effects of a distinct miRNA of choice. For example, miRNA-
129-5p was identified in a miRNA screening and a analysis bioinformatic analysis 
predicted that it could target CCL20, which was elevated in sEMPs compared to 
uEMPs and in sEMP-treated HUVECs compared to uEMP-treated cells; therefore, 
this and other miRNAs may also be playing a role in regulating CCL20 expression 
and in turn influence pathological processes, such as the enhanced cell migration 
capacity or activation of the NFκB pathway. 
 Do EMPs carry active/functional matrix metalloproteinases that activate 
the pathological cross-talk between the endothelium and the smooth 
muscle layer? 
This study is one of the first studies investigating the effects of EMPs on both 
endothelial function and vascular calcification and the cross-talk in the vessel wall. 
Our proteomic screening identified MMP-1 and MMP-10 in the AoEMPs. The results 
from our MMP activity assays are not conclusive and are not presented in this thesis. 
However, other authors have identified MMP activity in EMPs (123, 272). We 
suggest performing Gel Zymography studies of different EMP populations/subsets 
in order to determine their ability to degrade the intimal layer.  
 Does miRNA-3148 decrease OPG protein levels? 
OPG is a negative regulator of vascular calcification that plays a key role in 
osteoblast differentiation. This study described for the first time the role of miRNA-
3148 in vascular calcification, and confirmed a bioinformatic prediction on its target 
OPG. Due to time constraints, we were unable to investigate whether miRNA-3148 
had effects on OPG protein levels, and ultimately in the RANKL pathway, to confirm 
a mechanistic link with OPG and calcification. Additionally, and to further validate 
the role of miRNA-3148 in enhancing calcification, we suggest either transfecting 
HCoASMCs with anti-miRNA-3148 and co-treat with AoEMPs, or using a viral vector 
to knockdown miRNA-3148 in HAoECs and produce miRNA-3148 poor AoEMPs. 
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 Which other molecular components of AoEMPs contribute towards a 
calcification phenotype? 
It is well established that a myriad of promoters and inhibitors regulate vascular 
calcification. Previous studies in our laboratory described the role of HGF/C-met in 
increased microvessel density within plaques and vascular calcification, and 
concluded that HGF could play a role as a promoter of this pathology (166, 273). In 
the current study, it would appear that AoEMPs contain HGF among other proteins, 
therefore it would be interesting to further investigate the effects of HGF-containing 
EMPs in vascular calcification using a pharmacological inhibitor of the C-met 
receptor or a genetic approach using siRNA against the C-met receptor. This study 
also found that AoEMPs reduce mRNA abundance of the calcification inhibitor OPN. 
Therefore, it would be of interest to carry out bioinformatic analysis of the other 
miRNAs identified in this study in order to investigate their role in the regulation of 
OPN. Finally, the effects of the Ca2+ carried by AoEMPs could be further explored 
by using a chelation technique to remove calcium in order to describe its relevance 
in the SMC phenotypic switching. 
These studies would add to our understanding and provide valuable information on 
the role of EMPs on endothelial function and vascular calcification both in health 
and disease, and would contribute towards understanding the value of EMPs as 
biomarkers of disease or therapeutic targets in the near future. 
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